

Head and Neck Cancer ----- 13802 Cases

Report of Head and Neck Cancer Registry of Japan  
Clinical Statistics of Registered Patients, 2021

Japan Society for Head and Neck Cancer  
Cancer Registry Committee

## Contents

<i>Total Cases (2021).....</i>	<i>11</i>
<i>Oral Cavity (2021).....</i>	<i>26</i>
<i>Larynx (2021).....</i>	<i>46</i>
<i>Hypopharynx(2021) .....</i>	<i>74</i>
<i>Oropharynx(2021).....</i>	<i>103</i>
<i>Oropharynx p16 positive(2021) .....</i>	<i>106</i>
<i>Oropharynx p16 negative and unknown (2021).....</i>	<i>116</i>
<i>Nasopharynx(2021).....</i>	<i>126</i>
<i>Nasal Cavity and Paranasal Sinuses (Excluding the Maxillary Sinus) (2021).....</i>	<i>133</i>
<i>Maxillary Sinus (2021) .....</i>	<i>140</i>
<i>Major Salivary Glands (2021) .....</i>	<i>149</i>
<i>Primary Unknown (2021) .....</i>	<i>161</i>

## Preface

The Head and Neck Cancer Registry in Japan has been supported by the Japan Society for Head and Neck Cancer (JSHNC) since 2003. The annual reports have been published from 2003 to 2005 as supplements of the journal of the JSHNC. Because the Act of the Protection of Personal Information (APPI) was enforced in 2005, JSHNC had decided to discontinue this registration in 2004 and thereafter. After a seven-year interval, the JSHNC restarted the registry using the system of University hospital Medical Information Network (UMIN) Center in Japan. The online registration for patients in 2011 was initiated on May 25, 2012 after renewing the contents and methods of registration. This report is for the eleventh year of the registration after its renewal.

The importance of cancer registration has been recognized widely in Japan since the Act of Propulsion of Cancer Registration in 2013. Moreover, the number of participating institutions has increased since the Japanese Society of Head and Neck Surgery (JSHNS) decided a revision in the regime for board-certified head and neck surgeons and training facilities in 2014.

The improved Ethical Guidelines for Medical and Health Research Involving Human Subjects have been publicly announced on Feb 28, 2017 and the revised APPI was enforced on May 30, 2017 in Japan, so that the procedure for informed consent was changed and the data traceability was taken into consideration in this registration thereafter. The Ethical Guidelines was changed on March 23, 2021 and the protocol of this project was revised into version 1.3 on August 22, 2021 accordingly. The minor refinements of the contents are being prepared for introduction of the 8th UICC TNM classification. Moreover, the clinical study support center (CSSC) of Wakayama medical university hospital has participated in this registration system from July 2017. The data collection contents have been expanded to include the information on five-year prognosis from 2017. Hence, the prognosis data about the cases registered in 2014 were also disclosed this time. These reforms and expansion according to social, medical needs are important to achieve the further development of this registry. Actually, the total number of registered cases has remarkably increased by the assistance of data center, which reached 100000 on April, 2021. We expect that this vast organ-based registry led by doctors and CSSC with an increase in the number of participating institutions, will help better understand the statistics and modes of treatment of head and neck cancer, besides the hospital-based or national cancer registry in Japan.

We would like to express our deepest appreciation to all the doctors in the participating institutions. Furthermore, we would like to express our gratitude to the JSHNS, the member of specialists for head and neck cancer, and the members of UMIN Center as well.

December 31, 2024

Seiichi Yoshimoto, MD

Chairperson of the Board of Directors

Ken-ichi Nibu, MD

Chief Director of Cancer Registry

Daisuke Kawakita, MD

Chairperson of Cancer Registry Committee

Japan Society for Head and Neck Cancer

Cancer Registry Committee 2024

Japan Society for Head and Neck Cancer

Directors      Ken-ichi Nibu, Tsuyoshi Kodaira, and Narikazu Uzawa

Supervisor      Munenaga Nakamizo

Chairperson      Daisuke Kawakita

Members      Toshifumi Tomioka, Ryosuke Kamiyama, Hideaki Takahashi, Tatsuo Okui, Yoshio Ohyama, Souichi Yanamoto and Yuji Murakami

Data Collection

All the doctors who are members of the Japan Society for Head and Neck Cancer are advised to participate in the registration of cancer patients. More than one doctor from an institution could participate in this registration. A participant is provided a UMIN (University hospital Medical Information Network in Japan) ID and a password for INDICE (Internet Data and Information Center for Medical Research) from the UMIN center and registers the data of the cases in their institute to the INDICE system online. The completed registration provides information regarding the patients' age, gender, tumor pathology, TNM classification, therapies (surgery, radiation and chemotherapy), and prognosis. This year, the 9th year of registration, all the data stored in the INDICE system were reviewed by head and neck oncologists and analyzed from all aspects, including the prognosis data about cases registered in 2015.

Registration was restricted to previously untreated malignant head and neck tumor cases which had a confirmed pathological diagnosis, i.e. in the oral cavity, larynx, hypopharynx, oropharynx, nasopharynx, nasal cavity, paranasal sinuses, major salivary glands, and unknown primary. Tumors arising in the cervical esophagus and thyroid gland were excluded from the registry. These head and neck tumors were classified according the General Rules for Clinical Studies on Head and Neck Cancer (The Sixth Edition, Revised version December 2019, Japan Society for Head and Neck Cancer), which are based on the TNM Classification of Malignant Tumours (Eighth Edition, 2016) of the Union for International Cancer Control (UICC).

A total of 14312 cases (including cases other than in the year 2021 and with unknown presentation of diseases, unknown aim for therapies, previously treated) were registered from January 4, 2021 to Oct. 31, 2022. The data registered before Oct. 31, 2022, were checked and corrected after confirming with each institution, whereas, any data correction after the date by themselves were not verified. The total number of previously untreated patients was 13802 for the starting date of the initial therapy from Jan. 1 to Dec. 31, 2021, after excluding cases other than in the year 2021 and with unknown presentation of diseases and duplicated registration.

List of 196 Institutions which participate in the Registry in 2021

- 1 Department of Otorhinolaryngology, Japanese Red Cross Kitami Hospital
- 2 Department of Otorhinolaryngology, Asahikawa Medical University Hospital
- 3 Department of Otorhinolaryngology, Kushiro City General Hospital
- 4 Department of Dentistry and Oral Surgery, Hokuto Hospital
- 5 Department of Otorhinolaryngology, Obihiro Kosei Hospital
- 6 Department of Otorhinolaryngology, Keiyukai Sapporo Hospital
- 7 Department of Oral Surgery and Otorhinolaryngology, Sapporo Medical University Hospital
- 8 Department of Oral Surgery, Sapporo City General Hospital
- 9 Department of Otorhinolaryngology, Sapporo City General Hospital
- 10 Department of Otorhinolaryngology, Teine Keijinkai Hospital
- 11 Department of Otorhinolaryngology, KKR Sapporo Medical Center
- 12 Department of Head and Neck Surgery, Hokkaido Cancer Center
- 13 Department of Oral Surgery, Hokkaido University Hospital
- 14 Department of Otorhinolaryngology, Hokkaido University Hospital
- 15 Department of Oral Surgery, Sapporo Teishinkai Hospital
- 16 Department of Oral Surgery, Tonan Hospital
- 17 Department of Otorhinolaryngology, Nikko Memorial Hospital
- 18 Department of Otorhinolaryngology, Hirosaki University Hospital
- 19 Department of Otorhinolaryngology, Akita University Hospital
- 20 Department of Head and Neck Surgery, Miyagi Cancer Center
- 21 Department of Otorhinolaryngology, Sendai Medical Center
- 22 Department of Otorhinolaryngology, Tohoku University Hospital
- 23 Department of Otorhinolaryngology, Iwate Medical University
- 24 Department of Otorhinolaryngology, Yamagata Prefectural Central Hospital
- 25 Department of Otorhinolaryngology, Yamagata University Hospital
- 26 Department of Otorhinolaryngology, Nihonkai General Hospital
- 27 Department of Otorhinolaryngology, Minami Tohoku Hospital
- 28 Department of Otorhinolaryngology, Fukushima Medical University Hospital
- 29 Department of Otorhinolaryngology and Head and Neck Surgery, Takeda General Hospital
- 30 Department of Head and Neck Surgery, Niigata Cancer Center
- 31 Department of Otorhinolaryngology, Niigata University Medical & Dental Hospital
- 32 Department of Oral and Maxillofacial Surgery, Niigata University Medical & Dental Hospital
- 33 Department of Otorhinolaryngology and Head and Neckl Surgery, Nagaoka Chuo General Hospital
- 34 Department of Oral Surgery, Nippon Dental University Hospital
- 35 Department of Head and Neck Oncology and Otolaryngology, Tochigi Cancer Center
- 36 Department of Otorhinolaryngology, Ibaraki Prefectural Central Hospita
- 37 Department of Otorhinolaryngology, Tsukuba University Hospital

List of 196 Institutions which participate in the Registry in 2021

- 38 Department of Otorhinolaryngology, Saiseikai Utsunomiya Hospital  
39 Department of Otorhinolaryngology, Jichi University Hospital  
40 Department of Otorhinolaryngology, Gunma University Hospital  
41 Department of Head and Neck Surgery, Saitama Medical University International Medical Center  
42 Department of Oral Surgery, Saitama Cancer Center  
43 Department of Head and Neck Surgery, Saitama Cancer Center  
44 Department of Otorhinolaryngology, Ageo Central General Hospital  
45 Department of Otorhinolaryngology, National Defense Medical College Hospital  
46 Department of Otolaryngology-Head and Neck Surgery, Jichi Medical University Saitama Medical Center  
47 Department of Otorhinolaryngology, Kameda Medical Center  
48 Department of Otorhinolaryngology, Kimitsu Chuo Hospital  
49 Division of Head and Neck Surgery, National Cancer Center Hospital East  
50 Department of Otorhinolaryngology, Japanese Red Cross Narita Hospital  
51 Department of Head and Neck Surgery, Chiba Cancer Center  
52 Department of Oral Surgery, Tokyo Medical University, Chiba Dental Center  
53 Department of Otorhinolaryngology, Chiba University Hospital  
54 Department of Otorhinolaryngology, Jikei University Kashiwa Hospital  
55 Department of Otorhinolaryngology, Juntendo University Urayasu Hospital  
56 Department of Otorhinolaryngology, NTT Medical Center Tokyo  
57 Department of Head and Neck Surgery, Cancer Institute Hospital  
58 Department of Otorhinolaryngology, Keio University Hospital  
59 Department of Otorhinolaryngology, Showa General Hospital  
60 Head and Neck Oncology Center, International University of Health and Welfare, Mita Hospital  
61 Department of Head and Neck Surgery, National Cancer Center Hospital  
62 Department of Otorhinolaryngology, Juntendo University Hospital  
63 Department of Otorhinolaryngology, Showa University Hospital  
64 Department of Otorhinolaryngology, Teikyo University Hospital  
65 Department of Otorhinolaryngology, Tokyo Metropolitan Cancer and Infectious Disease Center  
Komagome Hospital  
66 Department of Otorhinolaryngology, Head and Neck Surgery, Faculty of Medicine, Tokyo Medical and  
Dental University Hospital  
67 Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Tokyo Medical and Dental University  
Hospital  
68 Department of Otorhinolaryngology, Tokyo Medical University, Hachioji Medical Center  
69 Department of Otorhinolaryngology, Tokyo Medical University Hospital  
70 Department of Otorhinolaryngology, Jikei University Hospital  
71 Department of Otorhinolaryngology, The University of Tokyo Hospital

List of 196 Institutions which participate in the Registry in 2021

- 72 Department of Otorhinolaryngology, Tokyo Women's Medical University Hospital  
73 Department of Otorhinolaryngology, Tokyo Metropolitan Tama Medical Center  
74 Department of Oral Surgery, Tokyo Metropolitan Tama Medical Center  
75 Department of Oral Surgery, Tokyo Metropolitan Otsuka Hospital  
76 Department of Otorhinolaryngology and Oral Surgery, Tokyo Medical Center  
77 Department of Otorhinolaryngology, Japanese Red Cross Musashino Hospital  
78 Department of Otorhinolaryngology, Nihon University Hospital  
79 Department of Otorhinolaryngology, Nippon Medical School Hospital  
80 Department of Otorhinolaryngology, Jikei University Third Hospital  
81 Department of Otorhinolaryngology, Yokosuka Kyosai Hospital  
82 Department of Dentistry and Oral Surgery, Yokohama City University Hospital  
83 Department of Otorhinolaryngology, Yokohama City University Hospital  
84 Department of Otorhinolaryngology, Yokohama City University Medical Center  
85 Department of Head and Neck Surgery, Kanagawa Cancer Center  
86 Department of Otorhinolaryngology, St.Marianna University School of Medicine Hospital  
87 Department of Otorhinolaryngology, Kawasaki Municipal Hospital  
88 Department of Otorhinolaryngology, Tokai University Hospital  
89 Department of Oral Surgery, Tokai University Hospital  
90 Department of Otorhinolaryngology, Kitasato University Hospital  
91 Department of Otorhinolaryngology, Shinshu University Hospital  
92 Department of Otorhinolaryngology, Yamanashi University Hospital  
93 Department of Otorhinolaryngology, Seirei Hamamatsu General Hospital  
94 Department of Head and Neck Surgery, Shizuoka Cancer Center  
95 Department of Otorhinolaryngology, Hamamatsu Medical University Hospital  
96 Department of Otorhinolaryngology, Japanese Red Cross Shizuoka Hospital  
97 Department of Dentistry and Oral Surgery, Kouseiren Takaoka Hospital  
98 Department of Otorhinolaryngology, Toyama University Hospital  
99 Department of Otorhinolaryngology, Kanazawa University Hospital  
100 Department of Otorhinolaryngology, Kanazawa Medical University Hospital  
101 Department of Matsumoto Dental University Hospital  
102 Department of Otorhinolaryngology, Gifu University Hospital  
103 Department of Otorhinolaryngology, Ogaki Municipal Hospital  
104 Department of Head and Neck Surgery, Central Japan International Medical Center  
105 Department of Head and Neck Surgery, Aichi Cancer Center  
106 Department of Otorhinolaryngology, Aichi Medical University Hospital  
107 Department of Otorhinolaryngology, Toyohashi Municipal Hospital  
108 Department of Otorhinolaryngology, Fujita Health University Hospital

List of 196 Institutions which participate in the Registry in 2021

- 109 Department of Otorhinolaryngology, Nagoya City University Hospital
- 110 Department of Otorhinolaryngology and Oral Surgery, Nagoya University Hospital
- 111 Department of Otorhinolaryngology, Fukui University Hospital
- 112 Department of Otorhinolaryngology, Shiga University of Medical Science Hospital
- 113 Department of Head and Neck Surgery, Kusatsu General Hospital
- 114 Department of Otorhinolaryngology, Japanese Red Cross Otsu Hospital
- 115 Department of Otorhinolaryngology, Shiga General Hospital
- 116 Department of Otorhinolaryngology, Ise Red Cross Hospital
- 117 Department of Otorhinolaryngology, Mie University Hospital
- 118 Department of Otorhinolaryngology, Kyoto Medical Center
- 119 Department of Otorhinolaryngology, Kyoto University Hospital
- 120 Department of Otorhinolaryngology, Japanese Red Cross Kyoto Daiichi Hospital
- 121 Department of Otorhinolaryngology, Kyoto Prefectural University Hospital
- 122 Department of Otorhinolaryngology, Kyoto Katsura Hospital
- 123 Department of Otorhinolaryngology, Kyoto City Hospital
- 124 Department of Otorhinolaryngology, Kinki University Nara Hospital
- 125 Department of Otorhinolaryngology, Nara City Hospital
- 126 Department of Otorhinolaryngology, Tenri Hospital
- 127 Department of Otorhinolaryngology and Oral and Maxillofacial Surgery, Nara Medical University Hospital
- 128 Department of Otorhinolaryngology, Head and Neck Surgery and Oral Surgery, Nara Prefecture General Medical Center
- 129 Department of Otorhinolaryngology, Rinku General Medical Center
- 130 Department of Otorhinolaryngology, Kansai Medical University Hospital
- 131 Department of Otorhinolaryngology, Kitano Hospital
- 132 Department of Oral and Maxillofacial Surgery and Otorhinolaryngology, Kinki University Hospital
- 133 Department of Otorhinolaryngology, Kishiwada City Hospital
- 134 Department of Otorhinolaryngology, Osaka Medical and Pharmaceutical University Hospital
- 135 Department of Otorhinolaryngology, Osaka General Medical Center
- 136 Department of Otorhinolaryngology, Osaka City University Hospital
- 137 Department of Otorhinolaryngology, Osaka City General Hospital
- 138 Department of Otorhinolaryngology, Japanese Red Cross Osaka Hospital
- 139 Department of Oral Surgery, Osaka University Hospital
- 140 Department of Oral and Maxillofacial Surgery 2, Osaka University Dental Hospital
- 141 Department of Otorhinolaryngology, Osaka Saiseikai Nakatsu Hospital
- 142 Department of Otorhinolaryngology, Yodogawa Christian Hospital
- 143 Department of Otorhinolaryngology, Osaka International Cancer Center
- 144 Department of Otorhinolaryngology, Kansai Rosai Hospital

List of 196 Institutions which participate in the Registry in 2021

- 145 Department of Oral Surgery and Otorhinolaryngology, Wakayama Medical University Hospital
- 146 Department of Otorhinolaryngology, Japanese Red Cross Wakayama Medical Center
- 147 Department of Otorhinolaryngology, Kobe City Medical Center General Hospital
- 148 Department of Otorhinolaryngology, Kobe University Hospital
- 149 Department of Oral Surgery, Kobe University Hospital
- 150 Department of Otorhinolaryngology, Hyogo College of Medicine
- 151 Department of Otorhinolaryngology, Hyogo Cancer Center
- 152 Department of Otorhinolaryngology, Hyogo Prefectural Amagasaki General Medical Center
- 153 Department of Otorhinolaryngology, Okayama University Hospital
- 154 Department of Otorhinolaryngology, Himeji Red Cross Hospital
- 155 Department of Otorhinolaryngology, Tottori University Hospital
- 156 Department of Otorhinolaryngology, Kawasaki Medical School Hospital
- 157 Department of Otorhinolaryngology, Kurashiki Central Hospital
- 158 Department of Dental, Kurashiki Central Hospital
- 159 Department of Otorhinolaryngology, Shimane University Hospital
- 160 Department of Otorhinolaryngology and Head and Neck Surgery, Matsue Red Cross Hospital
- 161 Department of Otorhinolaryngology, Fukuyama City Hospital
- 162 Department of Otorhinolaryngology, Hiroshima City Hiroshima Citizens Hospital
- 163 Department of Otorhinolaryngology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital
- 164 Department of Otorhinolaryngology, Hiroshima University Hospital
- 165 Department of Oral Oncology, Hiroshima University Hospital
- 166 Department of Otorhinolaryngology, Yamaguchi University Hospital
- 167 Department of Otorhinolaryngology, Yamaguchi Prefectural General Medical Center
- 168 Department of Otorhinolaryngology, Ehime Prefectural Central Hospital
- 169 Department of Otorhinolaryngology, Ehime University Hospital
- 170 Department of Head and Neck Surgery, Shikoku Cancer Center
- 171 Department of Otorhinolaryngology, Kochi Medical Center
- 172 Department of Otorhinolaryngology, Kochi Medical School Hospital
- 173 Department of Otorhinolaryngology, Kagawa University Hospital
- 174 Department of Oral Surgery, Tokushima University Hospital
- 175 Department of Otorhinolaryngology, Tokushima University Hospital
- 176 Department of Otorhinolaryngology, University of Occupational and Environmental Health
- 177 Department of Otorhinolaryngology, Kitakushu General Hospital
- 178 Department of Head and Neck Surgery, Kyushu Cancer Center
- 179 Department of Otorhinolaryngology, Kyushu University Hospital
- 180 Department of Otorhinolaryngology, Kyushu Medical Center
- 181 Department of Otorhinolaryngology, Hamanomachi Hospital

List of 196 Institutions which participate in the Registry in 2021

- 182 Department of Oral Surgery, Fukuoka University
- 183 Department of Oral Surgery, Fukuoka Dental University
- 184 Department of Otorhinolaryngology, Kurume University Hospital
- 185 Department of Otorhinolaryngology, Saga University Hospital
- 186 Department of Otorhinolaryngology, Sasebo City General Hospital
- 187 Department of Otorhinolaryngology, Nagasaki Medical Center
- 188 Department of Otorhinolaryngology, Nagasaki University Hospital
- 189 Department of Otorhinolaryngology, Kumamoto University Hospital
- 190 Department of Otorhinolaryngology, Miyazaki Prefectural Miyazaki Hospital
- 191 Department of Otorhinolaryngology, Kagoshima Medical Center
- 192 Department of Otorhinolaryngology, Kagoshima City Hospital
- 193 Department of Otorhinolaryngology, Kagoshima University Medical and Dental Hospital
- 194 Department of Otorhinolaryngology, Imakiire General Hospital
- 195 Department of Otorhinolaryngology, Okinawa Prefectural Chubu Hospital
- 196 Department of Otorhinolaryngology, Ryukyu University Hospital

Total Cases (2021)

13802 Cases

## Primary Site

<b>Site</b>	<b>Number of patients</b>	<b>(%)</b>
1) Oral cavity	3762	(27.3)
2) Larynx	2234	(16.2)
3) Hypopharynx	3095	(22.4)
4) Oropharynx	2439	(17.7)
5) Nasopharynx	401	(2.9)
6) Nasal cavity, etc	453	(3.3)
7) Maxillary sinus	463	(3.4)
8) Major salivary glands	788	(5.7)
9) Unknown primary	167	(1.2)
Total	13802	(100.0)

Nasal cavity, etc.: nasal cavity and paranasal sinuses (excluding the maxillary sinus).

## Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	2	4	6
10 - 19	19	8	27
20 - 29	55	55	110
30 - 39	163	122	285
40 - 49	554	304	858
50 - 59	1498	477	1975
60 - 69	2955	581	3536
70 - 79	4044	889	4933
80 - 89	1325	536	1861
90 - 99	113	94	207
100 - 109	1	3	4
Total	10729	3073	13802

# Histological Distribution by Primary Site

Histologic type	(1) Oral cavity	(2) Larynx	(3) Hypopharynx	(4) Oropharynx	(5) Nasopharynx	(6) Nasal cavity, etc	(7) Maxillary sinus	(8) Major salivary glands	(9) Unknown primary	Total
S.C.C., NOS	3208	2018	2781	2128	256	156	349	65	160	11121
S.C.C. in situ, NOS	93	75	157	65	1	7	2	0	0	400
S.C.C., keratinizing, NOS	176	67	60	53	8	14	12	3	4	397
Adenoid cystic ca.	39	2	1	12	8	24	25	115	0	226
Mucoepidermoid ca.	36	0	2	11	0	3	3	123	0	178
Salivary duct ca.	3	0	0	2	1	2	2	164	0	174
Ca., NOS	12	8	6	11	17	16	12	43	0	125
Malig. melanoma, NOS	14	1	0	2	0	85	9	1	0	112
S.C.C., large cell, nonkerat., NOS	5	4	25	19	41	4	3	0	0	101
Adenocarcinoma, NOS	10	1	1	5	7	27	2	46	0	99
Ca. ex pleomorphic adenoma	3	0	0	1	0	1	1	77	0	83
Olfactory neuroblastoma	0	0	0	0	0	53	0	0	0	53
Malig. lymphoma, NOS	8	1	0	12	1	1	3	21	0	47
Lymphoepithelial ca.	0	1	2	1	28	2	0	9	0	43
Acinar cell ca.	3	0	0	1	0	4	0	34	0	42
Verrucous ca., NOS	36	1	1	1	0	1	1	0	0	41
S.C.C., HPV positive	0	1	0	37	0	0	0	0	0	38
S.C.C., small cell, nonkerat.	4	1	3	3	18	3	0	0	1	33
S.C.C., spindle cell	12	6	4	3	0	1	5	0	0	31
Papillary S.C.C.	10	4	4	5	2	2	4	0	0	31
S.C.C., microinvasive	9	2	13	6	0	0	0	0	0	30
Ca., undiff., NOS	1	1	1	3	6	7	5	5	0	29
Neoplasm, malig.	10	4	0	1	1	5	2	4	1	28
Basaloid S.C.C.	6	3	7	6	0	0	0	0	1	23
S.C.C., HPV negative	1	1	1	20	0	0	0	0	0	23
Epithelial-myoepithelial ca.	5	1	0	1	0	0	0	16	0	23
Small cell ca., NOS	1	4	1	5	0	6	4	2	0	23
Myoepithelial ca.	4	1	0	1	0	1	1	13	0	21
Spindle cell ca., NOS	4	4	6	2	1	0	3	0	0	20
Carcinosarcoma, NOS	3	3	1	1	1	2	2	3	0	16
Adenosquamous ca.	4	4	1	1	1	2	1	0	0	14
Rhabdomyosarcoma, NOS	5	0	1	0	0	6	0	0	0	12
Basal cell adenocarcinoma	0	0	1	0	0	0	0	0	0	12
Malig. lymphoma, large B-cell, diffuse, NOS	1	0	0	4	1	3	1	1	0	11
Clear cell ca., NOS	4	0	1	3	1	1	0	0	0	10
S.C.C. in situ with quest. stromal invasion	3	2	5	0	0	0	0	0	0	10
Intraepithelial, NOS	3	2	0	3	0	0	0	0	0	8
Chondrosarcoma, NOS	3	2	0	0	0	1	1	0	0	7
Neuroendocrine ca., NOS	0	0	2	1	0	3	1	0	0	7
Secretory ca. of breast	1	0	0	0	0	0	0	6	0	7
Mucinous adenocarcinoma	1	0	0	0	0	0	0	5	0	6
Osteosarcoma, NOS	3	0	0	0	0	1	2	0	0	6
Polymorphous low grade adenocarcinoma	2	0	0	2	0	0	0	2	0	6
Transitional cell ca., NOS	2	1	2	0	0	0	0	0	0	5
S.C.C. with horn formation	4	0	1	0	0	0	0	0	0	5
Large cell ca., NOS	1	0	0	0	0	0	1	0	2	4
S.C.C., nonkerat.	0	2	2	0	0	0	0	0	0	4
Plasmacytoma, NOS	0	0	0	1	0	1	0	1	0	3
Oncocytic ca.	0	0	0	0	0	0	0	3	0	3
Carcinoid tumor, NOS	0	2	0	1	0	0	0	0	0	3
Cystadenocarcinoma	0	0	0	0	0	0	0	3	0	3
Sebaceous ca.	0	0	0	0	0	0	1	0	1	2
Plasmacytoma, extramedullary	0	0	0	1	1	0	0	0	0	2
Fibrosarcoma, NOS	0	0	0	0	0	0	0	2	0	2
Hemangiosarcoma	0	0	0	0	0	0	1	1	0	2
Intraductal ca., noninfiltrating, NOS	0	0	0	0	0	0	0	2	0	2
Lipoma-like liposarcoma	2	0	0	0	0	0	0	0	0	2
Alveolar rhabdomyosarcoma	0	0	0	0	0	0	2	0	0	2
Nuclear protein in testis (NUT)-associated ca.	0	0	0	0	0	0	1	1	0	2
S.C.C., keratinizing	1	1	0	0	0	0	0	0	0	2
Leiomyosarcoma, NOS	0	1	0	0	0	0	0	1	0	2
Chondrosarcoma	0	0	0	0	0	1	0	0	0	1
Papillary S.C.C., non-invasive	0	1	0	0	0	0	0	0	0	1
Mammary Analogue Secretory Ca.	0	1	0	0	0	0	0	0	0	1
Mixed tumor, malig., NOS	0	0	0	0	0	1	0	0	0	1
Schneiderian ca.	0	0	0	0	0	0	1	0	0	1
Spindle cell rhabdomyosarcoma	1	0	0	0	0	0	0	0	0	1
Synovial sarcoma, biphasic	0	0	1	0	0	0	0	0	0	1
Synovial sarcoma	1	0	0	0	0	0	0	0	0	1
Extraskeletal Ewing's sarcoma	1	0	0	0	0	0	0	0	0	1
Plasmablastic lymphoma	0	0	0	0	0	0	0	1	0	1
Liposarcoma, NOS	0	0	1	0	0	0	0	0	0	1
Malig. peripheral nerve sheath tumor	1	0	0	0	0	0	0	0	0	1
Marginal zone B-cell lymphoma, NOS	0	0	0	1	0	0	0	0	0	1
Malig. peripheral nerve sheath tumor, epithelioid	0	0	0	0	0	0	0	1	0	1
Odontogenic tumor, malig.	1	0	0	0	0	0	0	0	0	1
Follicular lymphoma, NOS	0	0	0	1	0	0	0	0	0	1
Giant cell sarcoma	0	0	0	0	0	0	0	1	0	1
Undiff. sarcoma	0	0	0	1	0	0	0	0	0	1
S.C.C., adenoid	1	0	0	0	0	0	0	0	0	1
Intraductal papillary adenocarcinoma with invasion	0	0	0	0	0	0	0	1	0	1
S.C.C. in situ, p16 positive	0	0	0	1	0	0	0	0	0	1
Infiltrating duct mixed with other types of ca.	0	0	0	0	0	0	0	1	0	1
Secretory ca.	0	0	0	0	0	0	0	1	0	1
Basal cell ca., NOS	0	0	0	0	0	0	0	1	0	1
Undiff. pleomorphic sarcoma	0	0	0	0	0	0	1	0	0	1
Total	3762	2234	3095	2439	401	453	463	788	167	13802

Nasal cavity, etc.: nasal cavity and paranasal sinuses (excluding the maxillary sinus).

ca., Ca.: carcinoma.

NOS: not otherwise specified.

malig., Malig.: malignant.

undiff.: undifferentiated.

kerat.: keratinizing.

quest.: questionable.

nonkerat.: nonkeratinizing.

## Histological Distribution by Primary Site (Male)

Histologic type	(1) Oral cavity	(2) Larynx	(3) Hypopharynx	(4) Oropharynx	(5) Nasopharynx	(6) Nasal cavity, etc	(7) Maxillary sinus	(8) Major salivary glands	(9) Unknown primary	Total
S.C.C., NOS	2011	1850	2542	1721	210	107	266	48	123	8878
S.C.C. in situ, NOS	51	66	146	58	1	7	2	0	0	331
S.C.C., keratinizing, NOS	112	60	50	48	6	6	11	3	3	299
Salivary duct ca.	2	0	0	2	1	2	2	131	0	140
Adenoid cystic ca.	17	2	1	5	5	15	14	46	0	105
Ca., NOS	9	6	6	9	14	11	8	34	0	97
Mucoepidermoid ca.	17	0	1	6	0	3	3	58	0	88
S.C.C., large cell, nonkerat., NOS	2	4	21	18	31	2	3	0	0	81
Adenocarcinoma, NOS	9	1	1	3	5	16	2	28	0	65
Malig. melanoma, NOS	8	1	0	1	0	45	7	1	0	63
Ca. ex pleomorphic adenoma	2	0	0	0	0	0	0	54	0	56
Olfactory neuroblastoma	0	0	0	0	0	33	0	0	0	33
Lymphoepithelial ca.	0	1	1	1	22	2	0	4	0	31
S.C.C., HPV positive	0	0	0	28	0	0	0	0	0	28
S.C.C., microinvasive	7	2	12	6	0	0	0	0	0	27
S.C.C., small cell, nonkerat.	4	1	3	2	13	1	0	0	1	25
Malig. lymphoma, NOS	4	0	0	6	0	1	2	11	0	24
Verrucous ca., NOS	19	1	1	0	0	1	1	0	0	23
S.C.C., spindle cell	9	5	3	1	0	1	4	0	0	23
Basaloid S.C.C.	5	3	7	6	0	0	0	0	1	22
Papillary S.C.C.	4	4	3	4	1	2	4	0	0	22
S.C.C., HPV negative	1	0	1	18	0	0	0	0	0	20
Neoplasm, malig.	7	3	0	1	1	4	1	3	0	20
Ca., undifferentiated, NOS	1	1	1	1	5	4	3	3	0	19
Acinar cell ca.	0	0	0	1	0	3	0	14	0	18
Small cell ca., NOS	1	4	1	4	0	4	2	2	0	18
Epithelial-myoepithelial ca.	3	1	0	0	0	0	0	13	0	17
Spindle cell ca., NOS	1	4	6	1	1	0	2	0	0	15
Myoepithelial ca.	3	0	0	0	0	1	0	8	0	12
Adenosquamous ca.	3	4	1	1	0	2	1	0	0	12
Carcinosarcoma, NOS	1	2	0	1	1	2	1	3	0	11
S.C.C. in situ with quest. stromal invasion	3	2	5	0	0	0	0	0	0	10
Intraepithelial, NOS	3	2	0	2	0	0	0	0	0	7
Clear cell ca., NOS	2	0	0	2	1	1	0	0	0	6
Neuroendocrine ca., NOS	0	0	2	1	0	2	1	0	0	6
Malig. lymphoma, large B-cell, diffuse, NOS	0	0	0	2	0	3	0	1	0	6
Mucinous adenocarcinoma	0	0	0	0	0	0	0	5	0	5
Chondrosarcoma, NOS	2	2	0	0	0	0	1	0	0	5
Rhabdomyosarcoma, NOS	1	0	1	0	0	2	0	0	0	4
Osteosarcoma, NOS	2	0	0	0	0	0	2	0	0	4
Basal cell adenocarcinoma	0	0	1	0	0	0	0	3	0	4
S.C.C. with horn formation	3	0	1	0	0	0	0	0	0	4
Secretory ca. of breast	1	0	0	0	0	0	0	3	0	4
Plasmacytoma, NOS	0	0	0	1	0	1	0	1	0	3
Transitional cell ca., NOS	1	1	1	0	0	0	0	0	0	3
Carcinoid tumor, NOS	0	2	0	1	0	0	0	0	0	3
Oncocytic ca.	0	0	0	0	0	0	0	2	0	2
Polymorphous low grade adenocarcinoma	1	0	0	1	0	0	0	0	0	2
Intraductal ca., noninfiltrating, NOS	0	0	0	0	0	0	0	2	0	2
S.C.C., nonkerat.	0	0	2	0	0	0	0	0	0	2
S.C.C., keratinizing	1	1	0	0	0	0	0	0	0	2
Leiomyosarcoma, NOS	0	1	0	0	0	0	0	1	0	2
Large cell ca., NOS	0	0	0	0	0	0	0	1	0	1
Sebaceous ca.	0	0	0	0	0	0	0	1	0	1
Plasmacytoma, extramedullary	0	0	0	1	0	0	0	0	0	1
Papillary S.C.C., non-invasive	0	1	0	0	0	0	0	0	0	1
Mammary Analogue Secretory Ca.	0	1	0	0	0	0	0	0	0	1
Fibrosarcoma, NOS	0	0	0	0	0	0	1	0	0	1
Hemangiosarcoma	0	0	0	0	0	0	1	0	0	1
Lipoma-like liposarcoma Sclerosing liposarcoma Inflammatory liposarcoma	1	0	0	0	0	0	0	0	0	1
Schneiderian ca.	0	0	0	0	0	1	0	0	0	1
Spindle cell rhabdomyosarcoma	1	0	0	0	0	0	0	0	0	1
Alveolar rhabdomyosarcoma	0	0	0	0	0	1	0	0	0	1
Synovial sarcoma, biphasic	0	0	1	0	0	0	0	0	0	1
Synovial sarcoma	1	0	0	0	0	0	0	0	0	1
Extraskeletal Ewing's sarcoma	1	0	0	0	0	0	0	0	0	1
Undifferentiated sarcoma	0	0	0	1	0	0	0	0	0	1
S.C.C., adenoid	1	0	0	0	0	0	0	0	0	1
Intraductal papillary adenocarcinoma with invasion	0	0	0	0	0	0	0	1	0	1
S.C.C. in situ, p16 positive	0	0	0	1	0	0	0	0	0	1
Secretory ca.	0	0	0	0	0	0	0	1	0	1
Undifferentiated pleomorphic sarcoma	0	0	0	0	0	0	1	0	0	1
Total	2338	2039	2822	1966	318	287	345	486	128	10729

Nasal cavity, etc.: nasal cavity and paranasal sinuses (excluding the maxillary sinus).

NOS: not otherwise specified.

S.C.C.: squamous cell carcinoma.

undiff.: undifferentiated.

quest.: questionable.

nonkerat.: nonkeratinizing.

ca., Ca.: carcinoma.

malig., Malig.: malignant.

kerat.: keratinizing.

## Histological Distribution by Primary Site (Female)

Histologic type	(1) Oral cavity	(2) Larynx	(3) Hypopharynx	(4) Oropharynx	(5) Nasopharynx	(6) Nasal cavity, etc.	(7) Maxillary sinus	(8) Major salivary glands	(9) Unknown primary	Total
S.C.C., NOS	1197	168	239	407	46	49	83	17	37	2243
Adenoid cystic ca.	22	0	0	7	3	9	11	69	0	121
S.C.C., keratinizing, NOS	64	7	10	5	2	8	1	0	1	98
Mucopidermoid ca.	19	0	1	5	0	0	0	65	0	90
S.C.C. in situ, NOS	42	9	11	7	0	0	0	0	0	69
Malig. melanoma, NOS	6	0	0	1	0	40	2	0	0	49
Salivary duct ca.	1	0	0	0	0	0	0	33	0	34
Adenocarcinoma, NOS	1	0	0	2	2	11	0	18	0	34
Ca., NOS	3	2	0	2	3	5	4	9	0	28
Ca. ex pleomorphic adenoma	1	0	0	1	0	1	1	23	0	27
Acina cell ca.	3	0	0	0	0	0	1	20	0	24
Malig. lymphoma, NOS	4	1	0	6	1	0	1	10	0	23
Olfactory neuroblastoma	0	0	0	0	0	20	0	0	0	20
S.C.C., large cell, nonkerat., NOS	3	0	4	1	10	2	0	0	0	20
Verrucous ca., NOS	17	0	0	1	0	0	0	0	0	18
Lymphoepithelial ca.	0	0	1	0	6	0	0	5	0	12
Ca., undifferentiated, NOS	0	0	0	2	1	3	2	2	0	10
S.C.C., HPV positive	0	1	0	9	0	0	0	0	0	10
Myoepithelial ca.	1	1	0	1	0	0	0	1	5	9
Papillary S.C.C.	6	0	1	1	1	0	0	0	0	9
Rhabdomyosarcoma, NOS	4	0	0	0	0	4	0	0	0	8
S.C.C., spindle cell	3	1	1	2	0	0	1	0	0	8
Neoplasm, malig.	3	1	0	0	0	1	1	1	1	8
S.C.C., small cell, nonkerat.	0	0	0	1	5	2	0	0	0	8
Basal cell adenocarcinoma	0	0	0	0	0	0	0	8	0	8
Epithelial-myoepithelial ca.	2	0	0	1	0	0	0	3	0	6
Spindle cell ca., NOS	3	0	0	1	0	0	1	0	0	5
Carcinosarcoma, NOS	2	1	1	0	0	0	1	0	0	5
Small cell ca., NOS	0	0	0	1	0	2	2	0	0	5
Malig. lymphoma, large B-cell, diffuse, NOS	1	0	0	2	1	0	1	0	0	5
Polymorphous low grade adenocarcinoma	1	0	0	1	0	0	0	2	0	4
Clear cell ca., NOS	2	0	1	1	0	0	0	0	0	4
Large cell ca., NOS	1	0	0	0	0	1	0	1	0	3
S.C.C., HPV negative	0	1	0	2	0	0	0	0	0	3
S.C.C., microinvasive	2	0	1	0	0	0	0	0	0	3
Secretory ca. of breast	0	0	0	0	0	0	0	3	0	3
Cystadenocarcinoma	0	0	0	0	0	0	0	3	0	3
Adenosquamous ca.	1	0	0	0	0	1	0	0	0	2
Osteosarcoma, NOS	1	0	0	0	0	1	0	0	0	2
Transitional cell ca., NOS	1	0	1	0	0	0	0	0	0	2
Chondrosarcoma, NOS	1	0	0	0	0	0	1	0	0	2
S.C.C., nonkerat.	0	2	0	0	0	0	0	0	0	2
Nuclear protein in testis (NUT)-associated ca.	0	0	0	0	0	1	1	0	0	2
Basaloid S.C.C.	1	0	0	0	0	0	0	0	0	1
Mucinous adenocarcinoma	1	0	0	0	0	0	0	0	0	1
Intraepithelial, NOS	0	0	0	1	0	0	0	0	0	1
Sebaceous ca.	0	0	0	0	0	1	0	0	0	1
Plasmacytoma, extramedullary	0	0	0	0	0	1	0	0	0	1
Chondrosarcoma	0	0	0	0	0	0	1	0	0	1
Oncocytic ca.	0	0	0	0	0	0	0	1	0	1
Fibrosarcoma, NOS	0	0	0	0	0	0	1	0	0	1
Mixed tumor, malig., NOS	0	0	0	0	0	0	1	0	0	1
Hemangiosarcoma	0	0	0	0	0	0	0	1	0	1
Lipoma-like liposarcoma Sclerosing liposarcoma Inflammatory liposarcoma	1	0	0	0	0	0	0	0	0	1
Neuroendocrine ca., NOS	0	0	0	0	0	1	0	0	0	1
Alveolar rhabdomyosarcoma	0	0	0	0	0	1	0	0	0	1
S.C.C. with horn formation	1	0	0	0	0	0	0	0	0	1
Plasmablastic lymphoma	0	0	0	0	0	0	1	0	0	1
Liposarcoma, NOS	0	0	1	0	0	0	0	0	0	1
Malig. peripheral nerve sheath tumor	1	0	0	0	0	0	0	0	0	1
Marginal zone B-cell lymphoma, NOS	0	0	0	1	0	0	0	0	0	1
Malig. peripheral nerve sheath tumor, epithelioid	0	0	0	0	0	0	0	1	0	1
Odontogenic tumor, malig.	1	0	0	0	0	0	0	0	0	1
Follicular lymphoma, NOS	0	0	0	1	0	0	0	0	0	1
Giant cell sarcoma	0	0	0	0	0	0	0	1	0	1
Infiltrating duct mixed with other types of ca.	0	0	0	0	0	0	0	1	0	1
Basal cell ca., NOS	0	0	0	0	0	0	0	1	0	1
<b>Total</b>	<b>1424</b>	<b>195</b>	<b>273</b>	<b>473</b>	<b>83</b>	<b>166</b>	<b>118</b>	<b>302</b>	<b>39</b>	<b>3073</b>

Nasal cavity, etc.: nasal cavity and paranasal sinuses (excluding the maxillary sinus).

NOS: not otherwise specified.

S.C.C.: squamous cell carcinoma.

undiff.: undifferentiated.

quest.: questionable.

nonkerat.: nonkeratinizing.

ca., Ca.: carcinoma.

malig., Malig.: malignant.

kerat.: keratinizing.

Head and Neck Cancer ----- 13802 Cases

**T and N Status**

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	16	47	16	4	22	8	5	1	62	7	1	189
T1	1868	270	36	8	65	17	28	0	54	25	1	2372
T1a	459	0	0	0	0	2	0	0	1	4	0	466
T1b	167	1	0	0	0	0	0	0	0	2	0	170
T2	2307	728	113	30	405	127	45	5	142	23	1	3926
T3	1254	407	92	16	431	221	27	1	138	7	2	2596
T4	95	138	131	0	14	11	35	0	10	3	1	438
T4a	930	294	8	18	578	326	5	6	233	6	2	2406
T4b	205	39	3	4	73	55	2	0	48	1	0	430
Tis	505	2	0	0	2	0	0	1	1	9	0	520
TX	52	7	0	1	3	0	1	1	4	95	3	167
T-	8	2	0	0	1	1	0	0	1	1	108	122
<b>Total</b>	<b>7866</b>	<b>1935</b>	<b>399</b>	<b>81</b>	<b>1594</b>	<b>768</b>	<b>148</b>	<b>15</b>	<b>694</b>	<b>183</b>	<b>119</b>	<b>13802</b>

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

**T and N Status (M0 Cases)**

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	15	46	16	4	19	5	4	1	57	4	0	171
T1	1857	265	35	8	62	15	24	0	48	16	0	2330
T1a	459	0	0	0	0	1	0	0	1	3	0	464
T1b	166	1	0	0	0	0	0	0	0	1	0	168
T2	2289	718	103	30	389	113	42	5	132	17	1	3839
T3	1232	393	82	15	402	201	24	1	116	4	1	2471
T4	89	130	107	0	12	9	28	0	9	2	1	387
T4a	897	281	6	16	545	285	5	4	201	0	1	2241
T4b	191	36	3	4	66	40	2	0	35	0	0	377
Tis	504	2	0	0	2	0	0	0	1	4	0	513
TX	52	7	0	1	3	0	1	1	2	15	0	82
T-	8	2	0	0	1	1	0	0	0	0	3	15
<b>Total</b>	<b>7759</b>	<b>1881</b>	<b>352</b>	<b>78</b>	<b>1501</b>	<b>670</b>	<b>130</b>	<b>12</b>	<b>602</b>	<b>66</b>	<b>7</b>	<b>13058</b>

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

Head and Neck Cancer ----- 13802 Cases

**T and N Status (M1 Cases)**

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	1	1	0	0	3	3	1	0	5	0	0	14
T1	6	2	1	0	2	2	4	0	6	0	0	23
T1a	0	0	0	0	0	1	0	0	0	0	0	1
T1b	0	0	0	0	0	0	0	0	0	0	0	0
T2	7	8	9	0	14	12	3	0	10	0	0	63
T3	16	13	10	1	23	18	3	0	21	1	0	106
T4	4	6	24	0	2	1	7	0	0	0	0	44
T4a	26	10	1	0	29	39	0	2	30	2	0	139
T4b	14	3	0	0	6	11	0	0	13	0	0	47
Tis	0	0	0	0	0	0	0	1	0	0	0	1
TX	0	0	0	0	0	0	0	0	1	2	0	3
T-	0	0	0	0	0	0	0	0	1	0	0	1
<b>Total</b>	<b>74</b>	<b>43</b>	<b>45</b>	<b>1</b>	<b>79</b>	<b>87</b>	<b>18</b>	<b>3</b>	<b>87</b>	<b>5</b>	<b>0</b>	<b>442</b>

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

**T and N Status (MX & M- Cases)**

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	0	0	0	0	0	0	0	0	0	3	1	4
T1	5	3	0	0	1	0	0	0	0	9	1	19
T1a	0	0	0	0	0	0	0	0	0	1	0	1
T1b	1	0	0	0	0	0	0	0	0	1	0	2
T2	11	2	1	0	2	2	0	0	0	6	0	24
T3	6	1	0	0	6	2	0	0	1	2	1	19
T4	2	2	0	0	0	1	0	0	1	1	0	7
T4a	7	3	1	2	4	2	0	0	2	4	1	26
T4b	0	0	0	0	1	4	0	0	0	1	0	6
Tis	1	0	0	0	0	0	0	0	0	5	0	6
TX	0	0	0	0	0	0	0	0	1	78	3	82
T-	0	0	0	0	0	0	0	0	0	1	105	106
<b>Total</b>	<b>33</b>	<b>11</b>	<b>2</b>	<b>2</b>	<b>14</b>	<b>11</b>	<b>0</b>	<b>0</b>	<b>5</b>	<b>112</b>	<b>112</b>	<b>302</b>

M-:without reported M classification.

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

Head and Neck Cancer ----- 13802 Cases

**Treatment Method for the Primary Lesion by Primary Site**

Treatment Method	(1) Oral cavity	(2) Larynx	(3) Hypopharynx	(4) Oropharynx	(5) Nasopharynx	(6) Nasal cavity, etc	(7) Maxillary sinus	(8) Major salivary glands	(9) Unknown primary	Total
Surgery										
without	446	1315	1544	1460	382	232	316	112	147	5954
with	3233	893	1526	939	16	218	141	658	20	7644
unknown	83	26	25	40	3	3	6	18	0	204
Radiotherapy										
without	2931	772	1397	890	36	139	106	407	109	6787
with	748	1436	1673	1509	362	311	351	363	58	6811
unknown	83	26	25	40	3	3	6	18	0	204
Chemotherapy										
without	2942	1601	1626	1038	66	272	160	636	115	8456
with	737	607	1444	1361	332	178	297	134	52	5142
unknown	83	26	25	40	3	3	6	18	0	204
Total	3762	2234	3095	2439	401	453	463	788	167	13802

Nasal cavity, etc. : nasal cavity and paranasal sinuses (excluding the maxillary sinus).

## Treatment Method for the Cervical Lymph Nodes by Primary Site

Treatment Method	(1) Oral cavity	(2) Larynx	(3) Hypopharynx	(4) Oropharynx	(5) Nasopharynx	(6) Nasal cavity, etc	(7) Maxillary sinus	(8) Major salivary glands	(9) Unknown primary	Total
Surgery										
without	2006	1748	2146	1824	383	414	378	361	66	9326
with	1672	452	921	573	15	34	78	408	101	4254
unknown	84	34	28	41	3	3	7	19	0	219
Radiotherapy										
without	3044	1698	1635	1066	81	388	310	511	62	8795
with	634	502	1432	1331	317	60	146	258	105	4785
unknown	84	34	28	41	3	3	7	19	0	219
Chemotherapy										
without	3048	1823	1760	1175	95	379	312	656	80	9328
with	630	377	1307	1222	303	69	144	113	87	4252
unknown	84	34	28	41	3	3	7	19	0	219
Total	3762	2234	3095	2438	401	451	463	788	167	13799

Treatment Method for the Cervical Lymph Nodes by Primary Site was not reported in 3 patients

Nasal cavity, etc. : nasal cavity and paranasal sinuses (excluding the maxillary sinus).

# Sequence of Treatment Methods for the Primary Lesion by Primary Site

Sequence of treatment methods	(1) Oral cavity	(2) Larynx	(3) Hypopharynx	(4) Oropharynx	(5) Nasopharynx	(6) Nasal cavity, etc	(7) Maxillary sinus	(8) Major salivary glands	(9) Unknown primary	Total
Unknown	83	26	25	40	3	3	6	18	0	204
No treatment	102	48	105	67	4	15	20	25	88	474
A) Surg. alone	2529	656	1055	650	8	86	42	337	6	5369
A)B) Surg.->Rad.	158	70	107	73	1	78	34	223	1	745
A)A) Surg.->Surg.	18	10	10	6	1	4	1	3	0	53
A)B)C) Surg.->Rad.->Chem.	4	0	6	1	0	5	2	8	0	26
A)C) Surg.-> Chem	37	5	15	11	0	7	2	13	0	90
A)F) Surg.->(Rad.+Chem.)	231	62	153	82	2	14	21	48	8	621
A)F)C) Surg.->(Rad.+Chem.)->Chem.	13	2	4	0	0	3	1	1	0	24
B) Rad. alone	109	799	330	235	51	79	54	35	15	1707
B)A) Rad.->Surg.	2	15	4	1	0	0	3	0	1	26
B)C) Rad.->Chem.	5	0	8	6	1	15	5	2	0	42
C) Chem. alone	85	18	117	86	20	17	23	27	8	401
C)A) Chem.->Surg.	116	22	60	51	1	3	7	0	0	260
C)A)B) Chem.->Surg.->Rad.	21	2	17	10	0	5	2	1	0	58
C)A)C) Chem.->Surg.->Chem.	12	0	4	6	0	0	1	0	0	23
C)A)F) Chem.->Surg.->(Rad.+Chem.)	32	4	34	13	0	2	2	0	0	87
C)B) Chem.->Rad.	12	6	27	27	6	6	6	2	1	93
C)C)Chem.->Chem.	7	5	8	6	1	3	1	0	1	32
C)C)C) Chem.->Chem.->Chem.	3	0	8	2	0	0	0	0	1	14
C)C)F) Chem.->Chem.->(Rad.+Chem.)	1	2	10	4	1	0	0	0	0	18
C)F) Chem. -> (Rad.+Chem.)	14	22	130	114	38	20	17	1	3	359
C)F)C) Chem.-> (Rad.+Chem.)->Chem.	6	3	9	9	1	0	2	1	0	31
D)(Surg.+Rad.)	8	0	5	4	0	2	0	3	1	23
E) (Surg.+Chem)	9	3	4	0	0	0	0	0	0	16
F)(Rad.+Chem.)	86	407	738	870	222	60	166	15	26	2590
F)A)(Rad.+Chem.)->Surg.	3	13	11	7	1	1	12	0	0	48
F)C)(Rad.+Chem.)->Chem.	2	6	27	21	30	5	13	2	0	106
G)Surg.+Rad.+Chem.	10	2	4	5	0	2	3	3	0	29
H)Nonspesific Immunotherapy	2	1	6	0	0	2	4	0	1	16
Other	42	25	54	32	9	16	13	20	6	217
Unknown	83	26	25	40	3	3	6	18	0	204
Total	3762	2234	3095	2439	401	453	463	788	167	13802

Nasal cavity, etc. : nasal cavity and paranasal sinuses (excluding the maxillary sinus).    Surg.: surgery.    Rad.: radiotherapy.    Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

Head and Neck Cancer ----- 13802 Cases

## Surgical Methods for the Primary Lesion by Primary Site

Surgical method	(1) Oral cavity	(2) Larynx	(3) Hypopharynx	(4) Oropharynx	(5) Nasopharynx	(6) Nasal cavity, etc	(7) Maxillary sinus	(8) Major salivary glands	(9) Unknown primary	Total
No surgery	437	1316	1545	1458	384	231	314	111	146	5942
Partial glossectomy	1222	0	0	3	0	0	0	0	0	1225
Total laryngectomy	0	469	21	4	0	0	0	0	1	495
Endoscopic resection	1	105	447	14	1	6	0	0	0	574
Total pharyngolaryngectomy	0	21	390	11	0	0	0	0	0	422
Unilateral resection of the lateral wall of the oropharynx	1	0	0	356	0	0	0	1	10	368
Transoral resection	4	237	316	43	1	0	0	0	0	601
Partial maxillectomy	240	0	0	1	0	26	27	0	0	294
Segmental mandibulectomy	262	0	0	2	0	0	0	5	0	269
Subtotal glossectomy	234	0	0	3	0	0	0	0	0	237
Total pharyngolaryngo-esophagectomy	0	8	226	1	0	0	0	0	0	235
Resection of the buccal mucosa	224	0	0	0	0	0	0	0	0	224
Marginal mandibulectomy	205	0	0	0	0	0	0	1	0	206
Resection of the floor of mouth	193	0	0	0	0	0	0	2	0	195
Hemiglossectomy	175	0	0	3	0	0	0	1	0	179
Resection of the oropharynx, other type	3	1	2	162	0	0	0	1	2	171
Superficial parotidectomy	0	0	0	0	0	0	0	159	0	159
Total parotidectomy	0	0	0	0	0	0	0	154	0	154
Submandibulectomy	0	0	0	0	0	0	0	154	0	154
Hemiglossectomy (anterior 2/3rds)	112	0	0	0	0	0	0	1	0	113
Total maxillectomy	32	0	0	0	0	2	71	0	0	105
Resection of oral cavity, NOS	91	0	0	3	0	0	0	0	0	94
Resection of the soft palate	6	0	0	79	0	1	0	0	0	86
Resection of the root of tongue	1	0	2	82	0	0	0	0	0	85
Maxillectomy, other type	8	0	0	0	0	59	16	0	0	83
Resection of the posterior wall	0	0	1	59	0	0	0	0	0	60
Extended total parotidectomy	0	0	0	0	0	0	0	59	0	59
Subtotal glossectomy (anterior 2/3rds)	55	0	0	0	0	0	0	0	0	55
Total glossectomy	44	1	0	10	0	0	0	0	0	55
Endoscopic skull base surgery	0	0	0	0	0	50	0	0	0	50
Partial parotidectomy	0	0	0	0	0	0	0	47	0	47
Partial hypopharyngectomy	0	0	36	1	0	0	0	0	0	37
Deep lobe resection of the parotid gland	0	0	0	0	0	0	0	37	0	37
Resection of lower gingiva	34	0	0	0	0	0	0	0	0	34
Hypopharyngectomy + Cervical esophagectomy	0	0	32	0	0	0	0	0	0	32
Resection of the uvula	0	0	0	30	0	0	0	0	1	31
Others	84	37	42	63	12	72	26	32	5	373
Unknown	94	39	35	51	3	6	9	23	2	262
Total	3762	2234	3095	2439	401	453	463	788	167	13802

Nasal cavity, etc.: nasal cavity and paranasal sinuses (excluding the maxillary sinus). NOS: not otherwise specified.

## Reconstructive Surgery by Primary Site

Reconstructive surgery	(1) Oral cavity	(2) Larynx	(3) Hypopharynx	(4) Oropharynx	(5) Nasopharynx	(6) Nasal cavity, etc	(7) Maxillary sinus	(8) Major salivary glands	(9) Unknown primary	Total
No reconstruction	2372	2105	2358	2188	396	371	370	594	159	10913
Free ALT flap	436	11	37	88	1	5	19	53	0	650
Free jejunal flap	1	31	590	16	0	0	0	0	0	638
Free RA MC flap	303	2	1	32	0	8	45	10	0	401
Unknown	103	41	37	55	3	6	9	26	1	281
Free FA flap	148	2	11	10	0	1	2	3	0	177
PM MC flap	62	26	22	24	0	0	1	15	5	155
Free fibular OC flap	121	0	0	2	0	0	4	2	0	129
Others	60	1	9	7	0	22	5	16	1	121
Skin graft	77	0	0	1	0	1	8	0	0	87
Local skin flap	40	3	2	7	1	10	0	12	1	76
Mucosal flap	21	2	0	5	0	28	0	0	0	56
Free nerve graft	1	0	0	0	0	0	0	55	0	56
Gastric pull-up	0	1	21	1	0	0	0	0	0	23
DP flap	5	8	7	1	0	0	0	1	0	22
Free scapular OC flap	12	1	0	2	0	1	0	1	0	17
Total	3762	2234	3095	2439	401	453	463	788	167	13802

Nasal cavity, etc.: nasal cavity and paranasal sinuses (excluding the maxillary sinus).

RA: rectus abdominis.

MC: musculocutaneous.

ALT: anterolateral thigh.

FA: forearm.

PM: pectoralis major.

OC: osteocutaneous.

DP: deltopectoral.

Head and Neck Cancer ----- 13802 Cases

## Neck Dissection on the Ipsilateral Side by Primary Site

Neck dissection	(1) Oral cavity	(2) Larynx	(3) Hypopharynx	(4) Oropharynx	(5) Nasopharynx	(6) Nasal cavity, etc	(7) Maxillary sinus	(8) Major salivary glands	(9) Unknown primary	Total
0) No N.D.	2001	1751	2144	1828	383	415	378	360	65	9325
1) Total N.D.	434	80	229	150	3	2	12	118	44	1072
2) Selective N.D.	1197	338	668	397	11	25	58	272	51	3017
3) Lymph node excision	11	3	0	8	0	0	3	10	4	39
8) Others	17	18	13	8	0	3	3	6	2	70
9) Unknown	102	44	41	48	4	8	9	22	1	279
Total	3762	2234	3095	2439	401	453	463	788	167	13802

Nasal cavity, etc. : nasal cavity and paranasal sinuses (excluding the maxillary sinus).

N.D.: neck dissection.

## Neck Dissection on the Contralateral Side by Primary Site

Neck dissection	(1) Oral cavity	(2) Larynx	(3) Hypopharynx	(4) Oropharynx	(5) Nasopharynx	(6) Nasal cavity, etc	(7) Maxillary sinus	(8) Major salivary glands	(9) Unknown primary	Total
0) No N.D.	3169	1933	2386	2283	396	435	442	741	154	11939
1) Total N.D.	65	25	102	20	0	1	1	3	5	222
2) Selective N.D.	401	215	550	79	1	5	7	13	6	1277
3) Lymph node excision	2	1	2	0	0	1	0	2	0	8
8) Others	21	15	15	9	0	3	4	6	1	74
9) Unknown	104	45	40	48	4	8	9	23	1	282
Total	3762	2234	3095	2439	401	453	463	788	167	13802

Nasal cavity, etc. : nasal cavity and paranasal sinuses (excluding the maxillary sinus). N.D.: neck dissection.

## Radiotherapy by Primary Site

Type of radiotherapy	(1) Oral cavity	(2) Larynx	(3) Hypopharynx	(4) Oropharynx	(5) Nasopharynx	(6) Nasal cavity, etc	(7) Maxillary sinus	(8) Major salivary glands	(9) Unknown primary	Total
0) No radiotherapy	2823	754	1352	865	36	138	96	381	58	6503
1) X-ray (and/or electron beam)	779	1437	1702	1499	355	229	335	346	108	6790
2) Particle beam	12	7	1	10	6	80	23	33	0	172
3) B.T.	19	0	0	3	0	0	0	0	0	22
4) X-ray + Particle beam	3	0	3	0	0	0	0	2	0	8
5) X-ray + B.T.	1	0	0	1	1	0	0	0	0	3
6) Particl beam + B.T.	0	0	0	0	0	0	0	0	0	0
7) X-ray + Particl beam + B.T.	0	0	0	0	0	0	0	0	0	0
8) Others	1	1	2	1	0	1	0	1	0	7
9) Unknown	124	35	35	60	3	5	9	25	1	297
Total	3762	2234	3095	2439	401	453	463	788	167	13802

Nasal cavity, etc. : nasal cavity and paranasal sinuses (excluding the maxillary sinus).

B.T.: brachytherapy.

Head and Neck Cancer ----- 13802 Cases

**Chemotherapy by Primary site**

Route of administration	(1) Oral cavity	(2) Larynx	(3) Hypopharynx	(4) Oropharynx	(5) Nasopharynx	(6) Nasal cavity, etc	(7) Maxillary sinus	(8) Major salivary glands	(9) Unknown primary	Total
0) No chemotherapy	2872	1592	1599	1027	65	274	155	625	76	8285
1) I.V.	624	547	1417	1300	325	161	141	134	86	4735
2) I.A.	45	4	11	28	5	10	147	2	1	253
3) Oral	86	49	28	24	2	1	3	5	2	200
4) I.V.+I.A.	12	0	1	2	0	1	6	0	0	22
5) I.V.+Oral	21	11	7	10	0	0	2	1	1	53
6) I.A.+Oral	3	0	0	1	0	1	1	0	0	6
7) I.V.+I.A.+Oral	2	0	0	0	0	0	0	0	0	2
8) Others	0	0	0	0	1	0	0	0	0	1
9) Unknown	97	31	32	47	3	5	8	21	1	245
Total	3762	2234	3095	2439	401	453	463	788	167	13802

Nasal cavity, etc. : nasal cavity and paranasal sinuses (excluding the maxillary sinus).

I.V.: intravenous.

I.A.: intraarterial.

Oral Cavity (2021)

3762 Cases

## Primary Site

<b>Site</b>	<b>Number of patients</b>	<b>(%)</b>
1) Lip	33	(0.9)
2) Buccal mucosa	276	(7.3)
3) Retro-molar area	71	(1.9)
4) Lower gingiva	583	(15.5)
5) Upper gingiva	338	(9.0)
6) Hard palate	126	(3.3)
7) Floor of mouth	308	(8.2)
8) Tongue	2017	(53.6)
9) Oral cavity, NOS	10	(0.3)
<b>Total</b>	<b>3762</b>	<b>(100.0)</b>

NOS: not otherwise specified

## Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	1	1	2
10 - 19	7	1	8
20 - 29	31	26	57
30 - 39	91	67	158
40 - 49	176	123	299
50 - 59	367	170	537
60 - 69	570	223	793
70 - 79	755	398	1153
80 - 89	307	352	659
90 - 99	32	60	92
100 - 109	1	3	4
<b>Total</b>	<b>2338</b>	<b>1424</b>	<b>3762</b>

### Carcinoma of the Lip Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	0	0	0
40 - 49	1	2	3
50 - 59	4	0	4
60 - 69	4	2	6
70 - 79	11	2	13
80 - 89	0	4	4
90 - 99	1	1	2
100 - 109	1	0	1
<b>Total</b>	<b>22</b>	<b>11</b>	<b>33</b>

### Carcinoma of the Buccal Mucosa Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	1	0	1
20 - 29	0	1	1
30 - 39	7	3	10
40 - 49	2	4	6
50 - 59	15	6	21
60 - 69	30	17	47
70 - 79	60	50	110
80 - 89	34	33	67
90 - 99	4	9	13
100 - 109	0	0	0
<b>Total</b>	<b>153</b>	<b>123</b>	<b>276</b>

Carcinoma of the Oral Cavity ----- 3762Cases

## Carcinoma of the Retromolar Area Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	1	0	1
40 - 49	3	0	3
50 - 59	6	0	6
60 - 69	18	5	23
70 - 79	25	4	29
80 - 89	6	2	8
90 - 99	0	1	1
100 - 109	0	0	0
<b>Total</b>	<b>59</b>	<b>12</b>	<b>71</b>

## Carcinoma of the Lower Gingiva Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	3	0	3
30 - 39	7	5	12
40 - 49	13	4	17
50 - 59	40	15	55
60 - 69	77	43	120
70 - 79	91	95	186
80 - 89	56	110	166
90 - 99	9	14	23
100 - 109	0	1	1
<b>Total</b>	<b>296</b>	<b>287</b>	<b>583</b>

### Carcinoma of the Upper Gingiva Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	1	1
30 - 39	1	0	1
40 - 49	6	2	8
50 - 59	17	8	25
60 - 69	35	21	56
70 - 79	74	56	130
80 - 89	33	64	97
90 - 99	6	13	19
100 - 109	0	1	1
<b>Total</b>	<b>172</b>	<b>166</b>	<b>338</b>

### Carcinoma of the Hard Palate Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	2	0	2
20 - 29	0	2	2
30 - 39	2	2	4
40 - 49	2	4	6
50 - 59	4	7	11
60 - 69	18	9	27
70 - 79	27	13	40
80 - 89	18	15	33
90 - 99	0	1	1
100 - 109	0	0	0
<b>Total</b>	<b>73</b>	<b>53</b>	<b>126</b>

## Carcinoma of the Floor of Mouth Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	2	2
30 - 39	1	0	1
40 - 49	17	10	27
50 - 59	46	15	61
60 - 69	67	8	75
70 - 79	97	12	109
80 - 89	21	10	31
90 - 99	0	2	2
100 - 109	0	0	0
<b>Total</b>	<b>249</b>	<b>59</b>	<b>308</b>

## Carcinoma of the Tongue Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	1	1	2
10 - 19	4	0	4
20 - 29	28	20	48
30 - 39	72	57	129
40 - 49	132	97	229
50 - 59	235	119	354
60 - 69	316	118	434
70 - 79	370	165	535
80 - 89	138	114	252
90 - 99	10	19	29
100 - 109	0	1	1
110 - 119	0	0	0
<b>Total</b>	<b>1306</b>	<b>711</b>	<b>2017</b>

## Carcinoma of the Oral Cavity, NOS Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	0	1	1
20 - 29	0	0	0
30 - 39	0	0	0
40 - 49	0	0	0
50 - 59	0	0	0
60 - 69	5	0	5
70 - 79	0	1	1
80 - 89	1	0	1
90 - 99	2	0	2
100 - 109	0	0	0
<b>Total</b>	<b>8</b>	<b>2</b>	<b>10</b>

NOS : Not Otherwise Specified

# Carcinoma of the Oral Cavity ----- 3762Cases

## Histological Distribution by Subsite

Histologic type	(1) Lip	(2) Buccal mucosa	(3) Retromolar area	(4) Lower gingiva	(5) Upper gingiva	(6) Hard palate	(7) Floor of mouth	(8) Tongue	(9) Oral cavity, NOS	Total
S.C.C., NOS	19	204	63	516	291	61	260	1789	5	3208
Ca., NOS	2	1	0	1	3	0	1	3	1	12
Salivary duct ca.	0	3	0	0	0	0	0	0	0	3
Malig. lymphoma, NOS	0	1	0	2	1	3	0	0	1	8
Large cell ca., NOS	0	0	0	0	0	0	1	0	0	1
Adenoid cystic ca.	3	5	0	1	2	18	8	2	0	39
Adenocarcinoma, NOS	0	2	1	0	2	4	1	0	0	10
S.C.C. in situ, NOS	1	10	0	5	3	4	6	64	0	93
Myoepithelial ca.	0	0	0	1	0	2	1	0	0	4
Mucoepidermoid ca.	2	8	3	4	2	10	2	3	2	36
Basaloid S.C.C.	1	1	0	0	0	0	2	2	0	6
Verrucous ca., NOS	2	6	1	6	3	0	1	17	0	36
Ca., undiff., NOS	0	0	0	0	0	1	0	0	0	1
Malig. melanoma, NOS	0	0	0	2	5	6	0	1	0	14
S.C.C., large cell, nonkerat., NOS	0	2	0	0	0	0	2	1	0	5
S.C.C., kerat., NOS	1	16	1	28	12	3	13	102	0	176
Mucinous adenocarcinoma	0	0	0	0	0	0	1	0	0	1
Intraepithelial, NOS	0	0	0	0	0	0	0	3	0	3
S.C.C., HPV negative	0	0	0	1	0	0	0	0	0	1
S.C.C., microinvasive	0	1	0	0	1	1	2	4	0	9
Rhabdomyosarcoma, NOS	0	3	0	1	1	0	0	0	0	5
Ca. ex pleomorphic adenoma	0	1	0	0	1	1	0	0	0	3
S.C.C., spindle cell	0	1	1	0	1	0	0	9	0	12
Epithelial-myoeplithelial ca.	1	0	0	0	1	3	0	0	0	5
Neoplasms, malig.	0	0	0	3	1	1	2	2	1	10
Papillary S.C.C.	0	0	1	4	1	1	0	3	0	10
Acinar cell ca.	0	2	0	0	0	0	0	1	0	3
Spindle cell ca., NOS	0	2	0	1	0	0	0	1	0	4
Carcinosarcoma, NOS	0	2	0	0	0	0	0	1	0	3
Adenosquamous ca.	0	0	0	0	0	0	1	0	0	4
Osteosarcoma, NOS	0	0	0	2	1	0	0	0	0	3
Transitional cell ca., NOS	0	1	0	0	0	0	1	0	0	2
S.C.C., small cell, nonkerat.	1	0	0	0	0	0	1	1	0	4
Small cell ca., NOS	0	0	0	0	1	0	0	0	0	1
Polymorphous low grade adenocarcinoma	0	0	0	1	0	1	0	0	0	2
Clear cell ca., NOS	0	0	0	1	1	2	0	0	0	4
Chondrosarcoma, NOS	0	0	0	1	1	1	0	0	0	3
Lipoma-like liposarcoma Sclerosing liposarcoma Inflammatory liposarcoma	0	1	0	0	0	1	0	0	0	2
S.C.C. in situ with questionable stromal invasion	0	0	0	0	0	0	0	3	0	3
Spindle cell rhabdomyosarcoma	0	1	0	0	0	0	0	0	0	1
S.C.C. with horn formation	0	1	0	1	0	0	1	1	0	4
Synovial sarcoma	0	0	0	0	0	0	1	0	0	1
Extraskeletal Ewing's sarcoma	0	0	0	1	0	0	0	0	0	1
S.C.C., kerat.	0	0	0	0	0	0	0	1	0	1
Malig. peripheral nerve sheath tumor	0	0	0	0	1	0	0	0	0	1
Malig. lymphoma, large B-cell, diffuse, NOS	0	0	0	0	1	0	0	0	0	1
Odontogenic tumor, malig.	0	0	0	0	1	0	0	0	0	1
Secretory ca. of breast	0	1	0	0	0	0	0	0	0	1
S.C.C., adenoid	0	0	0	0	0	0	1	0	0	1
Total	33	276	71	583	338	126	308	2017	10	3762

Nasal cavity, etc.: nasal cavity and paranasal sinuses (excluding the maxillary sinus).

NOS: not otherwise specified.

S.C.C.: squamous cell carcinoma.

undiff.: undifferentiated.

quest.: questionable.

nonkerat.: nonkeratinizing.

ca., Ca.: carcinoma.

malig., Malig.: malignant.

kerat.: keratinizing.

Carcinoma of the Oral Cavity ----- 3762Cases

T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	4(1)	0	0	0	0	0	0	0	0	0	0	4
T1	784(2)	19	0	1	7	2(1)	0	0	7	14	0	834
T2	837	99(1)	4	2	81(1)	16(2)	0	0	15	9	0	1063
T3	364(3)	109(2)	1	3	156(2)	55(1)	1	0	19(1)	2(1)	1	711
T4	8(1)	5	0	0	4	2	0	0	2	1	1	23
T4a	331(4)	122(3)	2	8	218(6)	101(6)	2	2	55(6)	2	1	844
T4b	42(1)	14	3	2	30(1)	9(3)	0	0	9(4)	0	0	109
Tis	98	0	0	0	0	0	0	0	0	4	0	102
TX	19	0	0	0	0	0	0	0	0	23	2	44
T-	0	0	0	0	0	1	0	0	0	0	27	28
<b>Total</b>	<b>2487(12)</b>	<b>368(6)</b>	<b>10</b>	<b>16</b>	<b>496(10)</b>	<b>86(13)</b>	<b>3</b>	<b>2</b>	<b>07(11)</b>	<b>55(1)</b>	<b>32</b>	<b>3762</b>

M1:53 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

Carcinoma of the Lip  
T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	11	1	0	0	0	0	0	0	0	0	0	12
T2	5	1(1)	0	0	2	1(1)	0	0	1	0	0	10
T3	1	2	0	0	0	1	0	0	0	0	0	4
T4	0	0	0	0	0	0	0	0	0	0	0	0
T4a	2(1)	1	0	0	1	0	0	0	0	0	0	4
T4b	0	0	0	0	0	0	0	0	0	0	0	0
Tis	0	0	0	0	0	0	0	0	0	0	0	0
TX	1	0	0	0	0	0	0	0	0	2	0	3
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>20(1)</b>	<b>5(1)</b>	<b>0</b>	<b>0</b>	<b>3</b>	<b>2(1)</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>2</b>	<b>0</b>	<b>33</b>

M1:3 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

### Carcinoma of the Buccal mucosa T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	52	3	0	0	1	0	0	0	1	1	0	58
T2	93	8	0	0	6	0	0	0	0	1	0	108
T3	19(1)	10(1)	0	0	12	0	0	1	2	0	0	44
T4	1	0	0	0	0	0	0	0	0	0	0	1
T4a	17	3(1)	0	0	11	0	0	1	3	0	0	35
T4b	5	3	0	1	2	0	0	2	1	0	0	14
Tis	10	0	0	0	0	0	0	0	0	0	0	10
TX	3	0	0	0	0	0	0	0	0	1	1	5
T-	0	0	0	0	0	0	0	0	0	0	1	1
Total	200(1)	27(2)	0	1	32	0	0	4	7	3	2	276

M1:3 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

### Carcinoma of the Retromolar Area T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	12	0	0	0	0	0	0	0	0	0	0	12
T2	17	2	0	1	0	0	0	0	0	0	0	20
T3	4	0	0	0	5	0	0	0	0	0	0	9
T4	1	0	0	0	0	0	0	0	0	0	0	1
T4a	4	4	0	0	10	0	0	0	0	0	0	18
T4b	4	1	0	0	4	0	0	0	0	0	0	9
Tis	1	0	0	0	0	0	0	0	0	0	0	1
TX	0	0	0	0	0	0	0	0	0	0	0	0
T-	0	0	0	0	0	0	0	0	0	0	1	1
Total	43	7	0	1	19	0	0	0	0	0	1	71

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Carcinoma of the Lower Gingiva T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	68	3	0	0	2	1	0	0	0	2	0	76
T2	96	11	2	0	9(1)	1	0	0	4	3	0	126
T3	24	6	0	2	7	1	0	0	1	0	0	41
T4	1	2	0	0	0	1	0	0	0	0	0	4
T4a	131	50	0	2	76(1)	17	1	1	14(1)	2	0	294
T4b	8	2	1	0	12	3(1)	0	0	2(1)	0	0	28
Tis	7	0	0	0	0	0	0	0	0	0	0	7
TX	1	0	0	0	0	0	0	0	0	1	0	2
T-	0	0	0	0	0	0	0	0	0	0	5	5
<b>Total</b>	<b>336</b>	<b>74</b>	<b>3</b>	<b>4</b>	<b>106(2)</b>	<b>24(1)</b>	<b>1</b>	<b>1</b>	<b>21(2)</b>	<b>8</b>	<b>5</b>	<b>583</b>

M1:5 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Carcinoma of the Upper Gingiva T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	37	2	0	0	0	0	0	0	0	0	0	39
T2	53	10	0	0	4	1	0	0	1	0	0	69
T3	19(1)	5	0	0	3	3	0	0	1	0	1	32
T4	1(1)	2	0	0	2	0	0	0	0	1	1	7
T4a	83(2)	20(2)	0	2	30(2)	14(2)	0	0	4(1)	0	0	153
T4b	14	5	1	1	9(1)	0	0	0	1	0	0	31
Tis	2	0	0	0	0	0	0	0	0	0	0	2
TX	1	0	0	0	0	0	0	0	0	2	0	3
T-	0	0	0	0	0	0	0	0	0	0	2	2
<b>Total</b>	<b>210(4)</b>	<b>44(2)</b>	<b>1</b>	<b>3</b>	<b>48(3)</b>	<b>18(2)</b>	<b>0</b>	<b>0</b>	<b>7(1)</b>	<b>3</b>	<b>4</b>	<b>338</b>

M1:12 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Carcinoma of the Hard Palate T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	27	0	0	0	0	0	0	0	1	0	0	28
T2	16	2	0	0	1	0	0	0	0	0	0	19
T3	11	2	0	0	3	0	0	0	1(1)	0	0	17
T4	3	0	0	0	0	0	0	0	0	0	0	3
T4a	22(1)	3	0	0	4	3	0	0	2	0	1	35
T4b	10	0	0	0	2	1	0	0	1(1)	0	0	14
Tis	5	0	0	0	0	0	0	0	0	0	0	5
TX	2	0	0	0	0	0	0	0	0	0	0	2
T-	0	0	0	0	0	0	0	0	0	0	3	3
Total	96(1)	7	0	0	10	4	0	0	5(2)	0	4	126

M1:3 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Carcinoma of the Floor Mouth T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	54(1)	1	0	1	0	1(1)	0	0	2	2	0	61
T2	52	14	0	0	14	6(1)	0	0	5	1	0	92
T3	35(1)	5	0	0	15(1)	14	0	0	6	1(1)	0	76
T4	0	0	0	0	0	0	0	0	1	0	0	1
T4a	17	12	0	0	9(1)	11(1)	1	1	6	0	0	57
T4b	1(1)	1	0	0	0	1(1)	0	0	0	0	0	3
Tis	9	0	0	0	0	0	0	0	0	0	0	9
TX	4	0	0	0	0	0	0	0	0	3	0	7
T-	0	0	0	0	0	0	0	0	0	0	2	2
Total	172(3)	33	0	1	38(2)	33(4)	1	1	20	7(1)	2	308

M1:10 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Carcinoma of the Tongue T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	4(1)	0	0	0	0	0	0	0	0	0	0	4
T1	521(1)	9	0	0	4	0	0	0	2	9	0	545
T2	505	51	2	1	45	7	0	0	4	4	0	619
T3	251	79(1)	1	1	111(1)	35(1)	1	0	8	1	0	488
T4	1	0	0	0	2	1	0	0	1	0	0	5
T4a	53	28	2	4	77(2)	55(3)	0	0	25(4)	0	0	244
T4b	0	1	1	0	1	2(1)	0	0	4(2)	0	0	9
Tis	64	0	0	0	0	0	0	0	0	4	0	68
TX	7	0	0	0	0	0	0	0	0	14	1	22
T-	0	0	0	0	0	1	0	0	0	0	12	13
Total	1406(2)	168(1)	6	6	240(3)	101(5)	1	0	44(6)	32	13	2017

M1:17 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Carcinoma of the Oral Cavity, NOS T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	2	0	0	0	0	0	0	0	1	0	0	3
T2	0	0	0	0	0	0	0	0	0	0	0	0
T3	0	0	0	0	0	0	0	0	0	0	0	0
T4	0	1	0	0	0	0	0	0	0	0	0	1
T4a	2	1	0	0	0	0	0	0	1	0	0	4
T4b	0	1	0	0	0	0	0	0	0	0	0	1
Tis	0	0	0	0	0	0	0	0	0	0	0	0
TX	0	0	0	0	0	0	0	0	0	0	0	0
T-	0	0	0	0	0	0	0	0	0	0	1	1
Total	4	3	0	0	0	0	0	0	2	0	1	10

NOS : Not Otherwise Specified

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Treatment Method for the Primary Lesion by Subsite

Treatment Method	(1) Lip	(2) Buccal mucosa	(3) Retromolar area	(4) Lower gingiva	(5) Upper gingiva	(6) Hard palate	(7) Floor of mouth	(8) Tongue	(9) Oral cavity, NOS	Total
Surgery										
without	7	39	10	83	75	40	46	143	3	446
with	25	234	58	483	256	82	254	1834	7	3233
unknown	1	3	3	17	7	4	8	40	0	83
Radiotherapy										
without	27	214	46	444	238	71	228	1656	7	2931
with	5	59	22	122	93	51	72	321	3	748
unknown	1	3	3	17	7	4	8	40	0	83
Chemotherapy										
without	26	233	46	442	241	93	224	1631	6	2942
with	6	40	22	124	90	29	76	346	4	737
unknown	1	3	3	17	7	4	8	40	0	83
Total	33	276	71	583	338	126	308	2017	10	3762

NOS: not otherwise specified.

## Treatment Method for the Cervical Lymph Nodes by Subsite

Treatment Method	(1) Lip	(2) Buccal mucosa	(3) Retromolar area	(4) Lower gingiva	(5) Upper gingiva	(6) Hard palate	(7) Floor of mouth	(8) Tongue	(9) Oral cavity, NOS	Total
Surgery										
without	24	182	35	229	216	98	136	1081	5	2006
with	8	91	33	337	115	24	164	895	5	1672
unknown	1	3	3	17	7	4	8	41	0	84
Radiotherapy										
without	28	232	51	459	258	97	239	1672	8	3044
with	4	41	17	107	73	25	61	304	2	634
unknown	1	3	3	17	7	4	8	41	0	84
Chemotherapy										
without	26	244	49	463	262	103	232	1661	8	3048
with	6	29	19	103	69	19	68	315	2	630
unknown	1	3	3	17	7	4	8	41	0	84
Total	33	276	71	583	338	126	308	2017	10	3762

NOS: not otherwise specified.

## Sequence of Treatment Methods for the Primary Lesion by Subsite

Sequence of treatment methods	(1) Lip	(2) Buccal mucosa	(3) Retromolar area	(4) Lower gingiva	(5) Upper gingiva	(6) Hard palate	(7) Floor of mouth	(8) Tongue	(9) Oral cavity, NOS	Total
No treatment	1	8	0	24	12	6	7	44	0	102
A) Surg. alone	23	191	37	364	184	55	190	1480	5	2529
A)F) Surg.->(Rad.+Chem.)	1	14	7	42	15	7	24	119	2	231
A)B) Surg.->Rad.	0	18	3	29	19	15	11	63	0	158
C)A) Chem.->Surg.	1	2	3	22	13	1	9	65	0	116
B) Rad. alone	2	14	6	16	14	14	13	29	1	109
F)(Rad.+Chem.)	1	7	3	7	25	10	7	26	0	86
C) Chem. alone	2	7	0	18	13	5	10	28	2	85
A)C) Surg. -> Chem	0	4	4	3	4	1	4	17	0	37
C)A)F) Chem.->Surg.->(Rad.+Chem.)	0	2	1	4	2	0	3	20	0	32
C)A)B) Chem.->Surg.->Rad.	0	0	0	2	0	1	2	16	0	21
A)A) Surg.->Surg.	0	1	0	4	4	1	0	8	0	18
C)F) Chem. -> (Rad.+Chem.)	0	0	0	7	0	1	3	3	0	14
A)F)C) Surg.->(Rad.+Chem.)->Chem.	0	0	0	2	1	0	0	10	0	13
C)A)C) Chem.->Surg.->Chem.	0	0	0	2	2	0	2	6	0	12
C)B) Chem.->Rad.	1	1	0	1	1	1	2	5	0	12
Other	0	4	4	19	22	4	13	38	0	104
Unknown	1	3	3	17	7	4	8	40	0	83
Total	33	276	71	583	338	126	308	2017	10	3762

NOS: not otherwise specified.

Surg.: surgery. Rad.: radiotherapy.

Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

## Surgical Methods for the Primary Lesion by Subsite

Surgical method	(1) Lip	(2) Buccal mucosa	(3) Retromolar area	(4) Lower gingiva	(5) Upper gingiva	(6) Hard palate	(7) Floor of mouth	(8) Tongue	(9) Oral cavity, NOS	Total
Partial glossectomy	0	0	0	1	1	0	1	1219	0	1222
No surgery	7	39	10	79	74	40	45	140	3	437
Segmental mandibulectomy	0	9	14	219	0	0	16	0	4	262
Partial maxillectomy	0	3	4	1	203	29	0	0	0	240
Subtotal glossectomy	1	0	0	1	0	0	9	223	0	234
Resection of the buccal mucosa	1	204	19	0	0	0	0	0	0	224
Marginal mandibulectomy	0	3	7	182	0	0	12	1	0	205
Resection of the floor of mouth	0	0	0	2	0	0	189	2	0	193
Hemiglossectomy	0	0	0	0	0	0	1	174	0	175
Hemiglossectomy (anterior 2/3rds)	0	0	0	0	0	0	1	111	0	112
Resection of oral cavity, NOS	1	6	11	4	20	38	10	0	1	91
Subtotal glossectomy (anterior 2/3rds)	0	0	0	0	0	0	5	50	0	55
Total glossectomy	0	0	0	0	0	0	4	40	0	44
Resection of lower gingiva	0	0	0	32	0	0	1	0	1	34
Total maxillectomy	0	0	0	0	23	9	0	0	0	32
Unknown	1	3	3	21	8	4	9	45	0	94
Others	22	9	3	41	9	6	5	12	1	108
Total	33	276	71	583	338	126	308	2017	10	3762

NOS: not otherwise specified.

## Reconstructive Surgery by Subsite

Reconstructive surgery	(1) Lip	(2) Buccal mucosa	(3) Retromolar area	(4) Lower gingiva	(5) Upper gingiva	(6) Hard palate	(7) Floor of mouth	(8) Tongue	(9) Oral cavity, NOS	Total
0) No reconstruction	21	171	34	287	246	99	151	1357	6	2372
E) Free ALT flap	3	23	15	42	10	7	63	273	0	436
D) Free RA MC flap	0	14	6	61	23	3	31	164	1	303
C) Free FA flap	0	11	4	9	6	1	19	98	0	148
G) Free fibular OC flap	0	4	2	94	5	3	7	3	3	121
1) Skin graft	0	23	1	8	26	3	6	10	0	77
5) PM MC flap	0	2	2	18	1	0	5	34	0	62
2) Local skin flap	4	9	0	7	6	2	7	5	0	40
3) Mucosal flap	2	7	2	7	0	1	1	1	0	21
F) Free scapular OC flap	0	1	0	10	0	0	1	0	0	12
4) DP flap	1	1	0	1	0	0	0	2	0	5
B) Free jejunal flap	0	0	0	0	0	0	0	1	0	1
I) Free nerve graft	0	0	0	0	0	0	0	1	0	1
7) Gastric pull-up	0	0	0	0	0	0	0	0	0	0
Others	1	7	2	17	7	2	6	18	0	60
9) Unknown	1	3	3	22	8	5	11	50	0	103
Total	33	276	71	583	338	126	308	2017	10	3762

NOS: not otherwise specified.

RA: rectus abdominis.

FA: forearm.

DP: deltopectoral.

MC: musculocutaneous.

PM: pectoralis major.

ALT: anterolateral thigh.

OC: osteocutaneous.

## Neck Dissection on the Ipsilateral Side by Subsite

Neck dissection	(1) Lip	(2) Buccal mucosa	(3) Retromolar area	(4) Lower gingiva	(5) Upper gingiva	(6) Hard palate	(7) Floor of mouth	(8) Tongue	(9) Oral cavity, NOS	Total
0) No N.D.	25	184	35	226	215	98	135	1078	5	2001
1) Total N.D.	3	32	5	76	28	6	43	241	0	434
2) Selective N.D.	4	55	27	249	84	18	119	636	5	1197
3) Lymph node excision	0	0	0	7	0	0	0	4	0	11
8) Others	0	1	0	2	3	0	2	9	0	17
9) Unknown	1	4	4	23	8	4	9	49	0	102
Total	33	276	71	583	338	126	308	2017	10	3762

NOS: not otherwise specified.

N.D.: neck dissection.

## Neck Dissection on the Contralateral Side by Subsite

Neck dissection	(1) Lip	(2) Buccal mucosa	(3) Retromolar area	(4) Lower gingiva	(5) Upper gingiva	(6) Hard palate	(7) Floor of mouth	(8) Tongue	(9) Oral cavity, NOS	Total
0) No N.D.	29	265	64	499	303	119	193	1688	9	3169
1) Total N.D.	1	2	0	4	1	0	16	41	0	65
2) Selective N.D.	2	3	3	55	23	3	86	225	1	401
3) Lymph node excision	0	0	0	1	0	0	1	0	0	2
8) Others	0	2	0	1	3	0	2	13	0	21
9) Unknown	1	4	4	23	8	4	10	50	0	104
Total	33	276	71	583	338	126	308	2017	10	3762

NOS: not otherwise specified.

N.D.: neck dissection.

## Radiotherapy by Subsite

Type of radiotherapy	(1) Lip	(2) Buccal mucosa	(3) Retromolar area	(4) Lower gingiva	(5) Upper gingiva	(6) Hard palate	(7) Floor of mouth	(8) Tongue	(9) Oral cavity, NOS	Total
0) No radiotherapy	27	206	45	423	235	68	217	1596	6	2823
1) X-ray (and/or electron beam)	5	59	20	132	92	46	76	346	3	779
2) Particle beam	0	4	0	1	2	4	0	1	0	12
3) B.T.	0	1	2	0	0	2	4	10	0	19
4) X-ray + Particle beam	0	0	0	0	0	0	0	3	0	3
5) X-ray + B.T.	0	1	0	0	0	0	0	0	0	1
6) Particl beam + B.T.	0	0	0	0	0	0	0	0	0	0
7) X-ray + Particl beam + B.T.	0	0	0	0	0	0	0	0	0	0
8) Others	0	1	0	0	0	0	0	0	0	1
9) Unknown	1	4	4	27	9	6	11	61	1	124
Total	33	276	71	583	338	126	308	2017	10	3762

NOS: not otherwise specified.

B.T.: brachytherapy.

## Chemotherapy by Subsite

Route of administration	(1) Lip	(2) Buccal mucosa	(3) Retromolar area	(4) Lower gingiva	(5) Upper gingiva	(6) Hard palate	(7) Floor of mouth	(8) Tongue	(9) Oral cavity, NOS	Total
0) No chemotherapy	26	230	45	429	237	92	216	1591	6	2872
1) I.V.	6	34	19	103	63	23	66	306	4	624
2) I.A.	0	0	0	4	18	1	2	20	0	45
3) Oral	0	8	4	17	7	5	11	34	0	86
4) I.V.+I.A.	0	0	0	3	3	0	0	6	0	12
5) I.V.+Oral	0	1	0	5	1	0	4	10	0	21
6) I.A.+Oral	0	0	0	0	2	0	0	1	0	3
7) I.V.+I.A.+Oral	0	0	0	0	0	0	0	2	0	2
8) Others	0	0	0	0	0	0	0	0	0	0
9) Unknown	1	3	3	22	7	5	9	47	0	97
Total	33	276	71	583	338	126	308	2017	10	3762

NOS: not otherwise specified.

I.V.: intravenous.

I.A.: intraarterial

Larynx (2021)

2234 Cases

Carcinoma of the Larynx ----- 2234cases

### Primary Site

<b>Site</b>	<b>Number of patients</b>	<b>(%)</b>
Glottis	1515	(67.8)
Supraglottis	610	(27.3)
Subglottis	75	(3.4)
Larynx, NOS	34	(1.5)
<b>Total</b>	<b>2234</b>	<b>(100.0)</b>

NOS: not otherwise specified

### Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	1	0	1
30 - 39	1	2	3
40 - 49	40	14	54
50 - 59	162	25	187
60 - 69	542	38	580
70 - 79	900	77	977
80 - 89	343	33	376
90 - 99	50	6	56
100 - 109	0	0	0
<b>Total</b>	<b>2039</b>	<b>195</b>	<b>2234</b>

### Glottis Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	1	0	1
40 - 49	33	2	35
50 - 59	113	13	126
60 - 69	368	22	390
70 - 79	606	42	648
80 - 89	251	22	273
90 - 99	37	5	42
100 - 109	0	0	0
<b>Total</b>	<b>1409</b>	<b>106</b>	<b>1515</b>

### Supraglottis Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	0	2	2
40 - 49	6	11	17
50 - 59	45	9	54
60 - 69	143	15	158
70 - 79	252	31	283
80 - 89	75	9	84
90 - 99	11	1	12
100 - 109	0	0	0
<b>Total</b>	<b>532</b>	<b>78</b>	<b>610</b>

### Subglottis

Carcinoma of the Larynx ----- 2234cases

### Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	1	0	1
30 - 39	0	0	0
40 - 49	0	1	1
50 - 59	2	2	4
60 - 69	22	0	22
70 - 79	28	3	31
80 - 89	12	2	14
90 - 99	2	0	2
100 - 109	0	0	0
<b>Total</b>	<b>67</b>	<b>8</b>	<b>75</b>

### Carcinoma of the Larynx, NOS

### Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	0	0	0
40 - 49	1	0	1
50 - 59	2	1	3
60 - 69	9	1	10
70 - 79	14	1	15
80 - 89	5	0	5
90 - 99	0	0	0
100 - 109	0	0	0
<b>Total</b>	<b>31</b>	<b>3</b>	<b>34</b>

NOS: not otherwise specified

Carcinoma of the Larynx ----- 2234cases

## Histological Distribution by Subsite

Histologic type	Glottis (C32.0)	Supraglottis (C32.1) (C10.1)	Subglottis (C32.2)	Larynx, NOS (C32.9)	Total
S.C.C., NOS	1371	548	68	31	2018
Ca., NOS	2	6	0	0	8
Malig. lymphoma, NOS	0	0	0	1	1
Adenoid cystic ca.	0	2	0	0	2
Adenocarcinoma, NOS	0	1	0	0	1
S.C.C. in situ, NOS	59	16	0	0	75
Myoepithelial ca.	0	0	1	0	1
Basaloid S.C.C.	0	3	0	0	3
Verrucous ca., NOS	1	0	0	0	1
Ca., undifferentiated, NOS	1	0	0	0	1
Malig. melanoma, NOS	0	0	1	0	1
S.C.C., large cell, nonkerat., NOS	0	2	2	0	4
S.C.C., kerat., NOS	52	15	0	0	67
S.C.C., HPV positive	0	1	0	0	1
Intraepithelial, NOS	2	0	0	0	2
S.C.C., HPV negative	0	1	0	0	1
S.C.C., microinvasive	0	2	0	0	2
S.C.C., spindle cell	5	1	0	0	6
Epithelial-myoeplithelial ca.	0	0	1	0	1
Neoplasm, malig.	3	1	0	0	4
Papillary S.C.C.	4	0	0	0	4
Lymphoepithelial ca.	0	1	0	0	1
Papillary S.C.C., non-invasive	1	0	0	0	1
Spindle cell ca., NOS	4	0	0	0	4
Mammary Analogue Secretory Ca.	0	1	0	0	1
Carcinosarcoma, NOS	2	1	0	0	3
Adenosquamous ca.	3	1	0	0	4
Transitional cell ca., NOS	1	0	0	0	1
S.C.C., small cell, nonkerat.	1	0	0	0	1
Small cell ca., NOS	1	2	1	0	4
Chondrosarcoma, NOS	0	0	0	2	2
Carcinoid tumor, NOS	0	2	0	0	2
S.C.C. in situ with quet. stromal invasion	1	1	0	0	2
S.C.C., nonkerat.	0	2	0	0	2
S.C.C., kerat.	1	0	0	0	1
Leiomysarcoma, NOS	0	0	1	0	1
<b>Total</b>	<b>1515</b>	<b>610</b>	<b>75</b>	<b>34</b>	<b>2234</b>

NOS: not otherwise specified.

ca., Ca.: carcinoma.

S.C.C.: squamous cell carcinoma.

malig., Malig.: malignant.

kerat.: keratinizing.

nonkerat.: nonkeratinizing

undiff.: undifferentiated.

HPV : Human papillomavirus.

Carcinoma of the Larynx ----- 2234cases

T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	3	0	0	0	0	0	0	0	0	0	0	3
T1	150	11	0	0	4(1)	3	0	0	2	0	1	171
T1a	459	0	0	0	0	2(1)	0	0	1	4	0	466
T1b	167	1	0	0	0	0	0	0	0	2	0	170
T2	452(2)	21	1	2	28(2)	20	0	0	14(1)	2	0	540
T3	360(5)	44	0	6	46(2)	44(5)	0	0	14(2)	3	1	518
T4	2	1	0	0	2	1	1	0	3	0	0	10
T4a	143(1)	30	1	0	32(1)	30(4)	1	0	19(6)	1	0	257
T4b	4	1	0	0	1	0	0	0	0	0	0	6
Tis	70	0	0	0	0	0	0	0	0	1	0	71
TX	8	0	0	0	0	0	0	0	0	8	0	16
T-	0	0	0	0	0	0	0	0	0	0	6	6
<b>Total</b>	<b>1818(8)</b>	<b>109</b>	<b>2</b>	<b>8</b>	<b>113(6)</b>	<b>100(10)</b>	<b>2</b>	<b>0</b>	<b>53(9)</b>	<b>21</b>	<b>8</b>	<b>2234</b>

M1:33 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Glottis

### T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	1	0	0	0	0	0	0	0	0	0	0	1
T1	51	0	0	0	0	0	0	0	0	0	0	51
T1a	454	0	0	0	0	2(1)	0	0	0	4	0	460
T1b	164	1	0	0	0	0	0	0	0	2	0	167
T2	315(1)	5	1	0	6(1)	3	0	0	1	1	0	332
T3	260(3)	16	0	1	12(1)	6(1)	0	0	3(1)	3	1	302
T4	2	1	0	0	1	0	0	1	2	0	0	7
T4a	91(1)	11	0	0	9	5	0	1	4(1)	0	0	121
T4b	1	1	0	0	0	0	0	0	0	0	0	2
Tis	55	0	0	0	0	0	0	0	0	1	0	56
TX	6	0	0	0	0	0	0	0	0	8	0	14
T-	0	0	0	0	0	0	0	0	0	0	2	2
<b>Total</b>	<b>1400(5)</b>	<b>35</b>	<b>1</b>	<b>1</b>	<b>28(2)</b>	<b>16(2)</b>	<b>0</b>	<b>2</b>	<b>10(2)</b>	<b>19</b>	<b>3</b>	<b>1515</b>

M1:11 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Supraglottis

### T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	2	0	0	0	0	0	0	0	0	0	0	2
T1	92	10	0	0	4(1)	3	0	0	2	0	1	112
T1a	2	0	0	0	0	0	0	0	1	0	0	3
T1b	0	0	0	0	0	0	0	0	0	0	0	0
T2	108(1)	16	0	2	21(1)	16	0	0	12	1	0	176
T3	88(2)	27	0	5	33(1)	37(4)	0	0	11(1)	0	0	201
T4	0	0	0	0	0	1	0	0	1	0	0	2
T4a	27	13	0	0	18(1)	25(4)	0	0	11(2)	1	0	95
T4b	2	0	0	0	1	0	0	0	0	0	0	3
Tis	14	0	0	0	0	0	0	0	0	0	0	14
TX	0	0	0	0	0	0	0	0	0	0	0	0
T-	0	0	0	0	0	0	0	0	0	0	2	2
<b>Total</b>	<b>335(3)</b>	<b>66</b>	<b>0</b>	<b>7</b>	<b>77(4)</b>	<b>82(8)</b>	<b>0</b>	<b>0</b>	<b>38(3)</b>	<b>2</b>	<b>3</b>	<b>610</b>

M1:18 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

Carcinoma of the Larynx ----- 2234cases

**Subglottis**  
**T and N Status**

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	6	1	0	0	0	0	0	0	0	0	0	7
T1a	0	0	0	0	0	0	0	0	0	0	0	0
T1b	0	0	0	0	0	0	0	0	0	0	0	0
T2	24	0	0	0	1	0	0	0	1(1)	0	0	26
T3	7	1	0	0	0	0	0	0	0	0	0	8
T4	0	0	0	0	1	0	0	0	0	0	0	1
T4a	20	3	1	0	4	0	0	0	4(3)	0	0	32
T4b	0	0	0	0	0	0	0	0	0	0	0	0
Tis	0	0	0	0	0	0	0	0	0	0	0	0
TX	1	0	0	0	0	0	0	0	0	0	0	1
T-	0	0	0	0	0	0	0	0	0	0	0	0
Total	58	5	1	0	6	0	0	0	5(4)	0	0	75

M1:4 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

**Carcinoma of the Larynx, NOS**  
**T and N Status**

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	1	0	0	0	0	0	0	0	0	0	0	1
T1a	3	0	0	0	0	0	0	0	0	0	0	3
T1b	3	0	0	0	0	0	0	0	0	0	0	3
T2	5	0	0	0	0	1	0	0	0	0	0	6
T3	5	0	0	0	1	1	0	0	0	0	0	7
T4	0	0	0	0	0	0	0	0	0	0	0	0
T4a	5	3	0	0	1	0	0	0	0	0	0	9
T4b	1	0	0	0	0	0	0	0	0	0	0	1
Tis	1	0	0	0	0	0	0	0	0	0	0	1
TX	1	0	0	0	0	0	0	0	0	0	0	1
T-	0	0	0	0	0	0	0	0	0	0	2	2
Total	25	3	0	0	2	2	0	0	0	0	2	34

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Treatment Method for the Primary Lesion by Subsite

Treatment Method	Glottis (C32.0)	Supraglottis (C32.1) (C10.1)	Subglottis (C32.2)	Larynx, NOS (C32.9)	Total
Surgery					
without	949	320	38	8	1315
with	548	283	37	25	893
unknown	18	7	0	1	26
Radiotherapy					
without	476	250	28	18	772
with	1021	353	47	15	1436
unknown	18	7	0	1	26
Chemotherapy					
without	1175	354	47	25	1601
with	322	249	28	8	607
unknown	18	7	0	1	26
Total	1515	610	75	34	2234

NOS : Not Otherwise Specified

## Sequence of Treatment Methods for the Primary Lesion by Subsite

Sequence of treatment methods	Glottis (C32.0)	Supraglottis (C32.1) (C10.1)	Subglottis (C32.2)	Larynx, NOS (C32.9)	Total
No treatment	26	20	2	0	48
B) Rad. alone	665	108	17	9	799
A) Surg. alone	418	200	22	16	656
F)(Rad.+Chem.)	241	148	15	3	407
A)B) Surg.->Rad.	46	20	3	1	70
A)F) Surg.->(Rad.+Chem.)	27	29	5	1	62
C)A) Chem.->Surg.	9	10	2	1	22
C)F) Chem. -> (Rad.+Chem.)	4	16	2	0	22
C) Chem. alone	8	9	1	0	18
B)A) Rad.->Surg.	11	2	2	0	15
F)A)(Rad.+Chem.)->Surg.	9	4	0	0	13
A)A) Surg.->Surg.	7	1	1	1	10
Other	26	36	3	1	66
Unknown	18	7	0	1	26
Total	1515	610	75	34	2234

NOS : Not Otherwise Specified

Treatment methods in parentheses were given concurrently

Surg.: surgery.

Rad.: radiotherapy.

Chem.: chemotherapy.

## Treatment Method for the Primary Lesion by T Classification

Treatment Method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
Surgery													
without	1	94	310	139	440	245	3	56	3	16	8	0	1315
with	2	77	152	29	95	265	7	200	3	55	7	1	893
unknown	0	0	4	2	5	8	0	1	0	0	1	5	26
Radiotherapy													
without	2	76	141	13	74	228	5	170	4	52	7	0	772
with	1	95	321	155	461	282	5	86	2	19	8	1	1436
unknown	0	0	4	2	5	8	0	1	0	0	1	5	26
Chemotherapy													
without	3	150	452	150	307	263	7	182	5	69	13	0	1601
with	0	21	10	18	228	247	3	74	1	2	2	1	607
unknown	0	0	4	2	5	8	0	1	0	0	1	5	26
<b>Total</b>	<b>3</b>	<b>171</b>	<b>466</b>	<b>170</b>	<b>540</b>	<b>518</b>	<b>10</b>	<b>257</b>	<b>6</b>	<b>71</b>	<b>16</b>	<b>6</b>	<b>2234</b>

T-: not within defined T classification or without reported T classification

## Sequence of Treatment Methods for the Primary Lesion by T Classification

Sequence of treatment methods	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No treatment	0	3	4	2	12	10	1	14	1	0	1	0	48
B) Rad. alone	1	71	300	128	220	47	1	10	1	14	6	0	799
A) Surg. alone	2	71	132	11	56	192	4	129	3	50	6	0	656
F)(Rad.+Chem.)	0	16	5	11	197	161	0	14	1	1	1	0	407
A)B) Surg.->Rad.	0	4	10	6	13	10	1	23	0	3	0	0	70
A)F) Surg.->(Rad.+Chem.)	0	0	2	2	7	30	1	19	0	0	1	0	62
C)A) Chem.->Surg.	0	0	0	0	1	8	0	13	0	0	0	0	22
C)F) Chem. -> (Rad.+Chem.)	0	1	0	0	5	10	0	6	0	0	0	0	22
C) Chem. alone	0	1	2	0	2	6	0	7	0	0	0	0	18
B)A) Rad.->Surg.	0	1	3	6	5	0	0	0	0	0	0	0	15
F)A)(Rad.+Chem.)->Surg.	0	1	0	1	3	7	0	1	0	0	0	0	13
A)A) Surg.->Surg.	0	0	3	0	0	3	0	2	0	2	0	0	10
Other	0	2	1	1	14	26	2	18	0	1	0	1	66
Unknown	0	0	4	2	5	8	0	1	0	0	1	5	26
Total	3	171	466	170	540	518	10	257	6	71	16	6	2234

T-: not within defined T classification or without reported T classification

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently

**Glottis**  
**Treatment Method for the Primary Lesion**  
**by T Classification**

Treatment Method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
Surgery													
without	0	33	306	138	279	150	2	17	1	15	8	0	949
with	1	18	150	27	49	148	5	103	1	41	5	0	548
unknown	0	0	4	2	4	4	0	1	0	0	1	2	18
Radiotherapy													
without	1	17	139	13	35	132	4	91	1	38	5	0	476
with	0	34	317	152	293	166	3	29	1	18	8	0	1021
unknown	0	0	4	2	4	4	0	1	0	0	1	2	18
Chemotherapy													
without	1	48	446	149	212	154	5	92	2	55	11	0	1175
with	0	3	10	16	116	144	2	28	0	1	2	0	322
unknown	0	0	4	2	4	4	0	1	0	0	1	2	18
Total	1	51	460	167	332	302	7	121	2	56	14	2	1515

T-: not within defined T classification or without reported T classification

## Glottis

### Sequence of Treatment Methods for the Primary Lesion by T Classification

Sequence of treatment methods	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No treatment	0	1	4	2	8	5	1	4	0	0	1	0	26
B) Rad. alone	0	29	296	125	167	26	0	1	1	14	6	0	665
A) Surg. alone	1	16	130	11	26	116	3	73	1	37	4	0	418
F)(Rad.+Chem.)	0	3	5	11	105	110	0	6	0	0	1	0	241
A)B) Surg.->Rad.	0	2	10	6	9	4	1	11	0	3	0	0	46
A)F) Surg.->(Rad.+Chem.)	0	0	2	2	4	12	0	6	0	0	1	0	27
B)A) Rad.->Surg.	0	0	3	6	2	0	0	0	0	0	0	0	11
Other	0	0	6	2	7	25	2	19	0	2	0	0	63
Unknown	0	0	4	2	4	4	0	1	0	0	1	2	18
<b>Total</b>	<b>1</b>	<b>51</b>	<b>460</b>	<b>167</b>	<b>332</b>	<b>302</b>	<b>7</b>	<b>121</b>	<b>2</b>	<b>56</b>	<b>14</b>	<b>2</b>	<b>1515</b>

T-: not within defined T classification or without reported T classification

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently

**Supraglottis**  
**Treatment Method for the Primary Lesion**  
**by T Classification**

Treatment Method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
Surgery													
without	1	55	1	0	140	89	1	30	2	1	0	0	320
with	1	57	2	0	35	108	1	65	1	13	0	0	283
unknown	0	0	0	0	1	4	0	0	0	0	0	2	7
Radiotherapy													
without	1	57	2	0	31	89	1	54	2	13	0	0	250
with	1	55	1	0	144	108	1	41	1	1	0	0	353
unknown	0	0	0	0	1	4	0	0	0	0	0	2	7
Chemotherapy													
without	2	96	3	0	74	101	2	61	2	13	0	0	354
with	0	16	0	0	101	96	0	34	1	1	0	0	249
unknown	0	0	0	0	1	4	0	0	0	0	0	2	7
Total	2	112	3	0	176	201	2	95	3	14	0	2	610

T-: not within defined T classification or without reported T classification

## Supraglottis

### Sequence of Treatment Methods for the Primary Lesion by T Classification

Sequence of treatment methods	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No treatment	0	2	0	0	3	4	0	10	1	0	0	0	20
A) Surg. alone	1	53	2	0	24	70	1	35	1	13	0	0	200
F)(Rad.+Chem.)	0	11	0	0	85	45	0	5	1	1	0	0	148
B) Rad. alone	1	38	1	0	41	20	1	6	0	0	0	0	108
A)F) Surg.->(Rad.+Chem.)	0	0	0	0	2	17	0	10	0	0	0	0	29
A)B) Surg.->Rad.	0	2	0	0	4	6	0	8	0	0	0	0	20
C)F) Chem. -> (Rad.+Chem.)	0	1	0	0	5	7	0	3	0	0	0	0	16
C)A) Chem.->Surg.	0	0	0	0	0	6	0	4	0	0	0	0	10
Other	0	5	0	0	12	26	0	14	0	0	0	2	59
Total	2	112	3	0	176	201	2	95	3	14	0	2	610

T-: not within defined T classification or without reported T classification

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently

**Subglottis**  
**Treatment Method for the Primary Lesion**  
**by T Classification**

Treatment Method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
Surgery													
without	0	6	0	0	18	5	0	9	0	0	0	0	38
with	0	1	0	0	8	3	1	23	0	0	1	0	37
unknown	0	0	0	0	0	0	0	0	0	0	0	0	0
Radiotherapy													
without	0	1	0	0	6	3	0	17	0	0	1	0	28
with	0	6	0	0	20	5	1	15	0	0	0	0	47
unknown	0	0	0	0	0	0	0	0	0	0	0	0	0
Chemotherapy													
without	0	5	0	0	16	4	0	21	0	0	1	0	47
with	0	2	0	0	10	4	1	11	0	0	0	0	28
unknown	0	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>0</b>	<b>7</b>	<b>0</b>	<b>0</b>	<b>26</b>	<b>8</b>	<b>1</b>	<b>32</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>75</b>

T-: not within defined T classification or without reported T classification

**Subglottis**  
**Sequence of Treatment Methods for the Primary Lesion**  
**by T Classification**

Sequence of treatment methods	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
A) Surg. alone	0	1	0	0	4	2	0	14	0	0	1	0	22
B) Rad. alone	0	4	0	0	9	1	0	3	0	0	0	0	17
F)(Rad.+Chem.)	0	2	0	0	7	3	0	3	0	0	0	0	15
Other	0	0	0	0	6	2	1	12	0	0	0	0	21
Total	0	7	0	0	26	8	1	32	0	0	1	0	75

T-: not within defined T classification or without reported T classification

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently

**Carcinoma of the Larynx, NOS**  
**Treatment Method for the Primary Lesion**  
**by T Classification**

Treatment Method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
Surgery													
without	0	0	3	1	3	1	0	0	0	0	0	0	8
with	0	1	0	2	3	6	0	9	1	1	1	1	25
unknown	0	0	0	0	0	0	0	0	0	0	0	1	1
Radiotherapy													
without	0	1	0	0	2	4	0	8	1	1	1	0	18
with	0	0	3	3	4	3	0	1	0	0	0	1	15
unknown	0	0	0	0	0	0	0	0	0	0	0	1	1
Chemotherapy													
without	0	1	3	1	5	4	0	8	1	1	1	0	25
with	0	0	0	2	1	3	0	1	0	0	0	76	83
unknown	0	0	0	0	0	0	0	0	0	0	0	1	1
Total	0	1	3	3	6	7	0	9	1	1	1	2	34

NOS : Not Otherwise Specified

T-: not within defined T classification or without reported T classification

**Carcinoma of the Larynx, NOS**  
**Sequence of Treatment Methods for the Primary Lesion**  
**by T Classification**

Sequence of treatment methods	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
A) Surg. alone	0	1	0	0	2	4	0	7	1	0	1	0	16
B) Rad. alone	0	0	3	3	3	0	0	0	0	0	0	0	9
F)(Rad.+Chem.)	0	0	0	0	0	3	0	0	0	0	0	0	3
Other	0	0	0	0	1	0	0	2	0	1	0	2	6
Total	0	1	3	3	6	7	0	9	1	1	1	2	34

NOS : Not Otherwise Specified

T-: not within defined T classification or without reported T classification

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently

Carcinoma of the Larynx ----- 2234cases

## Surgical Methods for the Primary Lesion by Subsite

Surgical method	Glottis (C32.0)	Supraglottis (C32.1) (C10.1)	Subglottis (C32.2)	Larynx, NOS (C32.9)	Total
No surgery	950	320	38	8	1316
Total laryngectomy	253	168	32	16	469
Transoral resection	191	36	3	2	232
Endoscopic resection	60	35	0	0	95
Total pharyngolaryngectomy	2	18	1	0	21
Partial laryngectomy	15	1	0	0	16
Others	19	23	1	3	46
Unknown	25	9	0	5	39
Total	1515	610	75	34	2234

NOS : Not Otherwise Specified

## Surgical Methods for the Primary Lesion by T Classification

Surgical method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No surgery	1	95	310	139	440	245	3	56	3	16	8	0	1316
Total laryngectomy	0	6	0	7	34	228	6	184	3	0	1	0	469
Transoral resection	1	39	116	10	23	6	0	1	0	32	4	0	232
Endoscopic resection	1	27	25	5	15	3	0	2	0	16	1	0	95
Others	0	4	9	4	20	24	1	12	0	7	1	1	83
Unknown	0	0	6	5	8	12	0	2	0	0	1	5	39
Total	3	171	466	170	540	518	10	257	6	71	16	6	2234

T-: not within defined T classification or without reported T classification

**Glottis**  
**Surgical Methods for the Primary Lesion**  
**by T Classification**

Surgical method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No surgery	0	33	306	138	280	150	2	17	1	15	8	0	950
Endoscopic resection	0	4	25	5	14	3	0	0	0	12	1	0	64
Transoral resection	1	13	117	10	15	4	0	1	0	29	4	0	194
Total laryngectomy+Partial pharyngectomy	0	0	0	0	0	1	0	1	0	0	0	0	2
Total pharyngolaryngectomy	0	0	0	0	0	1	1	0	0	0	0	0	2
Total pharyngolaryngo-esophagectomy	0	0	0	0	1	1	0	0	0	0	0	0	2
Partial laryngectomy	0	1	2	3	4	4	0	1	0	0	0	0	15
Subtotal laryngectomy	0	0	0	0	1	0	0	0	0	0	0	0	1
Total laryngectomy	0	0	0	7	11	131	4	99	1	0	0	0	253
Laryngectomy, other type	0	0	4	1	1	0	0	0	0	0	0	0	6
Unknown	0	0	6	3	5	6	0	2	0	0	1	2	25
Others	0	0	0	0	0	1	0	0	0	0	0	0	1
<b>Total</b>	<b>1</b>	<b>51</b>	<b>460</b>	<b>167</b>	<b>332</b>	<b>302</b>	<b>7</b>	<b>121</b>	<b>2</b>	<b>56</b>	<b>14</b>	<b>2</b>	<b>1515</b>

T-: not within defined T classification or without reported T classification

## Supraglottis Surgical Methods for the Primary Lesion by T Classification

Surgical method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No surgery	1	56	1	0	139	89	1	30	2	1	0	0	320
Total glossectomy	0	0	0	0	0	0	0	1	0	0	0	0	1
Resection of the base of tongue and epiglottis	0	0	0	0	0	0	0	0	0	1	0	0	1
Resection of the oropharynx, other type	0	1	0	0	0	0	0	0	0	0	0	0	1
Endoscopic resection	1	23	1	0	5	0	0	2	0	9	0	0	41
Transoral resection	0	25	1	0	7	2	0	0	0	3	0	0	38
Total laryngectomy+Partial pharyngectomy	0	0	0	0	0	2	0	0	0	0	0	0	2
Total pharyngolaryngectomy	0	0	0	0	2	10	0	6	0	0	0	0	18
Total pharyngolaryngo-esophagectomy	0	0	0	0	1	2	0	2	0	0	0	0	5
Partial laryngectomy	0	0	0	0	1	0	0	0	0	0	0	0	1
Total laryngectomy	0	6	0	0	16	91	1	53	1	0	0	0	168
Laryngectomy, other type	0	0	0	0	0	1	0	0	0	0	0	0	1
Others	0	1	0	0	2	0	0	1	0	0	0	0	4
Unknown	0	0	0	0	3	4	0	0	0	0	0	2	9
Total	2	112	3	0	176	201	2	95	3	14	0	2	610

T-: not within defined T classification or without reported T classification

## Subglottis Surgical Methods for the Primary Lesion by T Classification

Surgical method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No surgery	0	6	0	0	18	5	0	9	0	0	0	0	38
Total pharyngolaryngectomy	0	0	0	0	1	0	0	0	0	0	0	0	1
Transoral resection	0	1	0	0	2	0	0	0	0	0	0	0	3
Total laryngectomy	0	0	0	0	5	2	1	23	0	0	1	0	32
Laryngectomy, other type	0	0	0	0	0	1	0	0	0	0	0	0	1
Total	0	7	0	0	26	8	1	32	0	0	1	0	75

T-: not within defined T classification or without reported T classification

**Carcinoma of the Larynx, NOS  
Surgical Methods for the Primary Lesion  
by T Classification**

Surgical method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No surgery	0	0	3	1	3	1	0	0	0	0	0	0	8
Total pharyngolaryngo-esophagectomy	0	0	0	0	0	0	0	0	0	0	1	0	1
Transoral resection	0	1	0	0	0	0	0	0	0	1	0	0	2
Total laryngectomy	0	0	0	0	2	4	0	9	1	0	0	0	16
Laryngectomy, other type	0	0	0	0	1	0	0	0	0	0	0	0	1
Unknown	0	0	0	2	0	2	0	0	0	0	0	1	5
Others	0	0	0	0	0	0	0	0	0	0	0	1	1
Total	0	1	3	3	6	7	0	9	1	1	1	2	34

NOS: not otherwise specified.

T-: not within defined T classification or without reported T classification

## Treatment Method for the Cervical Lymph Nodes by Subsite

Treatment Method	Glottis (C32.0)	Supraglottis (C32.1) (C10.1)	Subglottis (C32.2)	Larynx, NOS (C32.9)	Total
Surgery					
without	1293	389	53	13	1748
with	201	213	22	16	452
unknown	21	8	0	5	34
Radiotherapy					
without	1261	359	52	26	1698
with	233	243	23	3	502
unknown	21	8	0	5	34
Chemotherapy					
without	1338	403	57	25	1823
with	156	199	18	4	377
unknown	21	8	0	5	34
Total	1515	610	75	34	2234

NOS: not otherwise specified.

## Neck Dissection on the Ipsilateral Side by Subsite

Neck dissection	Glottis (C32.0)	Supraglottis (C32.1) (C10.1)	Subglottis (C32.2)	Larynx, NOS (C32.9)	Total
0) No N.D.	1294	391	53	13	1751
1) Total N.D.	23	50	3	4	80
2) Selective N.D.	152	156	19	11	338
3) Lymph node excision	2	0	0	1	3
8) Others	14	4	0	0	18
9) Unknown	30	9	0	5	44
Total	1515	610	75	34	2234

NOS: not otherwise specified.

N.D.: neck dissection.

## Neck Dissection on the Contralateral Side by Subsite

Neck dissection	Glottis (C32.0)	Supraglottis (C32.1) (C10.1)	Subglottis (C32.2)	Larynx, NOS (C32.9)	Total
0) No N.D.	1386	469	59	19	1933
1) Total N.D.	5	17	1	2	25
2) Selective N.D.	82	110	15	8	215
3) Lymph node excision	0	1	0	0	1
8) Others	12	3	0	0	15
9) Unknown	30	10	0	5	45
<b>Total</b>	<b>1515</b>	<b>610</b>	<b>75</b>	<b>34</b>	<b>2234</b>

NOS: not otherwise specified.

N.D.: neck dissection

## Reconstructive Surgery by Subsite

Reconstructive surgery	Glottis (C32.0)	Supraglottis (C32.1) (C10.1)	Subglottis (C32.2)	Larynx, NOS (C32.9)	Total
0) No reconstruction	1466	542	73	24	2105
9) Unknown	27	9	0	5	41
B) Free jejunal flap	2	28	0	1	31
5) PM MC flap	5	18	1	2	26
E) Free ALT flap	5	6	0	0	11
4) DP flap	2	3	1	2	8
2) Local skin flap	2	1	0	0	3
3) Mucosal flap	1	1	0	0	2
C) Free FA flap	2	0	0	0	2
D) Free RA MC flap	1	1	0	0	2
7) Gastric pull-up	1	0	0	0	1
F) Free scapular OC flap	0	1	0	0	1
8) Others	1	0	0	0	1
1) Skin graft	0	0	0	0	0
6) Others	0	0	0	0	0
A) Others	0	0	0	0	0
G) Free fibular OC flap	0	0	0	0	0
H) Others	0	0	0	0	0
I) Free nerve graft	0	0	0	0	0
<b>Total</b>	<b>1515</b>	<b>610</b>	<b>75</b>	<b>34</b>	<b>2234</b>

NOS: not otherwise specified.

ALT: anterolateral thigh.

OC: osteocutaneous.

RA: rectus abdominis.

FA: forearm.

DP: deltopectoral.

MC: musculocutaneous.

PM: pectoralis major.

## Radiotherapy by Subsite

Type of radiotherapy	Glottis (C32.0)	Supraglottis (C32.1) (C10.1)	Subglottis (C32.2)	Larynx, NOS (C32.9)	Total
0) No radiotherapy	466	242	28	18	754
1) X-ray (and/or electron beam)	1024	351	47	15	1437
2) Particle beam	3	4	0	0	7
3) B.T.	0	0	0	0	0
4) X-ray + Particle beam	0	0	0	0	0
5) X-ray + B.T.	0	0	0	0	0
6) Particil beam + B.T.	0	0	0	0	0
7) X-ray + Particil beam + B.T.	0	0	0	0	0
8) Others	0	1	0	0	1
9) Unknown	22	12	0	1	35
Total	1515	610	75	34	2234

NOS: not otherwise specified

B.T.: brachytherapy.

## Chemotherapy by Subsite

Route of administration	Glottis (C32.0)	Supraglottis (C32.1) (C10.1)	Subglottis (C32.2)	Larynx, NOS (C32.9)	Total
0) No chemotherapy	1172	347	47	26	1592
1) I.V.	276	239	26	6	547
2) I.A.	4	0	0	0	4
3) Oral	37	10	1	1	49
4) I.V.+I.A.	0	0	0	0	0
5) I.V.+Oral	5	5	1	0	11
6) I.A.+Oral	0	0	0	0	0
7) I.V.+I.A.+Oral	0	0	0	0	0
8) Others	0	0	0	0	0
9) Unknown	21	9	0	1	31
Total	1515	610	75	34	2234

NOS: not otherwise specified

I.V.: intravenous.

I.A.: intraarterial.

Hypopharynx(2021)

3095 Cases

Carcinoma of the Hypopharynx ----- 3095 Cases

### Primary Site

<b>Site</b>	<b>Number of patients</b>	<b>(%)</b>
Postcricoid	304	(9.8)
Pyriform sinus	2180	(70.4)
Posterior wall	488	(15.8)
Hypopharynx, NOS	123	(4.0)
Total	3095	(100.0)

NOS: not otherwise specified.

### Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	1	1
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	11	4	15
40 - 49	49	32	81
50 - 59	323	74	397
60 - 69	860	68	928
70 - 79	1226	73	1299
80 - 89	344	18	362
90 - 99	9	3	12
100 - 109	0	0	0
Total	2822	273	3095

NOS: not otherwise specified.

### Postcricoid Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	0	1	1
40 - 49	6	5	11
50 - 59	26	8	34
60 - 69	70	6	76
70 - 79	123	11	134
80 - 89	43	2	45
90 - 99	2	1	3
100 - 109	0	0	0
<b>Total</b>	<b>270</b>	<b>34</b>	<b>304</b>

### Pyriform sinus Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	1	1
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	9	3	12
40 - 49	32	21	53
50 - 59	234	45	279
60 - 69	636	35	671
70 - 79	875	45	920
80 - 89	225	13	238
90 - 99	5	1	6
100 - 109	0	0	0
<b>Total</b>	<b>2016</b>	<b>164</b>	<b>2180</b>

### Posterior wall Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	1	0	1
40 - 49	9	4	13
50 - 59	49	16	65
60 - 69	130	21	151
70 - 79	176	15	191
80 - 89	62	3	65
90 - 99	1	1	2
100 - 109	0	0	0
<b>Total</b>	<b>428</b>	<b>60</b>	<b>488</b>

### Hypopharynx, NOS Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	1	0	1
40 - 49	2	2	4
50 - 59	14	5	19
60 - 69	24	6	30
70 - 79	52	2	54
80 - 89	14	0	14
90 - 99	1	0	1
100 - 109	0	0	0
<b>Total</b>	<b>108</b>	<b>15</b>	<b>123</b>

NOS: not otherwise specified.

Carcinoma of the Hypopharynx ----- 3095 Cases

## Histological Distribution by Subsite

Histologic type	Postcricoid (C13.0)	Pyriform sinus (C12.9) (C13.1)	Posterior wall (C13.2)	Hypopharynx, NOS (C13.9)	Total
S.C.C., NOS	283	1961	422	115	2781
Ca., NOS	1	3	0	2	6
Adenoid cystic ca.	0	1	0	0	1
Adenocarcinoma, NOS	0	0	0	1	1
S.C.C. in situ, NOS	12	118	26	1	157
Mucoepidermoid ca.	0	2	0	0	2
Basaloid S.C.C.	0	4	2	1	7
Verrucous ca., NOS	0	0	1	0	1
Ca., undiff., NOS	0	0	1	0	1
S.C.C., large cell, nonkerat., NOS	0	18	7	0	25
S.C.C., kerat., NOS	3	41	16	0	60
S.C.C., HPV negative	0	1	0	0	1
S.C.C., microinvasive	0	10	3	0	13
Rhabdomyosarcoma, NOS	0	0	0	1	1
S.C.C., spindle cell	0	2	1	1	4
Papillary S.C.C.	0	3	1	0	4
Lymphoepithelial ca.	0	2	0	0	2
Spindle cell ca., NOS	1	2	3	0	6
Carcinosarcoma, NOS	0	0	1	0	1
Adenosquamous ca.	0	1	0	0	1
Transitional cell ca., NOS	0	2	0	0	2
S.C.C., small cell, nonkerat.	1	2	0	0	3
Small cell ca., NOS	1	0	0	0	1
Clear cell ca., NOS	0	0	0	1	1
Basal cell adenocarcinoma	0	1	0	0	1
S.C.C. in situ with quest. stromal invasion	1	2	2	0	5
Neuroendocrine ca., NOS	0	2	0	0	2
S.C.C., nonkerat.	0	1	1	0	2
Synovial sarcoma, biphasic	0	1	0	0	1
S.C.C. with horn formation	0	0	1	0	1
Liposarcoma, NOS	1	0	0	0	1
<b>Total</b>	<b>304</b>	<b>2180</b>	<b>488</b>	<b>123</b>	<b>3095</b>

NOS: not otherwise specified.

malig., Malig.: malignant.

undiff.: undifferentiated.

ca., Ca.: carcinoma.

kerat.: keratinizing.

S.C.C.: squamous cell carcinoma.

nonkerat.: nonkeratinizing.

Carcinoma of the Hypopharynx ----- 3095 Cases

### T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	2	0	0	0	0	0	0	0	0	0	0	2
T1	474(1)	29	1(1)	5	35	4	3(1)	0	28(5)	5	0	584
T2	470(1)	124(2)	7(2)	16	206(2)	58(7)	2(1)	5	89(7)	5	0	982
T3	157(3)	89(2)	1	3	145(5)	85(6)	2	1	70(10)	1	0	554
T4	2	0	5(1)	0	4(1)	6	3(1)	0	3	0	0	23
T4a	93(3)	72(1)	2	9	183(11)	133(15)	0	2(2)	113(12)	1(1)	1	609
T4b	10(1)	10(1)	0	1	11(1)	19(2)	2	0	23(6)	0	0	76
Tis	247	0	0	0	2	0	0	0	0	2	0	251
TX	6	0	0	0	0	0	0	0	1	4	0	11
T-	0	0	0	0	0	0	0	0	0	0	3	3
<b>Total</b>	<b>1461(9)</b>	<b>324(6)</b>	<b>16(4)</b>	<b>34</b>	<b>586(20)</b>	<b>305(30)</b>	<b>12(3)</b>	<b>8(2)</b>	<b>327(40)</b>	<b>18(1)</b>	<b>4</b>	<b>3095</b>

M1:115 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

### Postcricoid T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	46(1)	3	0	0	2	0	0	0	4(1)	0	0	55
T2	63	19	1	1	24	6	0	1	4	0	0	119
T3	19	15	0	0	18	11(1)	0	0	3	0	0	66
T4	0	0	0	0	0	2	0	0	0	0	0	2
T4a	11(1)	1	0	1	8(1)	13(1)	0	0	8	0	0	42
T4b	0	0	0	0	0	2	0	0	0	0	0	2
Tis	15	0	0	0	0	0	0	0	0	0	0	15
TX	1	0	0	0	0	0	0	0	0	2	0	3
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>155(2)</b>	<b>38</b>	<b>1</b>	<b>2</b>	<b>52(1)</b>	<b>34(2)</b>	<b>0</b>	<b>1</b>	<b>19(1)</b>	<b>2</b>	<b>0</b>	<b>304</b>

M1:6 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

Carcinoma of the Hypopharynx ----- 3095 Cases

### Pyriform sinus T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	1	0	0	0	0	0	0	0	0	0	0	1
T1	319	20	0	4	32	2	2	0	22(4)	3	0	404
T2	314(1)	86(1)	4	15	167(2)	27(4)	2(1)	4	68(5)	4	0	691
T3	95(1)	62(2)	1	2	103(5)	41(4)	2	1	53(9)	0	0	360
T4	1	0	2	0	4(1)	3	3(1)	0	2	0	0	15
T4a	63	64(1)	1	7	154(9)	90(11)	0	2(2)	89(8)	0	1	471
T4b	3(1)	6(1)	0	0	9	7(1)	0	0	15(4)	0	0	40
Tis	189	0	0	0	1	0	0	0	0	0	0	190
TX	3	0	0	0	0	0	0	0	1	1	0	5
T-	0	0	0	0	0	0	0	0	0	0	3	3
Total	988(3)	238(5)	8	28	470(17)	170(20)	9(2)	7(2)	250(30)	8	4	2180

M1:79 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

### Posterior wall T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	1	0	0	0	0	0	0	0	0	0	0	1
T1	88	5	0	1	0	2	0	0	1	2	0	99
T2	79	17(1)	2(2)	0	11	22(1)	0	0	13(2)	1	0	145
T3	38(1)	10	0	0	21	25(1)	0	0	12(1)	1	0	107
T4	1	0	1	0	0	1	0	0	0	0	0	3
T4a	13(2)	4	1	1	13	24(3)	0	0	9(1)	0	0	65
T4b	5	3	0	1	2(1)	8	1	0	5	0	0	25
Tis	40	0	0	0	1	0	0	0	0	1	0	42
TX	1	0	0	0	0	0	0	0	0	0	0	1
T-	0	0	0	0	0	0	0	0	0	0	0	0
Total	266(3)	39(1)	4(2)	3	48(1)	82(5)	1	0	40(4)	5	0	488

M1:16 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Hypopharynx, NOS

### T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	21	1	1(1)	0	1	0	1(1)	0	1	0	0	26
T2	14	2	0	0	4	3(2)	0	0	4	0	0	27
T3	5(1)	2	0	1	3	8	0	0	2	0	0	21
T4	0	0	2(1)	0	0	0	0	0	1	0	0	3
T4a	6	3	0	0	8(1)	6	0	0	7(3)	1(1)	0	31
T4b	2	1	0	0	0	2(1)	1	0	3(2)	0	0	9
Tis	3	0	0	0	0	0	0	0	0	1	0	4
TX	1	0	0	0	0	0	0	0	0	1	0	2
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>52(1)</b>	<b>9</b>	<b>3(2)</b>	<b>1</b>	<b>16(1)</b>	<b>19(3)</b>	<b>2(1)</b>	<b>0</b>	<b>18(5)</b>	<b>3(1)</b>	<b>0</b>	<b>123</b>

NOS : Not Otherwise Specified

M1:14 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Treatment Method for the Primary Lesion by Subsite

Treatment Method	Postcricoid (C13.0)	Pyriform sinus (C12.9) (C13.1)	Posterior wall (C13.2)	Hypopharynx, NOS (C13.9)	Total
Surgery					
without	151	1115	218	60	1544
with	149	1052	263	62	1526
unknown	4	13	7	1	25
Radiotherapy					
without	131	947	254	65	1397
with	169	1220	227	57	1673
unknown	4	13	7	1	25
Chemotherapy					
without	166	1121	273	66	1626
with	134	1046	208	56	1444
unknown	4	13	7	1	25
<b>Total</b>	<b>304</b>	<b>2180</b>	<b>488</b>	<b>123</b>	<b>3095</b>

NOS: not otherwise specified.

Carcinoma of the Hypopharynx ----- 3095 Cases

Treatment Method for the Cervical Lymph Nodes by Subsite

Treatment Method	Postcricoid (C13.0)	Pyriform sinus (C12.9) (C13.1)	Posterior wall (C13.2)	Hypopharynx, NOS (C13.9)	Total
Surgery					
without	206	1520	335	85	2146
with	94	645	146	36	921
unknown	4	15	7	2	28
Radiotherapy					
without	159	1122	280	74	1635
with	141	1043	201	47	1432
unknown	4	15	7	2	28
Chemotherapy					
without	181	1217	291	71	1760
with	119	948	190	50	1307
unknown	4	15	7	2	28
Total	304	2180	488	123	3095

NOS: not otherwise specified.

Carcinoma of the Hypopharynx ----- 3095 Cases

Sequence of Treatment Methods for the Primary Lesion by Subsite

Sequence of treatment methods	Postcricoid (C13.0)	Pyriform sinus (C12.9) (C13.1)	Posterior wall (C13.2)	Hypopharynx, NOS (C13.9)	Total
No treatment	14	65	20	6	105
A) Surg. alone	98	720	195	42	1055
F)(Rad.+Chem.)	82	548	90	18	738
B) Rad. alone	33	242	41	14	330
A)F) Surg.->(Rad.+Chem.)	13	111	22	7	153
C)F) Chem. -> (Rad.+Chem.)	8	90	26	6	130
C) Chem. alone	7	79	18	13	117
A)B) Surg.->Rad.	18	71	14	4	107
C)A) Chem.->Surg.	7	39	12	2	60
C)A)F) Chem.->Surg.->(Rad.+Chem.)	2	23	8	1	34
C)B) Chem.->Rad.	1	20	6	0	27
F)C)(Rad.+Chem.)->Chem.	3	18	6	0	27
C)A)B) Chem.->Surg.->Rad.	3	11	2	1	17
A)C) Surg. -> Chem	1	12	1	1	15
F)A)(Rad.+Chem.)->Surg.	1	8	2	0	11
A)A) Surg.->Surg.	0	10	0	0	10
C)C)F) Chem.->Chem.->(Rad.+Chem.)	0	8	2	0	10
C)F)C) Chem.-> (Rad.+Chem.)->Chem.	0	6	3	0	9
B)C) Rad.->Chem.	0	6	1	1	8
C)C)Chem.->Chem.	1	5	1	1	8
C)C)C) Chem.->Chem.->Chem.	0	8	0	0	8
A)B)C) Surg.->Rad.->Chem.	1	5	0	0	6
H)Nonspesific Immunotherapy	1	3	2	0	6
D)(Surg.+Rad.)	0	5	0	0	5
Other	6	54	9	5	74
Unknown	4	13	7	1	25
Total	304	2180	488	123	3095

NOS : Not Otherwise Specified

Surg.: surgery. Rad.: radiotherapy.

Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

Carcinoma of the Hypopharynx ----- 3095 Cases

## Treatment Method for the Primary Lesion by T Classification

Treatment Method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
Surgery													
without	0	188	0	0	667	307	14	279	59	24	6	0	1544
with	2	393	0	0	310	243	9	326	16	222	5	0	1526
unknown	0	3	0	0	5	4	0	4	1	5	0	3	25
Radiotherapy													
without	2	410	0	0	286	200	5	231	26	230	7	0	1397
with	0	171	0	0	691	350	18	374	49	16	4	0	1673
unknown	0	3	0	0	5	4	0	4	1	5	0	3	25
Chemotherapy													
without	2	472	0	0	414	225	6	243	20	239	5	0	1626
with	0	109	0	0	563	325	17	362	55	7	6	0	1444
unknown	0	3	0	0	5	4	0	4	1	5	0	3	25
Total	2	584	0	0	982	554	23	609	76	251	11	3	3095

T-: not within defined T classification or without reported T classification

Carcinoma of the Hypopharynx ----- 3095 Cases

## Sequence of Treatment Methods for the Primary Lesion by T Classification

Sequence of treatment methods	T0	T1	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No treatment	0	16	21	18	1	33	6	8	2	0	105
A) Surg. alone	2	370	214	127	2	115	5	218	2	0	1055
F)(Rad.+Chem.)	0	69	401	142	8	93	17	5	3	0	738
B) Rad. alone	0	75	146	47	3	41	8	10	0	0	330
A)F) Surg.->(Rad.+Chem.)	0	7	28	39	4	73	2	0	0	0	153
C)F) Chem. -> (Rad.+Chem.)	0	4	43	39	1	36	7	0	0	0	130
C) Chem. alone	0	16	24	26	0	39	10	1	1	0	117
A)B) Surg.->Rad.	0	6	24	30	0	45	0	1	1	0	107
C)A) Chem.->Surg.	0	2	8	17	1	25	4	1	2	0	60
C)A)F) Chem.->Surg.->(Rad.+Chem.)	0	0	1	8	1	21	3	0	0	0	34
C)B) Chem.->Rad.	0	3	6	9	0	7	2	0	0	0	27
F)C)(Rad.+Chem.)->Chem.	0	0	6	8	1	8	4	0	0	0	27
C)A)B) Chem.->Surg.->Rad.	0	0	4	2	0	9	2	0	0	0	17
A)C) Surg. -> Chem	0	0	6	1	1	7	0	0	0	0	15
F)A)(Rad.+Chem.)->Surg.	0	0	6	4	0	1	0	0	0	0	11
A)A) Surg.->Surg.	0	3	2	2	0	1	0	2	0	0	10
C)C)F) Chem.->Chem.->(Rad.+Chem.)	0	0	4	5	0	1	0	0	0	0	10
Other	0	10	33	26	0	50	5	0	0	0	124
Unknown	0	3	5	4	0	4	1	5	0	3	25
Total	2	584	982	554	23	609	76	251	11	3	3095

T-: not within defined T classification or without reported T classification

Surg.: surgery.

Rad.: radiotherapy.

Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently

### Postcricoid Treatment Method for the Primary Lesion by T Classification

Treatment Method	T0	T1	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
Surgery											
without	0	15	79	34	2	16	2	1	2	0	151
with	0	40	38	31	0	25	0	14	1	0	149
unknown	0	0	2	1	0	1	0	0	0	0	4
Radiotherapy											
without	0	42	29	26	0	16	1	15	2	0	131
with	0	13	88	39	2	25	1	0	1	0	169
unknown	0	0	2	1	0	1	0	0	0	0	4
Chemotherapy											
without	0	44	51	28	2	25	1	15	0	0	166
with	0	11	66	37	0	16	1	0	3	0	134
unknown	0	0	2	1	0	1	0	0	0	0	4
Total	0	55	119	66	2	42	2	15	3	0	304

T-: not within defined T classification or without reported T classification

**Postcricoid**  
**Sequence of Treatment Methods for the Primary Lesion by T Classification**

Sequence of treatment methods	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No treatment	0	2	0	0	2	2	0	6	1	1	0	0	14
A) Surg. alone	0	38	0	0	23	16	0	7	0	14	0	0	98
F)(Rad.+Chem.)	0	7	0	0	50	19	0	5	0	0	1	0	82
B) Rad. alone	0	2	0	0	22	5	2	2	0	0	0	0	33
A)B) Surg.->Rad.	0	1	0	0	3	4	0	10	0	0	0	0	18
A)F) Surg.->(Rad.+Chem.)	0	0	0	0	5	5	0	3	0	0	0	0	13
C)F) Chem. -> (Rad.+Chem.)	0	0	0	0	4	2	0	1	1	0	0	0	8
C) Chem. alone	0	2	0	0	1	2	0	1	0	0	1	0	7
C)A) Chem.->Surg.	0	0	0	0	2	3	0	1	0	0	1	0	7
Unknown	0	0	0	0	2	1	0	1	0	0	0	0	4
Other	0	3	0	0	5	7	0	5	0	0	0	0	20
Total	0	55	0	0	119	66	2	42	2	15	3	0	304

T-: not within defined T classification or without reported T classification

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently

**Pyriform sinus**  
**Treatment Method for the Primary Lesion by T Classification**

Treatment Method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
Surgery													
without	0	143	0	0	486	210	8	212	31	22	3	0	1115
with	1	259	0	0	205	148	7	257	8	165	2	0	1052
unknown	0	2	0	0	0	2	0	2	1	3	0	3	13
Radiotherapy													
without	1	266	0	0	195	124	3	172	12	172	2	0	947
with	0	136	0	0	496	234	12	297	27	15	3	0	1220
unknown	0	2	0	0	0	2	0	2	1	3	0	3	13
Chemotherapy													
without	1	323	0	0	279	143	2	179	9	182	3	0	1121
with	0	79	0	0	412	215	13	290	30	5	2	0	1046
unknown	0	2	0	0	0	2	0	2	1	3	0	3	13
Total	1	404	0	0	691	360	15	471	40	190	5	3	2180

T-: not within defined T classification or without reported T classification

Carcinoma of the Hypopharynx ----- 3095 Cases

Pyriform sinus

Sequence of Treatment Methods for the Primary Lesion by T Classification

Sequence of treatment methods	T0	T1	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No treatment	0	9	12	10	0	23	3	7	1	0	65
A) Surg. alone	1	241	146	79	1	86	3	162	1	0	720
F)(Rad.+Chem.)	0	52	299	98	6	77	10	4	2	0	548
B) Rad. alone	0	64	98	33	1	33	3	10	0	0	242
A)F) Surg.->(Rad.+Chem.)	0	5	16	23	3	63	1	0	0	0	111
C)F) Chem. -> (Rad.+Chem.)	0	3	30	29	0	25	3	0	0	0	90
C) Chem. alone	0	9	18	20	0	27	4	1	0	0	79
A)B) Surg.->Rad.	0	5	16	19	0	29	0	1	1	0	71
C)A) Chem.->Surg.	0	2	4	9	1	21	2	0	0	0	39
C)A)F) Chem.->Surg.->(Rad.+Chem.)	0	0	1	2	1	18	1	0	0	0	23
C)B) Chem.->Rad.	0	2	6	6	0	4	2	0	0	0	20
F)C)(Rad.+Chem.)->Chem.	0	0	5	5	1	5	2	0	0	0	18
A)C) Surg. -> Chem	0	0	4	1	1	6	0	0	0	0	12
C)A)B) Chem.->Surg.->Rad.	0	0	1	1	0	8	1	0	0	0	11
A)A) Surg.->Surg.	0	3	2	2	0	1	0	2	0	0	10
C)C)C) Chem.->Chem.->Chem.	0	1	3	1	0	3	0	0	0	0	8
C)C)F) Chem.->Chem.->(Rad.+Chem.)	0	0	4	3	0	1	0	0	0	0	8
F)A)(Rad.+Chem.)->Surg.	0	0	3	4	0	1	0	0	0	0	8
Other	0	6	23	13	0	38	4	0	0	0	84
Unknown	0	2	0	2	0	2	1	3	0	3	13
<b>Total</b>	<b>1</b>	<b>404</b>	<b>691</b>	<b>360</b>	<b>15</b>	<b>471</b>	<b>40</b>	<b>190</b>	<b>5</b>	<b>3</b>	<b>2180</b>

T-: not within defined T classification or without reported T classification

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently

Posterior wall  
Treatment Method for the Primary Lesion by T Classification

Treatment Method	T0	T1	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
Surgery											
without	0	24	87	52	1	34	19	1	0	0	218
with	1	74	56	54	2	30	6	39	1	0	263
unknown	0	1	2	1	0	1	0	2	0	0	7
Radiotherapy											
without	1	79	51	43	1	32	7	39	1	0	254
with	0	19	92	63	2	32	18	1	0	0	227
unknown	0	1	2	1	0	1	0	2	0	0	7
Chemotherapy											
without	1	83	71	45	1	26	7	38	1	0	273
with	0	15	72	61	2	38	18	2	0	0	208
unknown	0	1	2	1	0	1	0	2	0	0	7
Total	1	99	145	107	3	65	25	42	1	0	488

T-: not within defined T classification or without reported T classification

Posterior wall  
Sequence of Treatment  
Methods for the Primary Lesion by T Classification

Sequence of treatment methods	T0	T1	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No treatment	0	5	5	6	0	3	1	0	0	0	20
A) Surg. alone	1	71	38	28	1	16	1	38	1	0	195
F)(Rad.+Chem.)	0	9	47	21	0	6	6	1	0	0	90
B) Rad. alone	0	7	22	5	0	3	4	0	0	0	41
C)F) Chem. -> (Rad.+Chem.)	0	1	7	7	1	7	3	0	0	0	26
A)F) Surg.->(Rad.+Chem.)	0	2	5	8	1	5	1	0	0	0	22
C) Chem. alone	0	2	3	2	0	9	2	0	0	0	18
A)B) Surg.->Rad.	0	0	5	6	0	3	0	0	0	0	14
C)A) Chem.->Surg.	0	0	2	4	0	3	2	1	0	0	12
C)A)F) Chem.->Surg.->(Rad.+Chem.)	0	0	0	6	0	1	1	0	0	0	8
C)B) Chem.->Rad.	0	0	0	3	0	3	0	0	0	0	6
F)C)(Rad.+Chem.)->Chem.	0	0	0	2	0	2	2	0	0	0	6
Other	0	1	9	8	0	3	2	0	0	0	23
Unknown	0	1	2	1	0	1	0	2	0	0	7
Total	1	99	145	107	3	65	25	42	1	0	488

T-: not within defined T classification or without reported T classification

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently

**Hypopharynx, NOS**  
**Treatment Method for the Primary Lesion by T Classification**

Treatment Method	T0	T1	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
Surgery											
without	0	6	15	11	3	17	7	0	1	0	60
with	0	20	11	10	0	14	2	4	1	0	62
unknown	0	0	1	0	0	0	0	0	0	0	1
Radiotherapy											
without	0	23	11	7	1	11	6	4	2	0	65
with	0	3	15	14	2	20	3	0	0	0	57
unknown	0	0	1	0	0	0	0	0	0	0	1
Chemotherapy											
without	0	22	13	9	1	13	3	4	1	0	66
with	0	4	13	12	2	18	6	0	1	0	56
unknown	0	0	1	0	0	0	0	0	0	0	1
<b>Total</b>	<b>0</b>	<b>26</b>	<b>27</b>	<b>21</b>	<b>3</b>	<b>31</b>	<b>9</b>	<b>4</b>	<b>2</b>	<b>0</b>	<b>123</b>

NOS: not otherwise specified.

T-: not within defined T classification or without reported T classification

**Hypopharynx, NOS****Sequence of Treatment Methods for the Primary Lesion by T Classification**

Sequence of treatment methods	T0	T1	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No treatment	0	0	2	0	1	1	1	0	1	0	6
A) Surg. alone	0	20	7	4	0	6	1	4	0	0	42
F)(Rad.+Chem.)	0	1	5	4	2	5	1	0	0	0	18
B) Rad. alone	0	2	4	4	0	3	1	0	0	0	14
C) Chem. alone	0	3	2	2	0	2	4	0	0	0	13
A)F) Surg.->(Rad.+Chem.)	0	0	2	3	0	2	0	0	0	0	7
C)F) Chem. -> (Rad.+Chem.)	0	0	2	1	0	3	0	0	0	0	6
A)B) Surg.->Rad.	0	0	0	1	0	3	0	0	0	0	4
Other	0	0	3	2	0	6	1	0	1	0	13
<b>Total</b>	<b>0</b>	<b>26</b>	<b>27</b>	<b>21</b>	<b>3</b>	<b>31</b>	<b>9</b>	<b>4</b>	<b>2</b>	<b>0</b>	<b>123</b>

NOS: not otherwise specified.

T-: not within defined T classification or without reported T classification

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently

Carcinoma of the Hypopharynx ----- 3095 Cases

### Surgical Methods for the Primary Lesion by Subsite

Surgical method	Pyriform sinus				Total
	Postcricoid (C13.0)	(C12.9) (C13.1)	Posterior wall (C13.2)	Hypopharynx, NOS (C13.9)	
No surgery	151	1117	217	60	1545
Endoscopic resection	29	307	84	14	434
Total pharyngolaryngectomy	30	273	76	11	390
Transoral resection	38	206	47	11	302
Total pharyngolaryngo-esophagectomy	32	148	28	18	226
Partial hypopharyngectomy	3	22	10	1	36
Hypopharyngectomy + Cervical esophagectomy	3	21	5	3	32
Total laryngectomy+Partial pharyngectomy	6	15	3	0	24
Total laryngectomy	5	16	0	0	21
Others	2	37	9	2	50
Unknown	5	18	9	3	35
Total	304	2180	488	123	3095

NOS: not otherwise specified.

Carcinoma of the Hypopharynx ----- 3095 Cases

## Surgical Methods for the Primary Lesion by T Classification

Surgical method	T0	T1	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No surgery	0	188	669	306	14	280	58	24	6	0	1545
Endoscopic resection	2	226	82	4	0	0	0	119	1	0	434
Total pharyngolaryngectomy	0	4	50	141	5	181	7	0	2	0	390
Transoral resection	0	134	77	3	0	0	0	87	1	0	302
Total pharyngolaryngo-esophagectomy	0	1	37	65	4	109	9	0	1	0	226
Partial hypopharyngectomy	0	8	22	2	0	4	0	0	0	0	36
Hypopharyngectomy + Cervical esophagectomy	0	0	5	12	0	15	0	0	0	0	32
Total laryngectomy+Partial pharyngectomy	0	1	9	7	0	6	0	1	0	0	24
Total laryngectomy	0	0	8	6	0	7	0	0	0	0	21
Others	0	17	14	2	0	2	0	15	0	0	50
Unknown	0	5	9	6	0	5	2	5	0	3	35
Total	2	584	982	554	23	609	76	251	11	3	3095

T-: not within defined T classification or without reported T classification

**Postcricoid  
Surgical Methods for the Primary Lesion by T Classification**

Surgical method	T0	T1	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No surgery	0	15	79	34	2	16	2	1	2	0	151
Endoscopic resection	0	18	5	0	0	0	0	7	0	0	30
Transoral resection	0	22	9	0	0	0	0	7	1	0	39
Partial hypopharyngectomy	0	0	2	0	0	1	0	0	0	0	3
Total laryngectomy+Partial pharyngectomy	0	0	3	2	0	1	0	0	0	0	6
Total pharyngolaryngectomy	0	0	8	12	0	10	0	0	0	0	30
Total pharyngolaryngo-esophagectomy	0	0	7	14	0	11	0	0	0	0	32
Hypopharyngectomy + Cervical esophagectomy	0	0	0	2	0	1	0	0	0	0	3
Total laryngectomy	0	0	3	1	0	1	0	0	0	0	5
Unknown	0	0	3	1	0	1	0	0	0	0	5
Total	0	55	119	66	2	42	2	15	3	0	304

T-: not within defined T classification or without reported T classification

Carcinoma of the Hypopharynx ----- 3095 Cases

**Pyriform sinus**  
**Surgical Methods for the Primary Lesion by T Classification**

Surgical method	T0	T1	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No surgery	0	143	488	209	8	213	31	22	3	0	1117
Resection of the root of tongue	0	0	0	0	0	0	0	1	0	0	1
Resection of the oropharynx, other type	0	2	0	0	0	0	0	0	0	0	2
Endoscopic resection	1	158	63	2	0	0	0	90	1	0	315
Transoral resection	0	86	55	1	0	0	0	74	0	0	216
Partial hypopharyngectomy	0	5	14	1	0	2	0	0	0	0	22
Total laryngectomy+Partial pharyngectomy	0	0	5	5	0	5	0	0	0	0	15
Total pharyngolaryngectomy	0	2	30	87	4	145	4	0	1	0	273
Total pharyngolaryngo-esophagectomy	0	1	19	38	3	83	4	0	0	0	148
Hypopharyngectomy + Cervical esophagectomy	0	0	2	6	0	13	0	0	0	0	21
Subtotal laryngectomy	0	0	0	1	0	0	0	0	0	0	1
Total laryngectomy	0	0	5	5	0	6	0	0	0	0	16
Others	0	3	9	1	0	2	0	0	0	0	15
Unknown	0	4	1	4	0	2	1	3	0	3	18
<b>Total</b>	<b>1</b>	<b>404</b>	<b>691</b>	<b>360</b>	<b>15</b>	<b>471</b>	<b>40</b>	<b>190</b>	<b>5</b>	<b>3</b>	<b>2180</b>

T-: not within defined T classification or without reported T classification

Carcinoma of the Hypopharynx ----- 3095 Cases

Posterior wall

Surgical Methods for the Primary Lesion by T Classification

Surgical method	T0	T1	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No surgery	0	24	87	52	1	34	18	1	0	0	217
Resection of the posterior wall	0	1	0	0	0	0	0	0	0	0	1
Endoscopic resection	1	44	14	2	0	0	0	27	0	0	88
Transoral resection	0	24	13	1	0	0	0	11	0	0	49
Partial hypopharyngectomy	0	2	6	1	0	1	0	0	0	0	10
Total laryngectomy+Partial pharyngectomy	0	1	1	0	0	0	0	1	0	0	3
Total pharyngolaryngectomy	0	1	11	39	1	20	3	0	1	0	76
Total pharyngolaryngo-esophagectomy	0	0	7	8	1	9	3	0	0	0	28
Hypopharyngectomy + Cervical esophagectomy	0	0	2	3	0	0	0	0	0	0	5
Laryngectomy, other type	0	0	1	0	0	0	0	0	0	0	1
Others	0	1	0	0	0	0	0	0	0	0	1
Unknown	0	1	3	1	0	1	1	2	0	0	9
Total	1	99	145	107	3	65	25	42	1	0	488

T-: not within defined T classification or without reported T classification

## Hypopharynx, NOS Surgical Methods for the Primary Lesion by T Classification

Surgical method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No surgery	0	6	0	0	15	11	3	17	7	0	1	0	60
Resection of the root of tongue	0	0	0	0	1	0	0	0	0	0	0	0	1
Endoscopic resection	0	10	0	0	1	0	0	0	0	3	0	0	14
Transoral resection	0	8	0	0	2	1	0	0	0	1	0	0	12
Partial hypopharyngectomy	0	1	0	0	0	0	0	0	0	0	0	0	1
Total pharyngolaryngectomy	0	1	0	0	1	3	0	6	0	0	0	0	11
Total pharyngolaryngo-esophagectomy	0	0	0	0	4	5	0	6	2	0	1	0	18
Hypopharyngectomy + Cervical esophagectomy	0	0	0	0	1	1	0	1	0	0	0	0	3
Unknown	0	0	0	0	2	0	0	1	0	0	0	0	3
Total	0	26	0	0	27	21	3	31	9	4	2	0	123

NOS: not otherwise specified.

T-: not within defined T classification or without reported T classification

Carcinoma of the Hypopharynx ----- 3095 Cases

## Neck Dissection on the Ipsilateral Side by Subsite

Neck dissection	Postcricoid (C13.0)	Pyriform sinus (C12.9) (C13.1)	Posterior wall (C13.2)	Hypopharynx, NOS (C13.9)	Total
0) No N.D.	205	1520	336	83	2144
1) Total N.D.	17	181	26	5	229
2) Selective N.D.	75	448	115	30	668
3) Lymph node excision	0	0	0	0	0
8) Others	1	8	3	1	13
9) Unknown	6	23	8	4	41
Total	304	2180	488	123	3095

NOS: not otherwise specified.

N.D.: neck dissection.

## Neck Dissection on the Contralateral Side by Subsite

Neck dissection	Postcricoid (C13.0)	Pyriform sinus (C12.9) (C13.1)	Posterior wall (C13.2)	Hypopharynx, NOS (C13.9)	Total
0) No N.D.	224	1701	369	92	2386
1) Total N.D.	12	71	13	6	102
2) Selective N.D.	61	373	95	21	550
3) Lymph node excision	0	2	0	0	2
8) Others	1	11	3	0	15
9) Unknown	6	22	8	4	40
Total	304	2180	488	123	3095

NOS: not otherwise specified.

N.D.: neck dissection.

## Reconstructive Surgery by Subsite

Reconstructive surgery	Postcricoid (C13.0)	Pyriform sinus (C12.9) (C13.1)	Posterior wall (C13.2)	Hypopharynx, NOS (C13.9)	Total
0) No reconstruction	227	1682	361	88	2358
B) Free jejunal flap	62	401	104	23	590
E) Free ALT flap	1	27	7	2	37
5) PM MC flap	3	14	2	3	22
7) Gastric pull-up	2	13	3	3	21
C) Free FA flap	0	10	1	0	11
4) DP flap	2	4	1	0	7
2) Local skin flap	0	2	0	0	2
D) Free RA MC flap	0	1	0	0	1
1) Skin graft	0	0	0	0	0
3) Mucosal flap	0	0	0	0	0
F) Free scapular OC flap	0	0	0	0	0
G) Free fibular OC flap	0	0	0	0	0
I) Free nerve graft	0	0	0	0	0
Others	2	5	1	1	9
9) Unknown	5	21	8	3	37
<b>Total</b>	<b>304</b>	<b>2180</b>	<b>488</b>	<b>123</b>	<b>3095</b>

RA: rectus abdominis.

MC: musculocutaneous.

ALT: anterolateral thigh.

FA: forearm.

PM: pectoralis major.

OC: osteocutaneous.

DP: deltopectoral.

NOS: not otherwise specified.

## Radiotherapy by Subsite

Type of radiotherapy	Postcricoid (C13.0)	Pyriform sinus (C12.9) (C13.1)	Posterior wall (C13.2)	Hypopharynx, NOS (C13.9)	Total
0) No radiotherapy	130	915	242	65	1352
1) X-ray (and/or electron beam)	167	1243	235	57	1702
2) Particle beam	0	1	0	0	1
3) B.T.	0	0	0	0	0
4) X-ray + Particle beam	0	2	1	0	3
5) X-ray + B.T.	0	0	0	0	0
6) Particl beam + B.T.	0	0	0	0	0
7) X-ray + Particl beam + B.T.	0	0	0	0	0
8) Others	2	0	0	0	2
9) Unknown	5	19	10	1	35
Total	304	2180	488	123	3095

NOS: not otherwise specified.

B.T.: brachytherapy.

## Chemotherapy by Subsite

Route of administration	Postcricoid (C13.0)	Pyriform sinus (C12.9) (C13.1)	Posterior wall (C13.2)	Hypopharynx, NOS (C13.9)	Total
0) No chemotherapy	162	1108	265	64	1599
1) I.V.	132	1020	210	55	1417
2) I.A.	0	11	0	0	11
3) Oral	6	16	4	2	28
4) I.V.+I.A.	0	1	0	0	1
5) I.V.+Oral	0	6	1	0	7
6) I.A.+Oral	0	0	0	0	0
7) I.V.+I.A.+Oral	0	0	0	0	0
8) Others	0	0	0	0	0
9) Unknown	4	18	8	2	32
Total	304	2180	488	123	3095

NOS: not otherwise specified.

I.V.: intravenous.

I.A.: intraarterial.

Oropharynx(2021)

2439 Cases

## Primary Site

<b>Site</b>	<b>Number of patients</b>	<b>(%)</b>
Superiorwall	218	(8.9)
Lateralwall	1449	(59.4)
Posteriorwall	167	(6.8)
Anteriorwall	527	(21.6)
Oropharynx, NOS	78	(3.2)
Total	2439	(100.0)

NOS: not otherwise specified.

## Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	2	3	5
30 - 39	11	6	17
40 - 49	128	58	186
50 - 59	369	87	456
60 - 69	604	129	733
70 - 79	687	139	826
80 - 89	156	47	203
90 - 99	9	4	13
100 - 109	0	0	0
Total	1966	473	2439

### p16 status

	<b>Total</b>
p16 positive	1234
p16 negative	881
p16 unknown	284
not reported	40
Total	2439

Oropharynx p16 positive(2021)

1234Cases

## Primary Site

<b>Site</b>	<b>Number of patients</b>	<b>(%)</b>
Superiorwall	31	(2.5)
Lateralwall	943	(76.4)
Posteriorwall	19	(1.5)
Anteriorwall	210	(17)
Oropharynx, NOS	31	(2.5)
Total	1234	(100)

NOS: not otherwise specified.

## Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	1	1
30 - 39	10	2	12
40 - 49	98	40	138
50 - 59	235	48	283
60 - 69	291	77	368
70 - 79	279	74	353
80 - 89	58	18	76
90 - 99	3	0	3
100 - 109	0	0	0
Total	974	260	1234

Carcinoma of the Oropharynx p16 positive ----- 1234Cases

## Histological Distribution by Subsite

Histologic type	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
S.C.C., NOS	30	865	15	198	30	1138
Ca., NOS	0	2	0	0	0	2
Adenocarcinoma, NOS	0	1	0	0	0	1
S.C.C. in situ, NOS	1	0	3	1	0	5
Basaloid S.C.C.	0	3	0	0	0	3
Ca., undiff., NOS	0	1	0	1	0	2
S.C.C., large cell, nonkerat., NOS	0	9	0	2	0	11
S.C.C., kerat., NOS	0	23	1	2	0	26
S.C.C., HPV positive	0	33	0	4	0	37
S.C.C., spindle cell	0	2	0	0	0	2
Papillary S.C.C.	0	0	0	1	0	1
Lymphoepithelial ca.	0	1	0	0	0	1
S.C.C., small cell, nonkerat.	0	1	0	0	1	2
Small cell ca., NOS	0	1	0	0	0	1
Clear cell ca., NOS	0	0	0	1	0	1
S.C.C. in situ, p16 positive	0	1	0	0	0	1
Total	31	943	19	210	31	1234

NOS: not otherwise specified.

S.C.C.: squamous cell carcinoma.

ca., Ca.: carcinoma.

HPV : Human papillomavirus.

Carcinoma of the Oropharynx p16 positive ----- 1234Cases

T and N Status

	N0	N1	N2	N2a	N2b	N3	N3a	N3b	NX	N-	Total
T0	0	8	4	0	0	0	0	0	0	0	12
T1	46	151	11	0	0	11(2)	0	0	2	0	221
T2	119	380(5)	71(4)	0	0	20	0	0	1	1	592
T3	28	82(2)	52(7)	0	0	4(1)	0	0	0	0	166
T4	26(1)	90(2)	93(18)	0	0	16(3)	0	0	1	0	226
T4a	1	2	0	0	0	0	0	0	0	0	3
T4b	0	0	0	0	0	0	0	0	0	0	0
Tis	5	1	0	0	0	0	0	0	1	0	7
TX	0	0	0	0	0	0	1	0	0	0	1
T-	0	1	0	0	0	0	0	0	1	4	6
Total	225(1)	715(9)	231(29)	0	0	51(6)	1	0	6	5	1234

M1:45 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

Treatment Method for the Primary Lesion by Subsite

Treatment Method	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
Surgery						
without	18	628	13	161	24	844
with	12	314	6	48	7	387
unknown	1	1	0	1	0	3
Radiotherapy						
without	9	240	6	48	11	314
with	21	702	13	161	20	917
unknown	1	1	0	1	0	3
Chemotherapy						
without	13	298	10	67	8	396
with	17	644	9	142	23	835
unknown	1	1	0	1	0	3
Total	31	943	19	210	31	1234

NOS : Not Otherwise Specified

## Treatment Method for the Cervical Lymph Nodes by Subsite

Treatment Method	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
Surgery						
without	26	644	18	162	26	876
with	4	297	1	47	5	354
unknown	1	1	0	1	0	3
Radiotherapy						
without	10	281	8	64	12	375
with	20	660	11	145	19	855
unknown	1	1	0	1	0	3
Chemotherapy						
without	15	336	11	76	10	448
with	15	605	8	133	21	782
unknown	1	1	0	1	0	3
Total	31	942	19	210	31	1233

Treatment Method for the Cervical Lymph Nodes by Primary Site was not reported in a patient.

NOS : Not Otherwise Specified

Treatment methods in parentheses were given concurrently

## Sequence of Treatment Methods for the Primary Lesion by Subsite

Sequence of treatment methods	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
No treatment	0	11	0	7	3	21
F)(Rad.+Chem.)	11	449	7	93	12	572
A) Surg. alone	8	177	5	23	3	216
B) Rad. alone	4	75	4	28	1	112
C)F) Chem. -> (Rad.+Chem.)	2	52	2	15	2	73
A)F) Surg.->(Rad.+Chem.)	2	43	0	4	2	51
A)B) Surg.->Rad.	1	32	0	8	1	42
C)A) Chem.->Surg.	1	27	0	4	0	32
C) Chem. alone	0	19	0	8	4	31
C)B) Chem.->Rad.	0	12	0	1	1	14
F)C)(Rad.+Chem.)->Chem.	1	6	0	3	0	10
C)A)F) Chem.->Surg.->(Rad.+Chem.)	0	6	0	3	0	9
A)C) Surg. -> Chem	0	3	0	2	0	5
C)A)B) Chem.->Surg.->Rad.	0	5	0	0	0	5
C)A)C) Chem.->Surg.->Chem.	0	4	0	1	0	5
Other	1	22	1	10	2	36
Total	31	943	19	210	31	1234

NOS : Not Otherwise Specified

Surg.: surgery.

Rad.: radiotherapy.

Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

## Surgical Methods for the Primary Lesion by Subsite

Surgical method	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
No surgery	17	626	13	162	24	842
Unilateral resection of the lateral wall of the oropharynx	1	223	0	2	1	227
Resection of the oropharynx, other type	1	42	0	9	3	55
Resection of the root of tongue	0	1	0	27	0	28
Transoral resection	1	12	1	2	0	16
Unilateral resection of the lateral wall of the oropharynx and soft palate	0	10	0	0	0	10
Unilateral resection of the lateral wall of the oropharynx, soft palate and the base of tongue	0	8	0	0	0	8
Resection of the posterior wall	0	1	5	0	1	7
Resection of the soft palate	4	2	0	0	0	6
Resection of the uvula	4	1	0	0	0	5
Resection of the base of tongue and epiglottis	0	1	0	2	1	4
Transoral resection	0	3	0	0	1	4
Others	1	5	0	5	0	11
Unknown	2	8	0	1	0	11
Total	31	943	19	210	31	1234

NOS: not otherwise specified.

## Reconstructive Surgery by Subsite

Reconstructive surgery	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
0) No reconstruction	28	881	19	200	28	1156
E) Free ALT flap	1	26	0	4	1	32
5) PM MC flap	0	9	0	2	0	11
D) Free RA MC flap	0	9	0	1	0	10
2) Local skin flap	0	1	0	2	0	3
C) Free FA flap	0	3	0	0	0	3
3) Mucosal flap	0	0	0	0	1	1
F) Free scapular OC flap	1	0	0	0	0	1
G) Free fibular OC flap	0	1	0	0	0	1
1) Skin graft	0	0	0	0	0	0
4) DP flap	0	0	0	0	0	0
7) Gastric pull-up	0	0	0	0	0	0
B) Free jejunal flap	0	0	0	0	0	0
I) Free nerve graft	0	0	0	0	0	0
Others	0	3	0	0	0	3
9) Unknown	1	10	0	1	1	13
Total	31	943	19	210	31	1234

RA: rectus abdominis.

FA: forearm.

DP: deltopectoral.

NOS: not otherwise specified.

MC: musculocutaneous.

PM: pectoralis major.

ALT: anterolateral thigh.

OC: osteocutaneous.

Carcinoma of the Oropharynx p16 positive ----- 1234Cases

### Neck Dissection on the Ipsilateral Side by Subsite

Neck dissection	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
0) No N.D.	26	644	18	164	26	878
1) Total N.D.	1	77	0	14	0	92
2) Selective N.D.	3	206	1	29	4	243
3) Lymph node excision	0	5	0	1	1	7
8) Others	0	4	0	1	0	5
9) Unknown	1	7	0	1	0	9
Total	31	943	19	210	31	1234

NOS: not otherwise specified.

N.D.: neck dissection.

### Neck Dissection on the Contralateral Side by Subsite

Neck dissection	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
0) No N.D.	30	914	19	200	30	1193
1) Total N.D.	0	4	0	2	0	6
2) Selective N.D.	0	15	0	6	1	22
3) Lymph node excision	0	0	0	0	0	0
8) Others	0	3	0	1	0	4
9) Unknown	1	7	0	1	0	9
Total	31	943	19	210	31	1234

NOS: not otherwise specified.

N.D.: neck dissection.

Carcinoma of the Oropharynx p16 positive ----- 1234Cases

### Radiotherapy by Subsite

Type of radiotherapy	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
0) No radiotherapy	8	232	6	46	9	301
1) X-ray (and/or electron beam)	22	699	13	161	21	916
2) Particle beam	0	4	0	0	0	4
3) B.T.	0	0	0	0	0	0
4) X-ray + Particle beam	0	0	0	0	0	0
5) X-ray + B.T.	0	0	0	0	0	0
6) Particl beam + B.T.	0	0	0	0	0	0
7) X-ray + Particl beam + B.T.	0	0	0	0	0	0
8) Others	0	0	0	0	0	0
9) Unknown	1	8	0	3	1	13
Total	31	943	19	210	31	1234

NOS: not otherwise specified.

B.T.: brachytherapy.

Carcinoma of the Oropharynx p16 positive ----- 1234Cases

**Chemotherapy by Subsite**

Route of administration	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
0) No chemotherapy	13	293	10	68	8	392
1) I.V.	17	619	8	138	20	802
2) I.A.	0	10	1	2	1	14
3) Oral	0	8	0	0	2	10
4) I.V.+I.A.	0	2	0	0	0	2
5) I.V.+Oral	0	6	0	1	0	7
6) I.A.+Oral	0	1	0	0	0	1
7) I.V.+I.A.+Oral	0	0	0	0	0	0
8) Others	0	0	0	0	0	0
9) Unknown	1	4	0	1	0	6
<b>Total</b>	<b>31</b>	<b>943</b>	<b>19</b>	<b>210</b>	<b>31</b>	<b>1234</b>

I.V.: intravenous.

I.A.: intraarterial.

NOS: not otherwise specified.

# Oropharynx p16 negative and unknown (2021)

1165 Cases

## Primary Site

<b>Site</b>	<b>Number of patients</b>	<b>(%)</b>
Superiorwall	183	(15.7)
Lateralwall	488	(41.9)
Posteriorwall	144	(12.4)
Anteriorwall	305	(26.2)
Oropharynx, NOS	45	(3.9)
<b>Total</b>	<b>1165</b>	<b>(100)</b>

NOS: not otherwise specified.

## Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	2	2	4
30 - 39	1	4	5
40 - 49	28	16	44
50 - 59	129	38	167
60 - 69	303	51	354
70 - 79	396	64	460
80 - 89	95	28	123
90 - 99	5	3	8
100 - 109	0	0	0
<b>Total</b>	<b>959</b>	<b>206</b>	<b>1165</b>

## Histological Distribution by Subsite

Histologic type	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
S.C.C., NOS	147	417	112	243	40	959
Ca., NOS	0	4	2	1	0	7
Salivary duct ca.	0	1	0	1	0	2
Malig. lymphoma, NOS	0	9	0	3	0	12
Adenoid cystic ca.	3	1	0	6	1	11
Adenocarcinoma, NOS	1	2	0	0	0	3
S.C.C. in situ, NOS	13	11	22	11	2	59
Myoepithelial ca.	1	0	0	0	0	1
Mucoepidermoid ca.	2	3	0	6	0	11
Basaloid S.C.C.	0	1	0	2	0	3
Verrucous ca., NOS	1	0	0	0	0	1
Ca., undiff., NOS	0	1	0	0	0	1
Malig. melanoma, NOS	1	1	0	0	0	2
S.C.C., large cell, nonkerat., NOS	1	6	0	1	0	8
S.C.C., kerat., NOS	7	10	0	10	0	27
Intraepithelial, NOS	0	0	1	1	0	2
S.C.C., HPV negative	2	10	2	5	0	19
S.C.C., microinvasive	1	1	3	1	0	6
Ca. ex pleomorphic adenoma	0	0	0	0	1	1
S.C.C., spindle cell	0	0	1	0	0	1
Epithelial-myoepithelial ca.	1	0	0	0	0	1
Neoplasm, malig.	0	0	0	1	0	1
Papillary S.C.C.	1	3	0	0	0	4
Acinar cell ca.	0	1	0	0	0	1
Spindle cell ca., NOS	0	0	0	2	0	2
Carcinosarcoma, NOS	0	1	0	0	0	1
Adenosquamous ca.	0	0	0	1	0	1
Plasmacytoma, NOS	0	0	0	1	0	1
S.C.C., small cell, nonkerat.	0	0	0	1	0	1
Small cell ca., NOS	0	1	1	2	0	4
Polymorphous low grade adenocarcinoma	1	0	0	1	0	2
Clear cell ca., NOS	0	0	0	1	0	1
Carcinoid tumor, NOS	0	0	0	1	0	1
Neuroendocrine ca., NOS	0	0	0	1	0	1
Malig. lymphoma, large B-cell, diffuse, NOS	0	2	0	1	1	4
Marginal zone B-cell lymphoma, NOS	0	1	0	0	0	1
Follicular lymphoma, NOS	0	1	0	0	0	1
Undiff. sarcoma	0	0	0	1	0	1
<b>Total</b>	<b>183</b>	<b>488</b>	<b>144</b>	<b>305</b>	<b>45</b>	<b>1165</b>

NOS: not otherwise specified.

S.C.C.: squamous cell carcinoma.

ca., Ca.: carcinoma.

HPV: Human papillomavirus.

Carcinoma of the Oropharynx p16 positive ----- 1165Cases

**T and N Status**

	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	2	0	0	0	2	0	0	0	2	0	0	6
T1	209(1)	18	0	2	13(1)	5	0	0	14(1)	3	0	264
T2	175	52	5	9	63(5)	32(3)	1	0	19(1)	4	0	360
T3	61	25(1)	0	1	29(4)	29(2)	0	0	17(1)	1	0	163
T4	4(1)	6	5	0	1	0	0	0	2	1	0	19
T4a	33	24	3(1)	1	56(4)	45(9)	2	2	37(5)	0	0	203
T4b	8	1	0	0	6(1)	13(3)	0	0	13(2)	0	0	41
Tis	76	1	0	0	0	0	0	1(1)	1	0	0	79
TX	4	2	0	0	0	0	0	0	1	8(1)	1	16
T-	0	0	0	0	0	0	0	0	0	0	14	14
Total	572(2)	129(1)	13(1)	13	170(15)	124(17)	3	3(1)	106(10)	17(1)	15	1165

M1:48 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

**Treatment Method for the Primary Lesion by Subsite**

Treatment Method	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
Surgery						
without	64	276	70	178	24	612
with	119	209	74	125	20	547
unknown	0	3	0	2	1	6
Radiotherapy						
without	105	226	77	138	25	571
with	78	259	67	165	19	588
unknown	0	3	0	2	1	6
Chemotherapy						
without	127	259	86	144	23	639
with	56	226	58	159	21	520
unknown	0	3	0	2	1	6
Total	183	488	144	305	45	1165

NOS : Not Otherwise Specified

Carcinoma of the Oropharynx p16 positive ----- 1165Cases

### Treatment Method for the Cervical Lymph Nodes by Subsite

Treatment Method	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
Surgery						
without	145	385	131	242	38	941
with	37	100	13	61	6	217
unknown	1	3	0	2	1	7
Radiotherapy						
without	119	267	97	173	29	685
with	63	218	47	130	15	473
unknown	1	3	0	2	1	7
Chemotherapy						
without	137	288	98	173	27	723
with	45	197	46	130	17	435
unknown	1	3	0	2	1	7
Total	183	488	144	305	45	1165

NOS : Not Otherwise Specified

### Sequence of Treatment Methods for the Primary Lesion by Subsite

Sequence of treatment methods	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
No treatment	1	26	4	10	5	46
A) Surg. alone	96	163	63	91	18	431
F)(Rad.+Chem.)	34	124	39	86	13	296
B) Rad. alone	21	54	17	31	0	123
C) Chem. alone	3	23	5	20	2	53
C)F) Chem. -> (Rad.+Chem.)	2	19	2	17	1	41
A)B) Surg.->Rad.	9	12	2	8	0	31
A)F) Surg.->(Rad.+Chem.)	6	16	0	7	1	30
C)A) Chem.->Surg.	3	6	4	6	0	19
C)B) Chem.->Rad.	0	10	0	3	0	13
F)C)(Rad.+Chem.)->Chem.	0	8	1	2	0	11
A)C) Surg. -> Chem	1	1	1	3	0	6
C)F)C) Chem.-> (Rad.+Chem.)->Chem.	0	4	1	0	1	6
F)A)(Rad.+Chem.)->Surg.	2	1	1	2	0	6
C)A)B) Chem.->Surg.->Rad.	2	2	1	0	0	5
C)C)Chem.->Chem.	0	2	0	3	0	5
Other	3	14	3	14	3	37
Unknown	0	3	0	2	1	6
Total	183	488	144	305	45	1165

NOS : Not Otherwise Specified

Surg.: surgery. Rad.: radiotherapy.

Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

## Surgical Methods for the Primary Lesion by Subsite

Surgical method	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
No surgery	64	275	70	178	24	611
Unilateral resection of the lateral wall of the oropharynx	6	119	1	2	1	129
Resection of the oropharynx, other type	8	43	10	32	12	105
Resection of the soft palate	65	6	0	0	2	73
Resection of the root of tongue	1	2	0	51	0	54
Resection of the posterior wall	0	2	49	0	1	52
Resection of the uvula	23	1	0	0	1	25
Transoral resection	2	7	4	3	3	19
Unilateral resection of the lateral wall of the oropharynx, soft palate and the base of tongue	2	10	0	0	0	12
Endoscopic resection	0	4	4	4	0	12
Unilateral resection of the lateral wall of the oropharynx and soft palate	4	7	0	0	0	11
Total pharyngolaryngectomy	0	1	4	6	0	11
Total glossectomy	0	2	0	5	0	7
Resection of the base of tongue and epiglottis	0	1	0	6	0	7
Total laryngectomy	0	0	0	4	0	4
Others	7	3	2	12	0	24
Unknown	1	5	0	2	1	9
Total	183	488	144	305	45	1165

NOS: not otherwise specified.

Carcinoma of the Oropharynx p16 negative and unknown ----- 1165Cases

Reconstructive Surgery by Subsite

Reconstructive surgery	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
0) No reconstruction	158	436	132	261	39	1026
E) Free ALT flap	10	30	1	12	1	54
D) Free RA MC flap	1	9	1	10	1	22
B) Free jejunal flap	0	3	6	6	1	16
5) PM MC flap	0	2	2	9	0	13
C) Free FA flap	3	2	1	1	0	7
2) Local skin flap	3	0	0	1	0	4
3) Mucosal flap	3	0	0	1	0	4
4) DP flap	1	0	0	0	0	1
7) Gastric pull-up	0	0	1	0	0	1
F) Free scapular OC flap	0	0	0	1	0	1
G) Free fibular OC flap	0	1	0	0	0	1
1) Skin graft	0	0	0	0	0	0
I) Free nerve graft	0	0	0	0	0	0
Others	2	0	0	0	2	4
9) Unknown	2	5	0	3	1	11
Total	183	488	144	305	45	1165

RA: rectus abdominis.

FA: forearm.

DP: deltopectoral.

NOS: not otherwise specified.

MC: musculocutaneous.

PM: pectoralis major.

ALT: anterolateral thigh.

OC: osteocutaneous.

Carcinoma of the Oropharynx p16 negative and unknown ----- 1165Cases

### Neck Dissection on the Ipsilateral Side by Subsite

Neck dissection	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
0) No N.D.	145	386	131	242	39	943
1) Total N.D.	9	27	2	15	3	56
2) Selective N.D.	27	69	10	46	2	154
3) Lymph node excision	0	1	0	0	0	1
8) Others	1	1	1	0	0	3
9) Unknown	1	4	0	2	1	8
<b>Total</b>	<b>183</b>	<b>488</b>	<b>144</b>	<b>305</b>	<b>45</b>	<b>1165</b>

NOS: not otherwise specified.

N.D.: neck dissection.

### Neck Dissection on the Contralateral Side by Subsite

Neck dissection	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
0) No N.D.	169	465	134	271	42	1081
1) Total N.D.	3	3	1	5	2	14
2) Selective N.D.	8	15	8	26	0	57
3) Lymph node excision	0	0	0	0	0	0
8) Others	2	1	1	1	0	5
9) Unknown	1	4	0	2	1	8
<b>Total</b>	<b>183</b>	<b>488</b>	<b>144</b>	<b>305</b>	<b>45</b>	<b>1165</b>

NOS: not otherwise specified.

N.D.: neck dissection.

Carcinoma of the Oropharynx p16 negative and unknown ----- 1165Cases

### Radiotherapy by Subsite

Type of radiotherapy	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
0) No radiotherapy	102	219	76	137	25	559
1) X-ray (and/or electron beam)	76	259	66	162	19	582
2) Particle beam	0	3	0	3	0	6
3) B.T.	2	1	0	0	0	3
4) X-ray + Particle beam	0	0	0	0	0	0
5) X-ray + B.T.	1	0	0	0	0	1
6) Particl beam + B.T.	0	0	0	0	0	0
7) X-ray + Particl beam + B.T.	0	0	0	0	0	0
8) Others	0	1	0	0	0	1
9) Unknown	2	5	2	3	1	13
Total	183	488	144	305	45	1165

NOS: not otherwise specified.

B.T.: brachytherapy.

Carcinoma of the Oropharynx p16 negative and unknown ----- 1165Cases

**Chemotherapy by Subsite**

Route of administration	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
0) No chemotherapy	125	257	84	143	23	632
1) I.V.	51	219	57	145	20	492
2) I.A.	3	3	1	7	0	14
3) Oral	3	4	1	5	1	14
4) I.V.+I.A.	0	0	0	0	0	0
5) I.V.+Oral	0	1	0	2	0	3
6) I.A.+Oral	0	0	0	0	0	0
7) I.V.+I.A.+Oral	0	0	0	0	0	0
8) Others	0	0	0	0	0	0
9) Unknown	1	4	1	3	1	10
Total	183	488	144	305	45	1165

I.V.: intravenous.

I.A.: intraarterial.

NOS: not otherwise specified.

Carcinoma of the Nasopharynx ----- 401 Cases

Nasopharynx(2021)

401 Cases

## Primary Site

<b>Site</b>	<b>Number of patients</b>	<b>(%)</b>
Posterosuperiorwall	180	(44.9)
Lateralwall	169	(42.1)
Inferiorwall	3	(0.7)
Nasopharynx, NOS	49	(12.2)
Total	401	(100)

NOS: not otherwise specified.

## Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	5	0	5
20 - 29	8	3	11
30 - 39	9	6	15
40 - 49	50	15	65
50 - 59	78	12	90
60 - 69	69	18	87
70 - 79	89	24	113
80 - 89	10	4	14
90 - 99	0	1	1
100 - 109	0	0	0
Total	318	83	401

Carcinoma of the Nasopharynx ----- 401 Cases

## Histological Distribution by Subsite

Histologic type	Postero-superior wall	Lateral wall	Inferior wall	Nasopharynx, NOS	Total
S.C.C., NOS	121	104	2	29	256
Ca., NOS	6	8	0	3	17
Salivary duct ca.	0	1	0	0	1
Malig. lymphoma, NOS	1	0	0	0	1
Adenoid cystic ca.	3	5	0	0	8
Adenocarcinoma, NOS	4	1	1	1	7
S.C.C. in situ, NOS	0	1	0	0	1
Ca., undiff., NOS	2	2	0	2	6
S.C.C., large cell, nonkerat., NOS	13	21	0	7	41
S.C.C., kerat., NOS	4	3	0	1	8
Plasmacytoma, extramedullary	1	0	0	0	1
Neoplasm, malig.	0	1	0	0	1
Papillary S.C.C.	1	1	0	0	2
Lymphoepithelial ca.	15	10	0	3	28
Spindle cell ca., NOS	1	0	0	0	1
Carcinosarcoma, NOS	0	1	0	0	1
Adenosquamous ca.	0	0	0	1	1
S.C.C., small cell, nonkerat.	8	9	0	1	18
Clear cell ca., NOS	0	1	0	0	1
Malig. lymphoma, large B-cell, diffuse, NOS	0	0	0	1	1
Total	180	169	3	49	401

NOS: not otherwise specified.

ca., Ca.: carcinoma.

S.C.C.: squamous cell carcinoma.

malig., Malig.: malignant.

nonkerat.: nonkeratinizing.

## T and N Status

	N0	N1	N2	N3	NX	N-	Total
T1	35	38(1)	23	13(1)	0	0	109
T2	21	36	23(3)	22(2)	1	0	103
T3	15(1)	29(3)	34(3)	19(2)	0	0	97
T4	19(1)	28(3)	24(4)	15(3)	0	0	86
Tis	1	0	0	0	0	0	1
TX	1	0	0	0	3	0	4
T-	0	0	0	0	0	1	1
Total	92(2)	131(7)	104(10)	69(8)	4	1	401

M1:27 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

**Treatment Method for the Primary Lesion by Subsite**

Treatment Method	Postero-superior wall	Lateral wall	Inferior wall	Nasopharynx, NOS	Total
Surgery					
without	170	165	1	46	382
with	10	1	2	3	16
unknown	0	3	0	0	3
Radiotherapy					
without	18	8	1	9	36
with	162	158	2	40	362
unknown	0	3	0	0	3
Chemotherapy					
without	25	31	1	9	66
with	155	135	2	40	332
unknown	0	3	0	0	3
Total	180	169	3	49	401

NOS: not otherwise specified.

**Treatment Method for the Cervical Lymph Nodes by Subsite**

Treatment Method	Postero-superior wall	Lateral wall	Inferior wall	Nasopharynx, NOS	Total
Surgery					
without	172	160	2	49	383
with	8	6	1	0	15
unknown	0	3	0	0	3
Radiotherapy					
without	34	33	2	12	81
with	146	133	1	37	317
unknown	0	3	0	0	3
Chemotherapy					
without	36	44	2	13	95
with	144	122	1	36	303
unknown	0	3	0	0	3
Total	180	169	3	49	401

NOS: not otherwise specified.

Carcinoma of the Nasopharynx ----- 401 Cases

**Sequence of Treatment Methods for the Primary Lesion by Subsite**

Sequence of treatment methods	Postero-superior wall	Lateral wall	Inferior wall	Nasopharynx, NOS	Total
No treatment	1	1	0	2	4
F)(Rad.+Chem.)	106	90	1	25	222
B) Rad. alone	18	28	0	5	51
C)F) Chem. -> (Rad.+Chem.)	19	18	0	1	38
F)C)(Rad.+Chem.)->Chem.	10	15	0	5	30
C) Chem. alone	9	6	0	5	20
A) Surg. alone	5	0	1	2	8
C)B) Chem.->Rad.	2	2	0	2	6
Other	10	6	1	2	19
Unknown	0	3	0	0	3
<b>Total</b>	<b>180</b>	<b>169</b>	<b>3</b>	<b>49</b>	<b>401</b>

NOS: not otherwise specified.

Surg.: surgery.

Rad.: radiotherapy.

Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

**Surgical Methods for the Primary Lesion by Subsite**

Surgical method	Postero-superior wall	Lateral wall	Inferior wall	Nasopharynx, NOS	Total
No surgery	172	165	1	46	384
Others	8	1	2	3	14
Unknown	0	3	0	0	3
<b>Total</b>	<b>180</b>	<b>169</b>	<b>3</b>	<b>49</b>	<b>401</b>

NOS: not otherwise specified.

**Reconstructive Surgery by Subsite**

Reconstructive surgery	Postero-superior wall	Lateral wall	Inferior wall	Nasopharynx, NOS	Total
0) No reconstruction	179	166	2	49	396
2) Local skin flap	1	0	0	0	1
E) Free ALT flap	0	0	1	0	1
Unknown	0	3	0	0	3
<b>Total</b>	<b>180</b>	<b>169</b>	<b>3</b>	<b>49</b>	<b>401</b>

ALT: anterolateral thigh.

NOS: not otherwise specified.

Carcinoma of the Nasopharynx ----- 401 Cases

### Neck Dissection on the Ipsilateral Side by Subsite

Neck dissection	Postero-superior wall	Lateral wall	Inferior wall	Nasopharynx, NOS	Total
0) No N.D.	172	160	2	49	383
1) Total N.D.	2	1	0	0	3
2) Selective N.D.	5	5	1	0	11
3) Lymph node excision	0	0	0	0	0
8) Others	0	0	0	0	0
9) Unknown	1	3	0	0	4
Total	180	169	3	49	401

NOS: not otherwise specified.

N.D.: neck dissection.

### Neck Dissection on the Contralateral Side by Subsite

Neck dissection	Postero-superior wall	Lateral wall	Inferior wall	Nasopharynx, NOS	Total
0) No N.D.	178	166	3	49	396
1) Total N.D.	0	0	0	0	0
2) Selective N.D.	1	0	0	0	1
3) Lymph node excision	0	0	0	0	0
8) Others	0	0	0	0	0
9) Unknown	1	3	0	0	4
Total	180	169	3	49	401

NOS: not otherwise specified.

N.D.: neck dissection.

### Radiotherapy by Subsite

Type of radiotherapy	Postero-superior wall	Lateral wall	Inferior wall	Nasopharynx, NOS	Total
0) No radiotherapy	17	9	1	9	36
1) X-ray (and/or electron beam)	160	153	2	40	355
2) Particle beam	2	4	0	0	6
5) X-ray + B.T.	1	0	0	0	1
9) Unknown	0	3	0	0	3
Total	180	169	3	49	401

NOS: not otherwise specified.

Carcinoma of the Nasopharynx ----- 401 Cases

**Chemotherapy by Subsite**

Route of administration	Postero-superior wall	Lateral wall	Inferior wall	Nasopharynx, NOS	Total
0) No chemotherapy	25	30	1	9	65
1) I.V.	151	134	2	38	325
2) I.A.	3	1	0	1	5
3) Oral	0	1	0	1	2
8) Others	1	0	0	0	1
9) Unknown	0	3	0	0	3
Total	180	169	3	49	401

NOS: not otherwise specified.

I.V.: intravenous.

I.A.: intraarterial.

Nasal Cavity and Paranasal Sinuses  
(Excluding the Maxillary Sinus)  
(2021)

453 Cases

## Primary Site

<b>Site</b>	<b>Number of patients</b>	<b>(%)</b>
Nasal cavity	269	(59.4)
Ethmoid sinus	72	(15.9)
Frontal sinus	5	(1.1)
Sphenoid sinus	17	(3.8)
Paranasal sinus,NOS	90	(19.9)
Total	453	(100)

NOS: not otherwise specified.

## Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	2	0	2
20 - 29	2	4	6
30 - 39	11	10	21
40 - 49	33	14	47
50 - 59	53	22	75
60 - 69	61	27	88
70 - 79	84	51	135
80 - 89	38	30	68
90 - 99	3	8	11
100 - 109	0	0	0
Total	287	166	453

NOS: not otherwise specified.

## Histological Distribution by Subsite

Histologic type	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
S.C.C., NOS	88	32	4	4	28	156
Ca., NOS	6	6	1	1	2	16
Salivary duct ca.	1	0	0	0	1	2
Malig. lymphoma, NOS	1	0	0	0	0	1
Large cell ca., NOS	1	0	0	0	0	1
Adenoid cystic ca.	17	2	0	2	3	24
Adenocarcinoma, NOS	11	10	0	1	5	27
S.C.C. in situ, NOS	6	0	0	1	0	7
Myoepithelial ca.	0	0	0	1	0	1
Mucoepidermoid ca.	1	0	0	0	2	3
Olfactory neuroblastoma	31	2	0	0	20	53
Verrucous ca., NOS	1	0	0	0	0	1
Ca. undiff., NOS	3	3	0	1	0	7
Malig. melanoma, NOS	57	6	0	1	21	85
S.C.C., large cell, nonkerat., NOS	3	0	0	0	1	4
S.C.C., kerat., NOS	10	1	0	1	2	14
Sebaceous ca.	1	0	0	0	0	1
Rhabdomyosarcoma, NOS	3	1	0	0	2	6
Ca. ex pleomorphic adenoma	1	0	0	0	0	1
Chondrosarcoma	1	0	0	0	0	1
S.C.C., spindle cell	0	0	0	1	0	1
Neoplasm, malig.	3	2	0	0	0	5
Papillary S.C.C.	1	0	0	1	0	2
Acinar cell ca.	4	0	0	0	0	4
Lymphoepithelial ca.	2	0	0	0	0	2
Carcinosarcoma, NOS	1	0	0	0	1	2
Adenosquamous ca.	1	1	0	0	0	2
Osteosarcoma, NOS	1	0	0	0	0	1
Plasmacytoma, NOS	1	0	0	0	0	1
S.C.C., small cell, nonkerat.	1	2	0	0	0	3
Small cell ca., NOS	3	2	0	0	1	6
Clear cell ca., NOS	0	1	0	0	0	1
Mixed tumor, malig., NOS	1	0	0	0	0	1
Chondrosarcoma, NOS	1	0	0	0	0	1
Schneiderian ca.	1	0	0	0	0	1
Neuroendocrine ca., NOS	2	1	0	0	0	3
Alveolar rhabdomyosarcoma	1	0	0	1	0	2
Nuclear protein in testis (NUT)-associated ca.	0	0	0	1	0	1
Malig. lymphoma, large B-cell, diffuse, NOS	2	0	0	0	1	3
Total	269	72	5	17	90	453

NOS: not otherwise specified.  
ca., Ca.: carcinoma.  
malig., Malig.: malignant.

S.C.C.: squamous cell carcinoma.  
nonkerat.: nonkeratinizing.

Carcinoma of the Nasal Cavity and Paranasal Sinuses -----453 Cases

T and N Status

	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	67	1	0	0	1	2	0	0	1	0	0	72
T2	53(1)	1	0	0	0	0	0	0	0	1	0	55
T3	69(1)	8(1)	0	0	4	0	0	0	0	0	0	81
T4	20	3(1)	1	0	1(1)	2(1)	0	0	0	0	0	27
T4a	84(5)	10(1)	0	0	3	1	0	0	0	1(1)	0	99
T4b	65(7)	4	0	0	5	5(1)	0	0	2	1	0	82
Tis	4	0	0	0	0	0	0	0	0	0	0	4
TX	8	0	0	0	0	0	0	0	0	11(1)	0	19
T-	6	0	0	0	0	0	0	0	0	0	8	14
Total	376(14)	27(3)	1	0	14(1)	10(2)	0	0	3	14(2)	8	453

M1:22 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

Treatment Method for the Primary Lesion by Subsite

Treatment Method	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
Surgery						
without	129	50	3	16	34	232
with	137	22	2	1	56	218
unknown	3	0	0	0	0	3
Radiotherapy						
without	92	19	0	5	23	139
with	174	53	5	12	67	311
unknown	3	0	0	0	0	3
Chemotherapy						
without	171	31	1	5	64	272
with	95	41	4	12	26	178
unknown	3	0	0	0	0	3
Total	269	72	5	17	90	453

NOS: not otherwise specified.

Carcinoma of the Nasal Cavity and Paranasal Sinuses -----453 Cases

### Treatment Method for the Cervical Lymph Nodes by Subsite

Treatment Method	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
Surgery						
without	248	69	5	17	77	416
with	18	3	0	0	13	34
unknown	3	0	0	0	0	3
Radiotherapy						
without	228	62	3	14	81	388
with	38	10	2	3	9	62
unknown	3	0	0	0	0	3
Chemotherapy						
without	224	60	4	12	80	380
with	42	12	1	5	10	70
unknown	3	0	0	0	0	3
Total	269	72	5	17	90	453

NOS: not otherwise specified.

### Sequence of Treatment Methods for the Primary Lesion by Subsite

Sequence of treatment methods	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
No treatment	8	3	0	2	2	15
A) Surg. alone	58	11	0	1	16	86
B) Rad. alone	48	11	1	0	19	79
A)B) Surg.->Rad.	47	5	0	0	26	78
F)(Rad.+Chem.)	27	18	2	4	9	60
C)F) Chem. -> (Rad.+Chem.)	12	5	0	2	1	20
C) Chem. alone	12	4	0	1	0	17
B)C) Rad.->Chem.	6	4	0	2	3	15
A)F) Surg.->(Rad.+Chem.)	8	0	2	0	4	14
A)C) Surg. -> Chem	5	0	0	0	2	7
C)B) Chem.->Rad.	4	1	0	0	1	6
A)B)C) Surg.->Rad.->Chem.	5	0	0	0	0	5
C)A)B) Chem.->Surg.->Rad.	2	2	0	0	1	5
F)C)(Rad.+Chem.)->Chem.	1	3	0	1	0	5
Other	26	5	0	4	6	41
Total	269	72	5	17	90	453

NOS: not otherwise specified.

Surg.: surgery. Rad.: radiotherapy.

Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

Carcinoma of the Nasal Cavity and Paranasal Sinuses -----453 Cases

## Surgical Methods for the Primary Lesion by Subsite

Surgical method	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
No surgery	128	50	3	16	34	231
Maxillectomy, other type	43	6	0	1	9	59
Endoscopic skull base surgery	15	11	2	0	22	50
Partial maxillectomy	21	1	0	0	4	26
Skull base surgery	11	2	0	0	6	19
Endoscopic resection	3	0	0	0	3	6
Total maxillectomy	0	0	0	0	2	2
Extended maxillectomy	1	0	0	0	1	2
Others	42	2	0	0	8	52
Unknown	5	0	0	0	1	6
Total	269	72	5	17	90	453

NOS: not otherwise specified.

## Reconstructive Surgery by Subsite

Reconstructive surgery	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
0) No reconstruction	226	61	3	17	64	371
3) Mucosal flap	7	6	1	0	14	28
2) Local skin flap	7	0	0	0	3	10
D) Free RA MC flap	1	2	1	0	4	8
E) Free ALT flap	4	0	0	0	1	5
1) Skin graft	1	0	0	0	0	1
C) Free FA flap	1	0	0	0	0	1
F) Free scapular OC flap	1	0	0	0	0	1
Others	16	3	0	0	3	22
9) Unknown	5	0	0	0	1	6
Total	269	72	5	17	90	453

RA: rectus abdominis.

MC: musculocutaneous.

ALT: anterolateral thigh.

FA: forearm.

OC: osteocutaneous.

NOS: not otherwise specified.

## Neck Dissection on the Ipsilateral Side by Subsite

Neck dissection	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
0) No N.D.	247	70	5	17	76	415
1) Total N.D.	1	0	0	0	1	2
2) Selective N.D.	15	2	0	0	8	25
8) Others	1	0	0	0	2	3
9) Unknown	5	0	0	0	3	8
Total	269	72	5	17	90	453

NOS: not otherwise specified.

N.D.: neck dissection.

Carcinoma of the Nasal Cavity and Paranasal Sinuses -----453 Cases

## Neck Dissection on the Contralateral Side by Subsite

Neck dissection	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
0) No N.D.	258	71	5	17	84	435
1) Total N.D.	0	0	0	0	1	1
2) Selective N.D.	5	0	0	0	0	5
3) Lymph node excision	0	1	0	0	0	1
8) Others	1	0	0	0	2	3
9) Unknown	5	0	0	0	3	8
<b>Total</b>	<b>269</b>	<b>72</b>	<b>5</b>	<b>17</b>	<b>90</b>	<b>453</b>

NOS: not otherwise specified.

N.D.: neck dissection.

## Radiotherapy by Subsite

Type of radiotherapy	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
0) No radiotherapy	91	18	0	5	24	138
1) X-ray (and/or electron beam)	130	40	5	10	44	229
2) Particle beam	44	13	0	2	21	80
8) Others	1	0	0	0	0	1
9) Unknown	3	1	0	0	1	5
<b>Total</b>	<b>269</b>	<b>72</b>	<b>5</b>	<b>17</b>	<b>90</b>	<b>453</b>

NOS: not otherwise specified.

B.T.: brachytherapy.

## Chemotherapy by Subsite

Route of administration	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
0) No chemotherapy	172	30	1	6	65	274
1) I.V.	87	36	4	11	23	161
2) I.A.	5	4	0	0	1	10
3) Oral	1	0	0	0	0	1
4) I.V.+I.A.	0	1	0	0	0	1
6) I.A.+Oral	1	0	0	0	0	1
9) Unknown	3	1	0	0	1	5
<b>Total</b>	<b>269</b>	<b>72</b>	<b>5</b>	<b>17</b>	<b>90</b>	<b>453</b>

NOS: not otherwise specified.

I.V.: intravenous. I.A.: intraarterial.

Maxillary Sinus (2021)

463 Cases

### Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	0	1	1
20 - 29	0	0	0
30 - 39	2	3	5
40 - 49	27	6	33
50 - 59	56	20	76
60 - 69	107	27	134
70 - 79	112	35	147
80 - 89	40	23	63
90 - 99	1	3	4
100 - 109	0	0	0
<b>Total</b>	<b>345</b>	<b>118</b>	<b>463</b>

## Histological Distribution by Subsite

Histologic type	Total	( % )
S.C.C., NOS	349	( 75 )
Ca., NOS	12	( 2.6 )
Salivary duct ca.	2	( 0.4 )
Malig. lymphoma, NOS	3	( 0.6 )
Adenoid cystic ca.	25	( 5.4 )
Adenocarcinoma, NOS	2	( 0.4 )
S.C.C. in situ, NOS	2	( 0.4 )
Myoepithelial ca.	1	( 0.2 )
Mucoepidermoid ca.	3	( 0.6 )
Verrucous ca., NOS	1	( 0.2 )
Ca., undiff., NOS	5	( 1.1 )
Malig. melanoma, NOS	9	( 1.9 )
S.C.C., large cell, nonkerat., NOS	3	( 0.6 )
S.C.C., kerat., NOS	12	( 2.6 )
Ca. ex pleomorphic adenoma	1	( 0.2 )
S.C.C., spindle cell	5	( 1.1 )
Neoplasm, malig.	2	( 0.4 )
Papillary S.C.C.	4	( 0.9 )
Spindle cell ca., NOS	3	( 0.6 )
Carcinosarcoma, NOS	2	( 0.4 )
Adenosquamous ca.	1	( 0.2 )
Osteosarcoma, NOS	2	( 0.4 )
Small cell ca., NOS	4	( 0.9 )
Fibrosarcoma, NOS	2	( 0.4 )
Hemangiosarcoma	1	( 0.2 )
Chondrosarcoma, NOS	1	( 0.2 )
Neuroendocrine ca., NOS	1	( 0.2 )
Nuclear protein in testis (NUT)-associated ca.	1	( 0.2 )
Plasmablastic lymphoma	1	( 0.2 )
Malig. lymphoma, large B-cell, diffuse, NOS	1	( 0.2 )
Giant cell sarcoma	1	( 0.2 )
Undiff. pleomorphic sarcoma	1	( 0.2 )
<b>Total</b>	<b>463</b>	<b>100.0</b>

NOS : Not Otherwise Specified  
malig., Malig.: malignant.

ca., Ca.: carcinoma.  
undiff.: undifferentiated.

S.C.C.: squamous cell carcinoma.

Carcinoma of the Maxillary Sinus ----- 463 Cases

**T and N Status**

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	Total
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	6	1	0	0	0	0	0	0	0	0	0	7
T2	11	2	0	0	1	0	0	0	0	0	0	14
T3	83(2)	7(1)	2	1	13(1)	3(1)	0	0	1	0	0	110
T4	11	1	1	0	0	0	0	0	0	0	0	13
T4a	157(5)	17(3)	0	0	33(2)	10(1)	0	0	4(1)	1	0	222
T4b	64(5)	4(1)	0	0	12(2)	8(2)	0	0	0	0	0	88
Tis	0	0	0	0	0	0	0	0	0	1	0	1
TX	0	0	0	0	0	0	0	0	0	1	0	1
T-	1	0	0	0	0	0	0	0	0	0	6	7
<b>Total</b>	<b>333(13)</b>	<b>32(5)</b>	<b>3</b>	<b>1</b>	<b>59(5)</b>	<b>21(4)</b>	<b>0</b>	<b>0</b>	<b>5(1)</b>	<b>3</b>	<b>6</b>	<b>463</b>

M1:28 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

**Treatment Method for the Primary Lesion by Subsite**

Treatment Method	Total ( % )
Surgery	
without	316 ( 68.3 )
with	141 ( 30.5 )
unknown	6 ( 1.3 )
Radiotherapy	
without	106 ( 22.9 )
with	351 ( 75.8 )
unknown	6 ( 1.3 )
Chemotherapy	
without	160 ( 34.6 )
with	297 ( 64.1 )
unknown	6 ( 1.3 )
<b>Total</b>	<b>463 ( 100.0 )</b>

## Treatment Method for the Cervical Lymph Nodes by Subsite

Treatment Method	Total ( % )
Surgery	
without	378 ( 81.6 )
with	78 ( 16.8 )
unknown	7 ( 1.5 )
Radiotherapy	
without	310 ( 67 )
with	146 ( 31.5 )
unknown	7 ( 1.5 )
Chemotherapy	
without	312 ( 67.4 )
with	144 ( 31.1 )
unknown	7 ( 1.5 )
Total	463 ( 100.0 )

## Sequence of Treatment Methods for the Primary Lesion by Subsite

Sequence of treatment methods	Total	( % )
No treatment	20	( 4.3 )
F)(Rad.+Chem.)	166	( 35.9 )
B) Rad. alone	54	( 11.7 )
A) Surg. alone	42	( 9.1 )
A)B) Surg.->Rad.	34	( 7.3 )
C) Chem. alone	23	( 5.0 )
A)F) Surg.->(Rad.+Chem.)	21	( 4.5 )
C)F) Chem. -> (Rad.+Chem.)	17	( 3.7 )
F)C)(Rad.+Chem.)->Chem.	13	( 2.8 )
F)A)(Rad.+Chem.)->Surg.	12	( 2.6 )
C)A) Chem.->Surg.	7	( 1.5 )
C)B) Chem.->Rad.	6	( 1.3 )
B)C) Rad.->Chem.	5	( 1.1 )
H)Nonspesific Immunotherapy	4	( 0.9 )
Other	33	( 7.1 )
Unknown	6	( 1.3 )
<b>Total</b>	<b>463</b>	<b>100.0</b>

Surg.: surgery.

Rad.: radiotherapy.

Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

## Surgical Methods for the Primary Lesion by Subsite

Surgical method	Total ( % )
No surgery	314 ( 67.8 )
Total maxillectomy	71 ( 15.3 )
Partial maxillectomy	27 ( 5.8 )
Extended maxillectomy	24 ( 5.2 )
Maxillectomy, other type	16 ( 3.5 )
Others	2 ( 0.4 )
Unknown	9 ( 1.9 )
<b>Total</b>	<b>463 ( 100.0 )</b>

## Reconstructive Surgery by Subsite

Reconstructive surgery	Total ( % )
0) No reconstruction	370 ( 79.9 )
D) Free RA MC flap	45 ( 9.7 )
E) Free ALT flap	19 ( 4.1 )
1) Skin graft	8 ( 1.7 )
G) Free fibular OC flap	4 ( 0.9 )
C) Free FA flap	2 ( 0.4 )
5) PM MC flap	1 ( 0.2 )
Others	5 ( 1.1 )
9) Unknown	9 ( 1.9 )
<b>Total</b>	<b>463 ( 100.0 )</b>

RA: rectus abdominis.

FA: forearm.

DP: deltopectoral

MC: musculocutaneous.

PM: pectoralis major.

ALT: anterolateral thigh.

OC: osteocutaneous.

## Neck Dissection on the Ipsilateral Side by Subsite

Neck dissection	Total	( % )
0) No N.D.	378	( 81.6 )
1) Total N.D.	12	( 2.6 )
2) Selective N.D.	58	( 12.5 )
3) Lymph node excision	3	( 0.6 )
8) Others	3	( 0.6 )
9) Unknown	9	1.9
<b>Total</b>	<b>463</b>	<b>100.0</b>

N.D.: neck dissection.

## Neck Dissection on the Contralateral Side by Subsite

Neck dissection	Total	( % )
0) No N.D.	442	( 95.5 )
1) Total N.D.	1	( 0.2 )
2) Selective N.D.	7	( 1.5 )
8) Others	4	( 0.9 )
9) Unknown	9	( 1.9 )
<b>Total</b>	<b>463</b>	<b>( 100.0 )</b>

N.D.: neck dissection.

### Radiotherapy by Subsite

Type of radiotherapy	Total ( % )
0) No radiotherapy	96 ( 20.7 )
1) X-ray (and/or electron beam)	335 ( 72.4 )
2) Particle beam	23 ( 5.0 )
9) Unknown	9 ( 1.9 )
<b>Total</b>	<b>463 ( 100.0 )</b>

### Chemotherapy by Subsite

Route of administration	Total ( % )
0) No chemotherapy	155 ( 33.5 )
1) I.V.	141 ( 30.5 )
2) I.A.	147 ( 31.7 )
3) Oral	3 ( 0.6 )
4) I.V.+I.A.	6 ( 1.3 )
5) I.V.+Oral	2 ( 0.4 )
6) I.A.+Oral	1 ( 0.2 )
9) Unknown	8 ( 1.7 )
<b>Total</b>	<b>463 ( 100.0 )</b>

I.V.: intravenous.

I.A.: intraarterial.

# **Major Salivary Glands (2021)**

**788 Cases**

## Primary Site

<b>Site</b>	<b>Number of patients</b>	<b>(%)</b>
Parotid gland	559	( 70.9 )
Submandibular gland	195	( 24.7 )
Sublingual gland	29	( 3.7 )
Majorsalivary gland, NOS	5	( 0.6 )
Total	788	( 100 )

NOS: not otherwise specified.

## Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	1	2	3
10 - 19	5	6	11
20 - 29	11	19	30
30 - 39	25	23	48
40 - 49	44	41	85
50 - 59	65	57	122
60 - 69	102	40	142
70 - 79	146	81	227
80 - 89	78	25	103
90 - 99	9	8	17
100 - 109	0	0	0
Total	486	302	788

Carcinoma of the Major Salivary Glands -----788 Cases

**Parotid gland**  
**Age Distribution by Gender**

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	1	2	3
10 - 19	3	5	8
20 - 29	9	16	25
30 - 39	19	17	36
40 - 49	27	33	60
50 - 59	50	37	87
60 - 69	76	27	103
70 - 79	94	58	152
80 - 89	57	16	73
90 - 99	6	6	12
100 - 109	0	0	0
Total	342	217	559

**Submandibular gland**  
**Age Distribution by Gender**

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	2	0	2
20 - 29	2	3	5
30 - 39	5	5	10
40 - 49	15	7	22
50 - 59	15	13	28
60 - 69	21	11	32
70 - 79	43	19	62
80 - 89	20	9	29
90 - 99	3	2	5
100 - 109	0	0	0
Total	126	69	195

### Sublingual gland Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	1	0	1
40 - 49	1	1	2
50 - 59	0	7	7
60 - 69	5	2	7
70 - 79	7	4	11
80 - 89	1	0	1
90 - 99	0	0	0
100 - 109	0	0	0
<b>Total</b>	<b>15</b>	<b>14</b>	<b>29</b>

### Major salivary gland, NOS Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	0	1	1
20 - 29	0	0	0
30 - 39	0	1	1
40 - 49	1	0	1
50 - 59	0	0	0
60 - 69	0	0	0
70 - 79	2	0	2
80 - 89	0	0	0
90 - 99	0	0	0
100 - 109	0	0	0
<b>Total</b>	<b>3</b>	<b>2</b>	<b>5</b>

NOS : Not Otherwise Specified

Carcinoma of the Major Salivary Glands -----788 Cases

## Histological Distribution by Primary Site

Histologic type	Parotid gland (C07.9)	Sub-mandibular gland (C08.0)	Sub-lingual gland (C08.1)	Major salivary gland, NOS (C08.9)	Total
S.C.C., NOS	49	13	3	0	65
Ca., NOS	36	7	0	0	43
Salivary duct ca.	114	46	1	3	164
Malig. lymphoma, NOS	9	11	1	0	21
Large cell ca., NOS	1	1	0	0	2
Adenoid cystic ca.	39	58	17	1	115
Adenocarcinoma, NOS	32	12	2	0	46
Myoepithelial ca.	10	3	0	0	13
Mucoepidermoid ca.	105	13	4	1	123
Ca., undiff., NOS	3	2	0	0	5
Malig. melanoma, NOS	0	1	0	0	1
S.C.C., kerat., NOS	3	0	0	0	3
Mucinous adenocarcinoma	4	1	0	0	5
Sebaceous ca.	1	0	0	0	1
Ca. ex pleomorphic adenoma	61	16	0	0	77
Epithelial-myoeplithelial ca.	16	0	0	0	16
Neoplasm, malig.	3	1	0	0	4
Acinar cell ca.	32	2	0	0	34
Lymphoepithelial ca.	7	2	0	0	9
Carcinosarcoma, NOS	3	0	0	0	3
Plasmacytoma, NOS	1	0	0	0	1
Oncocytic ca.	3	0	0	0	3
Small cell ca., NOS	2	0	0	0	2
Polymorphous low grade adenocarcinoma	2	0	0	0	2
Hemangiosarcoma	1	0	0	0	1
Basal cell adenocarcinoma	11	0	0	0	11
Intraductal ca., noninfiltrating, NOS	0	2	0	0	2
Malig. lymphoma, large B-cell, diffuse, NOS	0	1	0	0	1
Malig. peripheral nerve sheath tumor, epithelioid	1	0	0	0	1
Secretory ca. of breast	6	0	0	0	6
Intraductal papillary adenocarcinoma with invasion	0	1	0	0	1
Leiomyosarcoma, NOS	0	1	0	0	1
Infiltrating duct mixed with other types of ca.	1	0	0	0	1
Secretory ca.	1	0	0	0	1
Basal cell ca., NOS	0	1	0	0	1
Cystadenocarcinoma	2	0	1	0	3
<b>Total</b>	<b>559</b>	<b>195</b>	<b>29</b>	<b>5</b>	<b>788</b>

NOS: not otherwise specified.  
ca., Ca.: carcinoma.  
malig., Malig.: malignant.

ca., Ca.: carcinoma.  
nonkerat.: nonkeratinizing.

S.C.C.: squamous cell carcinoma.

Carcinoma of the Major Salivary Glands -----788 Cases

T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	4	0	1	0	0	0	0	0	1	0	1	7
T1	93(2)	2(1)	1	0	5	1(1)	1	0	2	1	0	106
T2	167(3)	13	2	0	25(4)	1	0	0	5(1)	0	0	213
T3	115(1)	11(1)	2	1(1)	38(9)	4(3)	1	0	17(7)	0	0	189
T4	3	1	0	0	2	0	0	0	0	0	0	6
T4a	87(7)	15(1)	0	0	51(5)	6(4)	0	0	4	0	0	163
T4b	11	5(1)	0	1	8(1)	1	0	0	1(1)	0	0	27
TX	6	0	0	1	0	0	0	0	1	35	0	43
T-	1	0	0	0	0	0	0	0	0	0	33	34
Total	487(13)	47(4)	6	3(1)	129(19)	13(8)	2	0	31(9)	36	34	788

M1:54 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

Parotid gland  
T and N Status

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	4	0	0	0	0	0	0	0	1	0	1	6
T1	66	2(1)	1	0	3	1(1)	0	0	2	1	0	76
T2	117	7	0	0	14(1)	0	0	0	3	0	0	141
T3	79	7	1	1(1)	20(1)	1(1)	0	0	6(3)	0	0	115
T4	2	1	0	0	1	0	0	0	0	0	0	4
T4a	80(5)	14(1)	0	0	42(5)	3(2)	0	0	3	0	0	142
T4b	10	4(1)	0	1	7(1)	1	0	0	1(1)	0	0	24
TX	4	0	0	0	0	0	0	0	1	27	0	32
T-	0	0	0	0	0	0	0	0	0	0	19	19
Total	362(5)	35(3)	2	2(1)	87(8)	6(4)	0	0	17(4)	28	20	559

M1:25 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

Carcinoma of the Major Salivary Glands -----788 Cases

**Submandibular gland**  
**T and N Status**

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	25(1)	0	0	0	2	0	1	0	0	0	0	28
T2	44(2)	6	2	0	9(3)	1	0	0	2(1)	0	0	64
T3	28(1)	4(1)	1	0	17(8)	3(2)	1	0	9(4)	0	0	63
T4	1	0	0	0	1	0	0	0	0	0	0	2
T4a	5(2)	0	0	0	7	3(2)	0	0	1	0	0	16
T4b	0	1	0	0	1	0	0	0	0	0	0	2
TX	0	0	0	0	0	0	0	0	0	7	0	7
T-	1	0	0	0	0	0	0	0	0	0	12	13
Total	104(6)	11(1)	3	0	37(11)	7(4)	2	0	12(5)	7	12	195

M1:27 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

**Sublingual gland**  
**T and N Status**

	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	0	0	1	0	0	0	0	0	0	0	0	1
T1	2(1)	0	0	0	0	0	0	0	0	0	0	2
T2	5(1)	0	0	0	2	0	0	0	0	0	0	7
T3	8	0	0	0	1	2	0	0	0	0	0	11
T4	0	0	0	0	0	0	0	0	0	0	0	0
T4a	2	0	0	0	1	0	0	0	0	0	0	3
T4b	1	0	0	0	0	0	0	0	0	0	0	1
TX	1	0	0	0	0	0	0	0	0	1	0	2
T-	0	0	0	0	0	0	0	0	0	0	2	2
Total	19(2)	0	1	0	4	2	0	0	0	1	2	29

M1:2 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Major salivary gland, NOS T and N Status

	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	0	0	0	0	0	0	0	0	0	0	0	0
T2	1	0	0	0	0	0	0	0	0	0	0	1
T3	0	0	0	0	0	0	0	0	0	0	0	2
T4	0	0	0	0	0	0	0	0	0	0	0	0
T4a	0	1	0	0	0	1	0	0	0	0	0	2
T4b	0	0	0	0	0	0	0	0	0	0	0	0
TX	1	0	0	1	0	0	0	0	0	0	0	2
T-	0	0	0	0	0	0	0	0	0	0	0	0
Total	2	1	0	1	0	1	0	0	0	0	0	5

NOS : Not Otherwise Specified

T-: not within defined T classification or without reported T classification

N-: not within defined N classification or without reported N classification

## Treatment Method for the Primary Lesion by Subsite

Treatment Method	Parotid gland (C07.9)	Sub-mandibular gland (C08.0)	Sub-lingual gland (C08.1)	Major salivary gland, NOS (C08.9)	Total
Surgery					
without	78	27	6	1	112
with	466	165	23	4	658
unknown	15	3	0	0	18
Radiotherapy					
without	274	113	17	3	407
with	270	79	12	2	363
unknown	15	3	0	0	18
Chemotherapy					
without	461	148	23	4	636
with	83	44	6	1	134
unknown	15	3	0	0	18
Total	559	195	29	5	788

NOS: not otherwise specified.

## Treatment Method for the Cervical Lymph Nodes by Subsite

Treatment Method	Parotid gland (C07.9)	Sub-mandibular gland (C08.0)	Sub-lingual gland (C08.1)	Major salivary gland, NOS (C08.9)	Total
Surgery					
without	295	54	10	2	361
with	248	138	19	3	408
unknown	16	3	0	0	19
Radiotherapy					
without	366	125	17	3	511
with	177	67	12	2	258
unknown	16	3	0	0	19
Chemotherapy					
without	473	154	25	4	656
with	70	38	4	1	113
unknown	16	3	0	0	19
Total	559	195	29	5	788

NOS: not otherwise specified.

## Sequence of Treatment Methods for the Primary Lesion by Subsite

Sequence of treatment methods	Parotid gland (C07.9)	Sub-mandibular gland (C08.0)	Sub-lingual gland (C08.1)	Major salivary gland, NOS (C08.9)	Total
No treatment	14	9	1	1	25
A) Surg. alone	239	83	13	2	337
A)B) Surg.->Rad.	165	51	6	1	223
A)F) Surg.->(Rad.+Chem.)	34	12	1	1	48
B) Rad. alone	31	3	1	0	35
C) Chem. alone	12	12	3	0	27
F)(Rad.+Chem.)	14	0	1	0	15
A)C) Surg. -> Chem	5	8	0	0	13
A)B)C) Surg.->Rad.->Chem.	4	4	0	0	8
A)A)B) Surg.->Surg.-> Rad. alone	5	0	2	0	7
A)A) Surg.->Surg.	2	1	0	0	3
D)(Surg.+Rad.)	2	1	0	0	3
G)Surg.+Rad.+Chem.	1	1	1	0	3
Other	16	7	0	0	23
Unknown	15	3	0	0	18
Total	559	195	29	5	788

Surg.: surgery.

Rad.: radiotherapy.

Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

NOS: not otherwise specified.

## Surgical Methods for the Primary Lesion by Subsite

Surgical method	Parotid gland (C07.9)	Sub-mandibular gland (C08.0)	Sub-lingual gland (C08.1)	Major salivary gland, NOS (C08.9)	Total
Superficial parotidectomy	159	0	0	0	159
Total parotidectomy	153	0	0	1	154
Submandibulectomy	1	152	0	1	154
No surgery	77	27	6	1	111
Extended total parotidectomy	58	0	0	1	59
Partial parotidectomy	47	0	0	0	47
Deep lobe resection of the parotid gland	37	0	0	0	37
Resection of the sublingual gland	0	1	16	0	17
Paroticectomy,NOS	5	3	1	1	10
Segmental mandibulectomy	0	3	2	0	5
Others	4	4	4	0	12
Unknown	18	5	0	0	23
Total	559	195	29	5	788

NOS: not otherwise specified.

## Reconstructive Surgery by Subsite

Reconstructive surgery	Parotid gland (C07.9)	Sub-mandibular gland (C08.0)	Sub-lingual gland (C08.1)	Major salivary gland, NOS (C08.9)	Total
0) No reconstruction	405	171	15	3	594
I) Free nerve graft	54	1	0	0	55
E) Free ALT flap	39	5	7	2	53
5) PM MC flap	9	4	2	0	15
2) Local skin flap	11	0	1	0	12
D) Free RA MC flap	7	2	1	0	10
C) Free FA flap	0	1	2	0	3
G) Free fibular OC flap	0	2	0	0	2
4) DP flap	0	1	0	0	1
F) Free scapular OC flap	0	1	0	0	1
9) Unknown	20	6	0	0	26
Others	14	1	1	0	16
Total	559	195	29	5	788

RA: rectus abdominis.

MC: musculocutaneous.

ALT: anterolateral thigh.

FA: forearm.

PM: pectoralis major.

OC: osteocutaneous.

DP: deltopectoral.

NOS: not otherwise specified.

## Neck Dissection on the Ipsilateral Side by Subsite

Treatment Method	Parotid gland (C07.9)	Sub-mandibular gland (C08.0)	Sub-lingual gland (C08.1)	Major salivary gland, NOS (C08.9)	Total
0) No N.D.	293	54	11	2	360
1) Total N.D.	83	31	3	1	118
2) Selective N.D.	152	103	15	2	272
3) Lymph node excision	9	1	0	0	10
8) Others	3	3	0	0	6
9) Unknown	19	3	0	0	22
Total	559	195	29	5	788

N.D.: neck dissection.

NOS: not otherwise specified.

## Neck Dissection on the Contralateral Side by Subsite

Neck dissection	Parotid gland (C07.9)	Sub-mandibular gland (C08.0)	Sub-lingual gland (C08.1)	Major salivary gland, NOS (C08.9)	Total
0) No N.D.	534	178	24	5	741
1) Total N.D.	0	3	0	0	3
2) Selective N.D.	2	7	4	0	13
3) Lymph node excision	2	0	0	0	2
8) Others	1	4	1	0	6
9) Unknown	20	3	0	0	23
Total	559	195	29	5	788

N.D.: neck dissection.

NOS: not otherwise specified.

Carcinoma of the Major Salivary Glands -----788 Cases

## Radiotherapy by Subsite

Type of radiotherapy	Parotid gland (C07.9)	Sub-mandibular gland (C08.0)	Sub-lingual gland (C08.1)	Major salivary gland, NOS (C08.9)	Total
0) No radiotherapy	259	104	15	3	381
1) X-ray (and/or electron beam)	252	79	14	1	346
2) Particle beam	28	4	0	1	33
4) X-ray + Particle beam	1	1	0	0	2
8) Others	1	0	0	0	1
9) Unknown	18	7	0	0	25
<b>Total</b>	<b>559</b>	<b>195</b>	<b>29</b>	<b>5</b>	<b>788</b>

NOS: not otherwise specified.

## Chemotherapy by Subsite

Route of administration	Parotid gland (C07.9)	Sub-mandibular gland (C08.0)	Sub-lingual gland (C08.1)	Major salivary gland, NOS (C08.9)	Total
0) No chemotherapy	454	144	23	4	625
1) I.V.	83	45	5	1	134
2) I.A.	2	0	0	0	2
3) Oral	4	1	0	0	5
5) I.V.+Oral	1	0	0	0	1
9) Unknown	15	5	1	0	21
<b>Total</b>	<b>559</b>	<b>195</b>	<b>29</b>	<b>5</b>	<b>788</b>

NOS: not otherwise specified.

I.V.: intravenous.

I.A.: intraarterial.

Primary Unknown (2021)

167 Cases

## Subtype

<b>Subtype</b>	<b>Number of patients</b>	<b>(%)</b>
EBV positive	2	(1.2)
p16 positive	60	(35.9)
Other	105	(62.9)
Total	167	100

Patients with both EBV-positive and p16-positive are classified as "EBV-positive" in all the tables.

## Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	2	1	3
40 - 49	7	1	8
50 - 59	25	10	35
60 - 69	40	11	51
70 - 79	45	11	56
80 - 89	9	4	13
90 - 99	0	1	1
100 - 109	0	0	0
Total	128	39	167

Primary Unknown-----167 Cases

### EBV positive

#### Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	1	0	0
40 - 49	0	0	0
50 - 59	0	1	0
60 - 69	0	0	0
70 - 79	0	0	0
80 - 89	0	0	0
90 - 99	0	0	0
100 - 109	0	0	0
<b>Total</b>	<b>1</b>	<b>1</b>	<b>2</b>

### p16 positive

#### Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	0	0	0
40 - 49	4	1	5
50 - 59	15	6	21
60 - 69	15	8	23
70 - 79	7	3	10
80 - 89	0	1	1
90 - 99	0	0	0
100 - 109	0	0	0
<b>Total</b>	<b>41</b>	<b>19</b>	<b>60</b>

Primary Unknown-----167 Cases

### Other

#### Age Distribution by Gender

<b>Age</b>	<b>Male</b>	<b>Female</b>	<b>Total</b>
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	1	1	2
40 - 49	3	0	3
50 - 59	10	3	13
60 - 69	25	3	28
70 - 79	38	8	46
80 - 89	9	3	12
90 - 99	0	1	1
100 - 109	0	0	0
<b>Total</b>	<b>86</b>	<b>19</b>	<b>105</b>

#### EBV positive N and M Status

	<b>N1</b>	<b>N2</b>	<b>N3</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
M0	2	0	0	0	0	2
M1	0	0	0	0	0	0
MX	0	0	0	0	0	0
M-	0	0	0	0	0	0
<b>Total</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>2</b>

N-: not within defined N classification or without reported N classification

M-: without reported M classification

### p16 positive N and M Status

	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
M0	32	11	1	4	0	5	0	2	1	0	56
M1	1	0	0	1	0	1	0	1	0	0	4
MX	0	0	0	0	0	0	0	0	0	0	0
M-	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>33</b>	<b>11</b>	<b>1</b>	<b>5</b>	<b>0</b>	<b>6</b>	<b>0</b>	<b>3</b>	<b>1</b>	<b>0</b>	<b>60</b>

N-: not within defined N classification or without reported N classification

M-: without reported M classification

### Other N and M Status

	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
M0	10	0	3	17	5	0	1	52	3	0	91
M1	0	0	0	2	3	0	0	6	0	0	11
MX	0	0	0	0	0	0	0	0	3	0	3
M-	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>10</b>	<b>0</b>	<b>3</b>	<b>19</b>	<b>8</b>	<b>0</b>	<b>1</b>	<b>58</b>	<b>6</b>	<b>0</b>	<b>105</b>

N-: not within defined N classification or without reported N classification

M-: without reported M classification

## Treatment Methods for the Primary Lesion by Subsite

Treatment Method	EBV positive	p16 positive	Other	Total
Surgery				
without	2	46	99	147
with	0	14	6	20
unknown	0	0	0	0
Radiotherapy				
without	2	38	69	109
with	0	22	36	58
unknown	0	0	0	0
Chemotherapy				
without	2	45	68	115
with	0	15	37	52
unknown	0	0	0	0
Total	2	60	105	167

## Treatment Method for the Cervical Lymph Nodes by Subsite

Treatment Method	EBV positive	p16 positive	Other	Total
Surgery				
without	1	22	43	66
with	1	38	62	101
unknown	0	0	0	0
Radiotherapy				
without	0	22	40	62
with	2	38	65	105
unknown	0	0	0	0
Chemotherapy				
without	0	30	50	80
with	2	30	55	87
unknown	0	0	0	0
Total	2	60	105	167

Primary Unknown-----167 Cases

**Sequence of Treatment Methods for the Cervical Lymph Nodes by Subtype**

Sequence of treatment methods	EBV positive	p16 positive	Other	Total
No treatment	0	0	6	6
A) Surg. alone	0	15	20	35
A)F) Surg.->(Rad.+Chem.)	1	12	21	34
F)(Rad.+Chem.)	1	10	13	24
A)B) Surg.->Rad.	0	7	15	22
B) Rad. alone	0	5	7	12
C) Chem. alone	0	3	9	12
C)F) Chem. -> (Rad.+Chem.)	0	2	4	6
C)A) Chem.->Surg.	0	0	2	2
A)A)B) Surg.->Surg.-> Rad. alone	0	0	1	1
A)C) Surg. -> Chem	0	0	1	1
A)C)C) Surg. -> Chem-> Chem	0	1	0	1
A)E) Surg. alone->(Surg.+Chem)	0	1	0	1
A)F)F) Surg.->(Rad.+Chem.)->(Rad.+Chem.)	0	0	1	1
B)A) Rad.->Surg.	0	0	1	1
C)B) Chem.->Rad.	0	0	1	1
C)C)Chem.->Chem.	0	0	1	1
C)C)C) Chem.->Chem.->Chem.	0	0	1	1
C)F)C) Chem.-> (Rad.+Chem.)->Chem.	0	0	1	1
D)(Surg.+Rad.)	0	1	0	1
F)A)(Rad.+Chem.)->Surg.	0	1	0	1
H)Nonspesific Immunotherapy	0	1	0	1
Other	0	1	0	1
Total	2	60	105	167

Surg.: surgery.

Rad.: radiotherapy.

Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

### Neck Dissection on the Ipsilateral Side by Subtype

Neck dissection	EBV positive	p16 positive	Other	Total
0) No N.D.	1	21	43	65
1) Total N.D.	1	9	34	44
2) Selective N.D.	0	24	27	51
3) Lymph node excision	0	3	1	4
8) Others	0	2	0	2
9) Unknown	0	1	0	1
Total	2	60	105	167

N.D.: neck dissection.

### Neck Dissection on the Contralateral Side by Subtype

Neck dissection	EBV positive	p16 positive	Other	Total
0) No N.D.	2	54	98	154
1) Total N.D.	0	2	3	5
2) Selective N.D.	0	2	4	6
3) Lymph node excision	0	0	0	0
8) Others	0	1	0	1
9) Unknown	0	1	0	1
Total	2	60	105	167

N.D.: neck dissection.

## Radiotherapy by Subtype

Type of radiotherapy	EBV positive	p16 positive	Other	Total
0) No radiotherapy	0	20	38	58
1) X-ray (and/or electron beam)	2	39	67	108
2) Particle beam	0	0	0	0
3) B.T.	0	0	0	0
4) X-ray + Particle beam	0	0	0	0
5) X-ray + B.T.	0	0	0	0
6) Particl beam + B.T.	0	0	0	0
7) X-ray + Particl beam + B.T.	0	0	0	0
8) Others	0	0	0	0
9) Unknown	0	1	0	1
Total	2	60	105	167

B.T.: brachytherapy.

## Chemotherapy by Subtype

Route of administration	EBV positive	p16 positive	Other	Total
0) No chemotherapy	0	28	48	76
1) I.V.	2	28	56	86
2) I.A.	0	1	0	1
3) Oral	0	1	1	2
4) I.V.+I.A.	0	0	0	0
5) I.V.+Oral	0	1	0	1
6) I.A.+Oral	0	0	0	0
7) I.V.+I.A.+Oral	0	0	0	0
8) Others	0	0	0	0
9) Unknown	0	1	0	1
Total	2	60	105	167

I.V.: intravenous.

I.A.: intraarterial.